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Abstract 
 
Congenital myasthenic syndromes (CMS) are inherited disorders characterised by 
fatigable muscle weakness resulting from impaired transmission at the neuromuscular 
junction (NMJ). CMS occur due to mutations in genes encoding proteins responsible for 
maintaining the structure and function of the NMJ.  
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in 
the hexosamine biosynthetic pathway which yields precursors required for protein and 
lipid glycosylation. Mutations in GFPT1 and genes downstream of this pathway are 
pathogenic for CMS. One hypothesis is that hypoglycosylation of NMJ proteins results 
in defective neurotransmission.  
The aim of this study is to generate and characterise a GFPT1 deficient mouse model of 
CMS. One of the challenges we face is the viability of Gfpt1 knockout mice. Here we 
generate a novel muscle-specific GFPT1 knockout mouse model using Cre/loxP 
technology. We demonstrate that a deficiency of GFPT1 in muscle only, is sufficient for 
causing a CMS phenotype. Our model recapitulates many aspects of the phenotype 
observed in patients with GFPT1-related CMS. Mutant mice display early changes in 
the morphology of postsynaptic components of the NMJ, which are accompanied by 
presynaptic alterations. They later develop a myopathic phenotype and formation of 
tubular aggregates. We further identify proteins in skeletal muscle that are differentially 
regulated because of GFPT1 deficiency. 
Our data demonstrates a critical role for GFPT1 in the development of the NMJ, 
neurotransmission, and skeletal muscle integrity. The muscle-specific GFPT1 deficient 
mouse model allows us to investigate the implications of not only GFPT1 mutations, 
but may also give us an insight into the pathophysiological consequences of mutations 
in genes downstream of GFPT1, which also result in hypoglycosylation. This model has 
the potential to enhance our understanding of current drug therapies, and to drive 
forward the development of new compounds which can be implemented in the clinic.  
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Chapter 1. Introduction 
 
1.1 Myasthenic syndromes 
Myasthenic Syndromes are a group of autoimmune and inherited disorders characterised 
by muscle weakness and fatigability. Both arise due to impairment of neuromuscular 
transmission and are categorised in terms of etiological mechanisms and clinical 
phenotype (Verschuuren et al., 2010; Parr et al., 2014). Congenital Myasthenic 
Syndromes (CMS) are caused by gene mutations which affect proteins responsible for 
maintaining the structure and function of the neuromuscular junction (NMJ). CMS 
differ to the more common myasthenia gravis and Lambert-Eaton myasthenic 
syndrome, which are autoimmune disorders characterised by the presence of antibodies 
targeting the acetylcholine receptor (AChR) or the Muscle Specific Kinase (MuSK), and 
PQ-type voltage-gated calcium channels respectively (Hoch et al., 2001; Jacob et al., 
2009; Finlayson et al., 2013; Le Panse and Berrih-Aknin, 2013). Whilst there are 
currently no cures for myasthenic syndromes, symptomatic treatments are widely 
available. Correct treatment is highly dependent on recognising the type of myasthenic 
syndrome, molecular pathology, and identification of the gene mutated in inherited 
myasthenic syndromes (Basiri et al., 2013). Myasthenia gravis and CMS can be 
distinguished according to phenotypic presentation, onset and progression of disease 
and response to immunosuppressive therapy (Abicht et al., 2012). More recently, the 
discovery of gene mutations that give rise to CMS, alongside functional studies to 
determine whether these mutations are indeed pathogenic have facilitated the 
differential diagnosis of CMS subtypes and selection of effective drugs for treatment.  
 
1.2 Congenital myasthenic syndromes  
CMS are a heterogeneous group of rare inherited disorders of neurotransmission. The 
prevalence of genetically confirmed CMS is approximately 9.2 cases per million 
children under 18 years old in the UK (Parr et al., 2014). CMS are usually characterised 
by fatigable muscle weakness in skeletal muscle affecting the ocular, bulbar and limb 
muscles, whilst cardiac and smooth muscle remain unaffected. The severity and 
progression of CMS is highly variable amongst patients, ranging from mild weakness to 
more disabling symptoms. If left untreated CMS can potentially cause life threatening 
respiratory insufficiency (Senderek et al., 2011). The different types of CMS are 
2 
 
 
classified based on the site of the underlying defect, which primarily involves the 
presynaptic compartment, synaptic cleft or the postsynaptic basal lamina of the NMJ. 
They are further subdivided according to the pathophysiological involvement of specific 
proteins that impair the formation, maintenance and function of the NMJ. The genes 
implicated in CMS encode membrane receptors, enzymes, ion channels and neurally 
secreted proteins at the NMJ (Huze et al., 2009). More recently, mutations in genes 
encoding ubiquitously expressed enzymes involved in glycosylation have also been 
implicated in CMS (Senderek et al., 2011; Belaya et al., 2012; Selcen et al., 2013; 
Belaya et al., 2015). Table 1.1 provides a summary of the known genes encoding 
proteins implicated in CMS (Abicht et al., 2016; O'Connor et al., 2016; Souza et al., 
2016).  
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Type of 
CMS/protein 
impaired 
Genes % of CMS attributed to 
pathogenic variants in this 
gene 
Molecular Pathology Treatment 
POSTSYNAPTIC 
AChR deficiency  CHRNE 
CHRNA 
CHRNB 
CHRND 
 
 
<1% CHRNA, 
 
<1% CHRNB, 
 
<1% CHRND, 
 
50% CHRNE 
 
 
Low expression of AChR in the postsynaptic 
membrane 
Pyridostigmine, 3,4 
DAP 
AChR-Slow channel 
syndrome 
CHRNA* 
CHRNE* 
CHRNB* 
CHRND* 
Prolonged channel opening in response to ACh Fluoxetine, quinidine 
AChR-Fast channel 
syndrome 
CHRNA 
CHRNE 
CHRND 
Shortened channel opening in response to ACh Pyridostigmine, 3,4 
DAP 
Escobar Syndrome CHRNG <1% Low expression of fetal AChR gamma subunit ___ 
Rapsyn deficiency RAPSN 15%-20% Impaired AChR clustering Pyridostigmine, 3,4 
DAP 
Dok-7 synaptopathy DOK7 10%-15% Synaptopathy; small and simplified 
presynaptic and postsynaptic structures  
Ephedrine, 
salbutamol, 3,4 DAP 
MuSK MUSK <1% Impaired AChR clustering Pyridostigmine, 3,4 
DAP 
LRP4  LRP4  <1% Impaired AChR clustering Pyridostigmine, 3,4 
DAP (no/negative 
effect on patients) 
Nav1.4 (voltage-gated 
sodium channel) 
SCN4A <1% Altered postsynaptic voltage-gated sodium 
function  
AChE inhibitors 
Plectin  PLEC <1% Reduced plectin (cytoskeletal linking protein 
at the postsynaptic junctional folds) 
Pyridostigmine, 3,4 
DAP 
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Type of 
CMS/Protein 
impaired 
Genes % of CMS attributed to 
pathogenic variant in this 
gene 
Molecular Pathology Treatment 
SYNAPTIC 
Laminin beta-2  LAMB2 <1% Reduced β2-laminin, required for the 
alignment of nerve and muscle at the NMJ  
Ephedrine 
Acetylcholinesterase 
deficiency 
COLQ 10%-15% Failure to anchor AChE in the synaptic cleft Ephedrine 
PRESYNAPTIC 
Choline 
acetyltransferase 
deficiency 
CHAT 4%-5% Failure of ACh synthesis Pyridostigmine, 3,4 
DAP 
Agrin AGRN <1% Impaired AChR clustering Pyridostigmine, 3,4 
DAP 
MYO9A  MYO9A <1% Impairment of neuronal morphology and 
function 
Pyridostigmine 
High-affinity choline 
transporter 
SLC5A7 <1% Impairs reuptake of choline from the synaptic 
cleft  
AChE inhibitors, 
Salbutamol 
Vesicular acetylcholine 
transporter  
SLC18A3 <1% Impairs uptake of ACh into presynaptic 
vesicles 
Pyridostigmine 
SLC25A1  SLC25A1 <1% Abnormal mitochondrial citrate carrier 
function.  
Pyridostigmine, 3,4 
DAP 
SNAP25 SNAP25* <1% Compromised quantal release at endplates 3,4 DAP  
Synaptobrevin-1  SYB1 (also known as 
VAMP1) 
<1% Reduction in EPP amplitude Pyridostigmine 
 
Synaptotagmin-2 SYT2* <1% Calcium sensors - Disruption of synaptic 
vesicle exocytosis  
3,4 DAP 
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Table 1.1. Congenital myasthenic syndromes. 3,4 DAP, 3,4-diaminopyridine; ACh, acetylcholine; AChE, acetylcholinesterase; AChR, acetylcholine 
receptor. Slow channel syndromes, SNAP25 and SYT2 mutations are acquired via autosomal dominant inheritance, *; All other syndromes are 
autosomal recessive. NB: Agrin is expressed neurally but acts postsynaptically.  
 
Type of 
CMS/Protein 
impaired 
Genes % of CMS attributed to 
pathogenic variant in this 
gene 
Molecular Pathology Treatment 
PROTEINS AT MULTIPLE SITES 
Glycosylation 
deficiency  
DPAGT1 
GFPT1 
ALG2  
ALG14  
GMPPB 
<1% 
2% 
<1%  
<1% 
<1% 
Abnormal glycosylation of synaptic 
components   
Pyridostigmine, 
Pyridostigmine & 
Salbutamol 
(GMPPB) 
PREPL  PREPL <1% Reduced ACh content within vesicles Pyridostigmine 
COL13A1 COL13A1 <1% Abnormal formation and maintenance of the 
NMJ 
3,4 DAP 
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1.3 The neuromuscular junction  
In order to identify the pathological mechanisms underlying CMS, it is important to 
understand how the NMJ functions in healthy individuals. The two main processes 
associated with normal NMJ function involves proteins and signalling events 
responsible for (i) neurotransmission; (ii) formation and maintenance of the NMJ. Here 
we describe the functional significance of the proteins that are implicated in CMS.  
 
1.3.1 The acetylcholine receptor system and neurotransmission   
The neuromuscular junction is highly specialised to enable synaptic transmission 
through the activation of AChRs on the postsynaptic membrane. When an action 
potential reaches the presynaptic nerve terminal, voltage gated Ca2+ channels are opened 
causing an increase in intracellular Ca2+ levels. This is detected by the Ca2+ sensor, 
synaptotagmin-2 which subsequently results in trafficking of neurotransmitter filled 
vesicles to the presynaptic membrane. Vesicle fusion to the membrane is facilitated by 
soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) 
proteins, including synaptobrevin-1 attached to synaptic vesicles, and synaptosomal-
associated protein 25 (SNAP25) which are anchored in the presynaptic membrane 
(Mohrmann et al., 2013; Sudhof, 2013; Shen et al., 2014; Salpietro et al., 2017; Shen et 
al., 2017). Once fused, acetylcholine (ACh) is released from motor neurons into the 
synaptic cleft where it binds to postsynaptic AChRs. The AChR ion channel opens, 
allowing a flow of cations through the central pore which depolarises the muscle 
membrane and generates an endplate potential (EPP). If the EPP reaches threshold, 
voltage gated- Na+ channels (Nav1.4) along the membrane open to produce an action 
potential resulting in Ca2+ release from the sarcoplasmic reticulum (SR) into the cytosol 
which ultimately induces muscle contraction (Ferraro et al., 2012). 
After dissociation from the AChR, ACh molecules are hydrolysed by 
acetylcholinesterase (AChE) which comprises a collagenic-tail (COLQ). Choline is 
transported back into the nerve terminal by a high-affinity choline uptake transporter. 
ACh is resynthesized from choline and acetyl coenzyme A by choline acetyltransferase 
(ChAT), and is packaged into synaptic vesicles via the vesicular acetylcholine 
transporter (VAChT), (Figure 1.1). 
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Figure 1.1 Schematic of the acetylcholine receptor system and neurotransmission. 
Key proteins directly involved in neurotransmission are shown. ACh synthesis is 
catalysed by ChAT. ACh are packaged into synaptic vesicles via VAChT. 
Neurotransmitter filled vesicles are transported to the presynaptic membrane and 
released into the synaptic cleft by SNARE proteins (synaptotagmin-2, synaptobrevin-1 
and SNAP25). ACh binds to AChRs to depolarise the muscle membrane. Subsequently 
Nav1.4 channels along the membrane open to produce an action potential. AChE 
hydrolyses ACh, and the resulting choline molecules are transported back into the 
presynaptic terminal for recycling via the high affinity choline transporter. Genes 
encoding proteins implicated in CMS are shown (red). CHRN* represents genes 
encoding all the AChR subunits (CHRNA, CHRNB, CHRND, CHRNE).  
8 
 
 
1.3.2 Proteins involved in the development and maintenance of the NMJ 
Presynaptic and postsynaptic differentiation of the NMJ involves various proteins that 
participate in a series of signalling cascades. MuSK is a key molecule located on the 
postsynaptic muscle membrane. It is an important organiser that acts as a scaffold 
protein and plays a central role in co-ordinating the formation of the NMJ through its 
binding partners (Zong and Jin, 2013). Activation of MuSK mediates postsynaptic 
differentiation and aggregation of AChR on the postsynaptic membrane (Okada et al., 
2006; Chevessier et al., 2008). One mechanism by which MuSK is activated is through 
the binding of neurally secreted agrin to low-density lipoprotein-related protein receptor 
4 (LRP4) (Maselli et al., 2010; Choi et al., 2013). Formation of the agrin-LRP4-MuSK 
complex stimulates tyrosine phosphorylation of MuSK. This complex is essential for 
mediating the downstream signalling cascade required for AChR clustering (Zong and 
Jin, 2013). Once phosphorylated, MuSK recruits docking-protein 7 (Dok-7), a 
cytoplasmic adaptor protein selectively expressed in muscle. Dok-7 further stimulates 
MuSK kinase activity through phosphorylation (Maselli et al., 2010). Together, this 
stimulates rapsyn which is also a scaffolding protein at the NMJ. Activation of rapsyn 
results in the reorganisation of the cytoskeleton and anchoring of AChR on the muscle 
membrane (Ohkawara et al., 2014), (Figure 1.2). 
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Figure 1.2 Key molecules involved in the development and maintenance of the 
NMJ. AChRs are recruited and anchored to the muscle membrane through a series of 
presynaptic and postsynaptic protein interactions involving agrin, LRP4, MuSK, Dok-7 
and rapsyn. Genes encoding proteins directly involved in AChR clustering are shown 
(black). Additional genes encoding proteins that are implicated in CMS are shown (red).  
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1.4. The safety margin of neurotransmission is compromised in CMS 
Neurotransmission is a highly reliable process whereby an excess of neurotransmitters 
is released into the synaptic cleft, which is more than the amount required to initiate an 
action potential. Even during prolonged high-frequency activation of muscles, 
transmission does not fail due to the substantial number of neurotransmitters available. 
This has given rise to the idea of a ‘safety margin’ at the NMJ. The safety margin of the 
NMJ is described as the factors that maintain the efficacy of chemical synapses. In 
CMS, the safety margin of neurotransmission is compromised by one or more 
mechanisms. Factors affecting the ability to propagate an action potential are grouped 
into the following categories: (i) compromised number of ACh molecules available per 
synaptic vesicle which arises due to impaired synthesis, hydrolysis and packaging of 
ACh into vesicles, and the reuptake of choline; (ii) impaired quantal release of ACh due 
to impairment in trafficking, vesicle docking and fusion to the membrane; (iii) factors 
affecting the efficacy of quanta released such as the rate of ACh hydrolysis in the 
synaptic space, AChR affinity for ACh, and the density, kinetic properties and 
localization of AChRs and Nav1.4 ion channels. These factors ultimately compromise 
the amplitude of the EPP and formation of an action potential (Wood and Slater, 2001; 
Engel and Sine, 2005; Slater, 2008; Engel, 2012).  
The safety margin may also be compromised by structural changes in presynaptic or 
postsynaptic components of the NMJ. The number of neurotransmitters released is 
relative to the size of the motor nerve terminal, therefore abnormally smaller nerve 
terminals may impair quantal release. Postsynaptic junctional folds harbour a high 
density of Na+ channels in the troughs of the folds and increase the series resistance of 
the postsynaptic membrane, which are both important for membrane depolarisation. 
Another possibility is an increased chance of acetylcholine escaping the synaptic cleft 
before it reaches the postsynaptic membrane. Simplification of the folds may therefore 
be a major contributor to impaired neurotransmission (Wood and Slater, 2001).  
 
1.4.1 Pathology of the acetylcholine receptor system 
The most common type of CMS arises due to defects in the nictonic AChR itself, which 
accounts for approximately 60% of all CMS cases (Hantai et al., 2013). The adult 
AChR is a pentameric structure composed of alpha (α), beta (β), delta (δ), and epsilon 
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(ε) subunits in a 2:1:1:1 ratio. The fetal form of AChR contains a gamma (γ) subunit in 
place of the ε subunit. This structure permits binding of two ACh molecules to the 
AChR ion channel. The correct configuration of AChR is important for 
neurotransmission. Mutations in individual subunits can result in reduced expression of 
the AChR or impair the kinetic properties of the channel, giving rise to fast and slow 
channel CMS. Dominantly inherited slow channel syndromes occur because of 
prolonged opening of the AChR ion channel. This is in contrast to the recessively 
inherited fast channel syndromes, which occur due to premature closure of the AChR 
channel (Webster et al., 2013). Each AChR subunit is also subject to post-translational 
modifications including glycosylation. Defective glycosylation of AChR subunits 
impair the assembly, structure, and function of AChRs on the postsynaptic membrane 
(Ramanathan and Hall, 1999). Mutations in the CHRNG gene encoding the fetal γ 
subunit of the ACh gives rise to the fetal myasthenic disease, Escobar syndrome. This 
disease is believed to affect neuromuscular organogenesis, with no pathogenicity later in 
life since γ expression is restricted to early development (Hoffmann et al., 2006).  
CMS also arise due to defects in the processes involved in the synthesis and hydrolysis 
of ACh. Mutations in SLC5A7 encoding the high affinity choline transporter impairs 
reuptake of choline into the presynaptic nerve terminal (Bauche et al., 2016), and 
mutations in SLC18A3 encoding the vesicular ACh transporter impairs uptake of ACh 
into synaptic vesicle (O’Grady et al., 2016; Aran et al., 2017). The synthesis of ACh is 
impaired as a result of CHAT mutations (Brandon et al., 2003; Dilena et al., 2014), and 
mutations in COLQ, (the gene encoding the collagenic-tail subunit that binds AChE) 
resulting in endplate AChE deficiency (Sigoillot et al., 2016). Consequently, 
hydrolysis of ACh is disrupted (Guven et al., 2012; Wargon et al., 2012).  
More recently, genes encoding proteins required for mediating exocytosis have been 
identified as pathogenic in CMS. Mutations in SYT2, the gene encoding   
synaptotagmin-2, impairs trafficking of neurotransmitter filled vesicles to the 
presynaptic membrane (Herrmann et al., 2014; Whittaker et al., 2015). Docking and 
fusion of vesicles to the presynaptic membrane is compromised by mutations in 
SNAP25 (Mohrmann et al., 2013) and SBY1 (Shen et al., 2017) that express defective 
SNAP25 and synaptobrevin-1 proteins respectively. Defects in any of the processes 
described that lead to compromised quantal release and a reduction of EPP amplitude, 
ultimately leads to impaired neurotransmission.   
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Defective Nav1.4 channels on the muscle membrane directly affects the ability to 
propagate an action potential which demonstrates that the safety margin for 
neuromuscular transmission can be compromised despite have a normal EPP (Tsujino et 
al., 2003). 
 
1.4.2 Impaired development and maintenance of the NMJ 
Efficient neurotransmission can only occur upon the correct assembly and maintenance 
of the NMJ which is dependent on several signalling molecules and sequential 
communication between the presynaptic motor neuron and the postsynaptic muscle 
membrane (Witzemann et al., 2013; Zong and Jin, 2013). Neurotransmission is 
compromised in the absence of fully functional proteins encoded by AGRN, MUSK, 
LRP4, DOK7, and RAPSN (Gautam et al., 1996; Ioos et al., 2004; Okada et al., 2006; 
Chevessier et al., 2008; Huze et al., 2009;). Ultimately, defective proteins involved in 
this signalling complex affect the clustering properties of AChR on the postsynaptic 
membrane.       
 
1.4.3 Mutations in CMS-causing genes with indirect functions 
Several proteins have been identified as causative genes in CMS other than those having 
a direct effect on the development and maintenance of the NMJ and neurotransmission. 
Some of these proteins are known to affect NMJ morphology, which subsequently 
affects neurotransmission. Other proteins are required to yield precursors, or undergo 
protein interactions upstream or downstream of NMJ formation and synaptic 
transmission.  
Mutations in genes encoding plectin, laminin beta-2, COL13A, and MYO9A induce 
morphological changes to the NMJ. A deficiency in plectin results in a lack of 
cytoskeletal support of the junctional folds at the NMJ. Simplified junctional folds 
affect the density of Nav1.4 channels concentrated in troughs between the folds, thus 
increasing the threshold for the generation of an action potential (Selcen et al., 2011). 
Laminin beta-2 deficiency also induces simplification of synaptic folds as well as 
hypoplastic nerve terminals. Together these morphological changes impair EPP quantal 
content and efficacy (Maselli et al., 2009).  
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A deficiency in COL13A results in impaired maturation and maintenance of the 
synaptic structure, whereby AChR clustering and co-localisation of the nerve terminal 
and postsynaptic AChR is compromised, and overshooting of the presynaptic nerve 
terminal is observed (Logan et al., 2015). Mutations in MYO9A lead to impairment of 
neuronal morphology and function through the regulation of Rho activity in neurons 
(O'Connor et al., 2016). Mutations in SLC25A1 results in abnormal mitochondrial 
citrate carrier function, and abnormal nerve outgrowth and synapse formation is 
observed (Chaouch et al., 2014). Defects in the geometry of both presynaptic and 
postsynaptic structures reduces the surface contact at the NMJ which ultimately impairs 
neurotransmission.   
The safety factor of neurotransmission is also compromised by mutations in PREPL. 
PREPL is an essential activator of the clathrin associated adaptor protein 1 (AP1). AP1 
facilitates packaging of ACh molecules into synaptic vesicles. Impaired PREPL 
function results in decreased vesicular content of ACh (Régal et al., 2014; Engel et al., 
2015).  
 
1.4.4 The role of glycosylation defects in CMS  
Whilst mutations in proteins active at the NMJ are known to be pathogenic in CMS, 
recent genetic analysis has also led to the implication of genes involved in the 
glycosylation of these proteins. Protein glycosylation is important for protein folding, 
secretion, solubility, stability and ability to bind to other proteins (Ramanathan and 
Hall, 1999; Martin, 2003). To date, 5 CMS-causing glycosylation genes have been 
discovered, GFPT1 (Senderek et al., 2011), DPAGT1 (Belaya et al., 2012), ALG2 and 
ALG14 (Cossins et al., 2013), and GMPPB (Belaya et al., 2015). GFPT1 encodes an 
enzyme that catalyses the rate-limiting step of the hexosamine pathway (Figure 1.5). 
DPAGT1, ALG2 and ALG14 encode the early components of the N-linked glycosylation 
pathway (Bretthauer, 2009; Basiri et al., 2013; Cossins et al., 2013). GMMPB catalyses 
the synthesis of GDP-mannose which is a precursor for N- and O-linked glycosylation 
(Belaya et al., 2015).   
All 5 glycosylation genes identified are ubiquitous and potentially modify hundreds of 
proteins in other biological process in addition to NMJ proteins. DPAGT1 (Wu et al., 
2003; Carrera et al., 2012; Wurde et al., 2012), ALG2 (Thiel et al., 2003) and GMPPB 
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(Carss et al., 2013) have previously been associated with congenital disorders of 
glycosylation (CDG). CDG encompass an array of phenotypically diverse disorders 
affecting multiple systems including the central nervous system, muscle function, 
transport of molecules, the immune and endocrine systems, and coagulation (Leroy, 
2006; Scott et al., 2014). It is therefore surprising why mutations in CMS-causing genes 
predominantly affect the NMJ with little or no involvement of multiple organ systems.  
 
1.5 Glycosylation 
Glycosylation is a post-translational modification which occurs in numerous 
biosynthetic pathways and is essential for obtaining functional lipids and proteins 
(Parkinson et al., 2013; Freeze et al., 2014). The attachment of glycans (sugar residues) 
to a protein through enzymatic glycosylation is essential to produce functional proteins 
(Parkinson et al., 2013; Zoltowska et al., 2013). Two major protein glycosylation 
pathways are the N- and O-glycosylation pathways (Spiro, 2002).   
 
1.5.1 N- and O- linked glycosylation pathways  
N-glycosylation is the most prevalent type of post-translational modification where 
glycans attach onto an amide nitrogen on an asparagine residue of the protein being 
modified. The N-acetylglucosamine (GlcNAc) glycan linkage is the most common type 
of N-glycosylation (Parkinson et al., 2013). O-linked carbohydrate attachments to 
proteins involve a linkage between a monosaccharide and amino acids serine or 
threonine. There are many different classes of O-linked glycosylation that differ based 
on the monosaccharide involved in the linkage. Examples of O-linked glycans include 
O-GalNAc, O-fucose, O-glucose, O-mannose and O-GlcNAc. In this study we are 
interested in the O-GlcNAc modification whereby proteins are modified by the 
attachment of GlcNAc in an O-glycosidic linkage to serine or threonine residues (Figure 
1.3).
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Figure 1.3. Examples of protein-glycan linkages in N- and O-linked glycosylation. 
The difference between the two types of glycosylation is where the oligosaccharide is 
attached to the protein. In N-linked glycosylation the glycan is attached through a 
nitrogen atom (NH) at the asparagine or arginine residues on the protein. In O-
linked glycosylation the glycan is attached through an oxygen on a hydroxyl group 
(OH) to a serine or threonine residue. This image was adapted from (Lodish et al., 
2000). 
 
The biosynthesis of N-linked glycans occurs via 3 major steps. The first step is the 
synthesis of a dolichol-linked precursor oligosaccharide. This process occurs whereby 
dolichol phosphate (Dol-P) located on the cytoplasmic face of the endoplasmic 
reticulum (ER) membrane receives GlcNAc-1-P from the nucleotide sugar donor 
Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to generate dolichol 
pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc). This reaction is catalysed by 
Dolichyl-Phosphate N-Acetylglucosaminephosphotransferase 1 enzyme encoded by 
DPAGT1.   
The second step involves the addition of glucose and mannose sugar molecules in a 
step-wise manner. The addition of each sugar is catalysed by specific glycotransferases. 
ALG2 and ALG14 encode glycotransferase enzymes required for extension of the 
glycan.   
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During assembly, the oligosaccharide is transported to the luminal side of the ER where 
further sugar residues are added. Once formation of the oligosaccharide is completed, 
the glycan is transferred from the dolichol to a nascent protein. The final step is 
remodelling of the protein bound N-glycan in the ER and Golgi through the addition 
and removal of sugar residues to produce different glycoforms (Figure 1.4), (Stanley et 
al., 2009; Aebi, 2013).  
O-linked glycosylation is a more diverse and complex process which involves the 
attachment of a single monosaccharide to a hydroxyl group on serine or threonine 
residues on the newly synthesised protein. The O-GlcNAc modification is a highly 
dynamic process that takes place within the nuclear and cytoplasmic compartments of a 
cell. This reaction utilises the UDP-GlcNAc precursor and is catalysed by O-GlcNAc 
transferase (OGT) (Hanover et al., 2010). The GlcNAc is generally not extended by 
sugar residues to form more complex structures. Instead, it is attached and removed 
several times at the same or different O-linked sites on a polypeptide, mimicking 
phosphorylation of proteins rather than the extension of sugars observed in the typical 
protein glycosylation system (Yang et al., 2007). This process is commonly referred to 
as O-GlcNAcylation (Hart and Akimoto, 2009).  
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Figure 1.4. Schematic showing the N-glycosylation and O-mannosylation 
pathways. N-glycosylation begins with the addition of UDP-GlcNAc to a dolichol 
anchor. Subsequent steps involve the addition of sugar residues in the cytoplasm and 
ER. Once assembled, the oligosaccharide is transferred to an N-linked site on a nascent 
protein. O-mannosylation involves the transfer of a mannose sugar to an O-linked site 
on a nascent protein. All 5 glycosylation enzymes associated with CMS are shown 
(red). This image was adapted from (Belaya et al., 2015). 
 
1.5.2 Essential precursors for N- linked glycosylation, O-GlcNAcylation, and O-
mannosylation  
The first step of the N-linked glycosylation and O-GlcNAcylation pathways require 
UDP-GlcNAc which acts as a nucleotide sugar donor. This activated precursor is 
produced by a series of enzymatic reactions in the hexosamine biosynthesis pathway 
(Freeze et al., 2014). The GFPT1 enzyme catalyses the first rate-limiting step of these 
reactions which ultimately yields UDP-GlcNAc (Figure 1.5).  
 
 
 
18 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. The hexosamine biosynthetic pathway. GFPT1 catalyses the conversion 
of fructose-6-phosphate and glutamine to glucosamine-6-phosphate and glutamate. 
Subsequent steps yield UDP-GlcNAc, an important precursor required for N- and O- 
linked glycosylation of proteins. This figure was adapted from (Zoltowska et al., 2013).  
  
Subsequent steps involving the extension of glycans in the N-glycosylation pathway 
require GDP-mannose precursor molecules. GDP-mannose is also the substrate of 
cytosolic mannosyltransferases required for the first step in O-mannosylation of 
proteins (Figure 1.4) (Carss et al., 2013; Belaya et al., 2015; Rodriguez Cruz et al., 
2016). GMPPB catalyses the synthesis of GDP-mannose from GTP and mannose-1-
phosphate. Mutations in GMPPB have also been implicated in CMS (Belaya et al., 
2015). 
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1.5.3 NMJ proteins that undergo glycosylation 
Several presynaptic, synaptic and postsynaptic NMJ proteins are known to harbour N-
linked glycosylation sites (Table 1.2). These proteins use UDP-GlcNAc as the initial 
precursor for N-linked glycosylation. Importantly, some proteins mentioned here also 
undergo O-linked glycosylation, but are processed in pathways which require sugar 
nucleotide donors other than GlcNAc. Mutations in these proteins have previously been 
implicated in CMS (Herbst et al., 2009; Senderek et al., 2011; Zoltowska et al., 2013).  
Protein Gene 
PRESYNAPTIC 
Agrin AGRN 
High-affinity choline transporter SLC5A7 
Vesicular acetylcholine transporter  SLC18A3 
Synaptotagmin-2 SYT2 
SYNAPTIC 
Collagen-like tail of AChE  COLQ 
Laminin beta-2 LAMB2 
POSTSYNAPTIC 
MuSK MUSK 
LRP4  LRP4  
Nav1.4 - voltage-gated sodium channel SCN4A 
AChR (α, β, δ, ε, fetal γ) subunits CHRN* 
MULTIPLE SITES 
Dolichyl-Phosphate N-
Acetylglucosaminephosphotransferase 1 
DPAGT1 
 
Table 1.2. NMJ proteins with known N-linked glycosylation sites. Mutations in these 
proteins have previously been implicated in CMS, (* represents any AChR subunit). 
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1.6 Mutations in GFPT1 cause CMS 
 
1.6.1 Biology of the GFPT1 protein  
The GFPT1 gene is located on chromosome 2p13.3 and comprises 19 exons, plus an 
additional alternative exon 8a. Splicing of GFPT1 gives rise to two variants, the 
ubiquitous GFPT1 isoform and GFPT1-L. The latter is a long muscle-specific isoform 
expressed predominantly in skeletal muscle and the heart. This isoform contains a 54-bp 
(18 amino acid) insertion (exon 8a) in the coding sequence of GFPT1, at the position 
229 in human GFPT1. Missense mutations in GFPT1 have been found outside of the 
muscle-specific exon, yet impaired function seems to be restricted to the muscle, and in 
particular the NMJ (Zoltowska et al., 2013). Since protein glycosylation is an essential 
process for cell survival, it is believed that mutations in GFPT1 may generate 
hypomorphic alleles. A total of 31 GFPT1 pathogenic variants have been identified 
which comprise missense, frameshifts, nonsense and one variant in the 3’-UTR (Figure 
1.6). No individual with CMS that harbour 2 null variants have been identified (Abicht 
et al., 2016). These variants lead to reduced expression of the GFPT1 protein. Only one 
patient has been identified who harbours a nonsense mutation in the ubiquitous GFPT1 
isoform and a second mutation that disrupts the muscle-specific exon, leading to a 
complete loss of glycoprotein expression in muscle (Senderek et al., 2011; Selcen et al., 
2013).  
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Figure 1.6. Schematic representation of the GFPT1 exon and protein structure. (A) 
GFPT1 exon structure with 3 domains. The muscle-specific exon is shown in red. 
Predicted peptides of mutant transcripts from a patient with a nonsense mutation in the 
ubiquitous GFPT1 isoform, and a nonsense mutation in the muscle-specific GFPT1 
isoform are shown. (B) The localization of the missense and truncation mutations 
identified in GFPT1-CMS patients are shown. A single mutation was identified in the 
muscle specific exon (red). GATase_2, glutamine amidotransferase type 2 domain; 
SIS1, sugar isomerase domain-1, SIS-2, sugar isomerase domain-2. This image was 
adapted from (Zoltowska et al., 2013).  
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1.6.2 Clinical presentation of patients with mutations in GFPT1 
Patients with mutations in GFPT1 usually display a limb-girdle pattern of weakness that 
may present as early as infancy through to adulthood. The limb-girdle phenotype is 
characterised by weakness of the proximal limb muscles including the shoulders and 
pelvis. The weakness is slowly progressive, but the rate of progression varies between 
patients. These patients also demonstrate sparing of the ocular, facial and bulbar 
muscles (Guergueltcheva et al., 2012; Huh et al., 2012; Selcen et al., 2013). 
Studies have shown that some patients display a decremental response to 
electromyography (EMG) (Selcen et al., 2013; Maselli et al., 2014) and repetitive nerve 
stimulation (Guergueltcheva et al., 2012; Huh et al., 2012). Patients display endplates 
with a simplification of the postsynaptic membrane with fewer poorly developed 
junctional folds and the presence of tubular aggregates of the SR in muscle biopsies 
(Huh et al., 2012; Selcen et al., 2013; Maselli et al., 2014). These individuals 
demonstrate an improvement in symptoms in response to cholinesterase inhibitors and 
3,4-diaminopyridine (3,4-DAP) (Nicole et al., 2014). More recently magnetic resonance 
imaging (MRI) studies have detected fatty infiltration of muscles in GFPT1-CMS 
patients, indicative of progressive muscle damage (Finlayson et al., 2016).    
Until now there has only been one report of a mutation which disrupts the GFPT1-L 
isoform resulting in the absence of glycosylated proteins. A muscle biopsy from this 
patient demonstrates a vacuolar autophagic myopathy with abnormal variation of 
myofibre size, sparse regenerating and necrotic muscle fibres and densely packed 
membranous tubular aggregates (Selcen et al., 2013). A molecular link between the 
presence of tubular aggregates and NMJ remains to be established.    
Notably, patients with GFPT1-related CMS share many phenotypic and morphological 
characteristics to patients with mutations in other glycosylation enzymes implicated in 
CMS. Patients with mutations in DPAGT1 also demonstrate a limb-girdle pattern of 
weakness, tubular aggregates in muscle biopsies and a prominent fatty infiltration of 
muscles revealed by MRI imaging (Belaya et al., 2012; Basiri et al., 2013; Carss et al., 
2013; Belaya et al., 2015; Finlayson et al., 2016).  
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1.7 Diagnosis and treatment of CMS 
 
1.7.1 Diagnosis of CMS  
Indications for CMS at initial presentation are based on a clinical examination and 
family history of fatigable weakness consistent with the patterns of autosomal dominant 
or recessive inheritance. Electrophysiological testing using a decremental EMG 
response of the compound muscle action potential (CMAP) is also a good indicator of 
CMS. Differential diagnosis is based on the absence of AChRs and anti-MuSK auto-
antibodies in serum, and failure to respond to immunosuppressive therapy as a test to 
rule out myasthenia gravis. Furthermore, lack of major pathology in skeletal muscle 
biopsies can help distinguish CMS from other neuromuscular diseases (Abicht et al., 
2012).  
Pharmacological intervention greatly depends on our understanding of the mechanisms 
underlying the different subtypes of CMS. Some drugs used to treat one subtype of 
CMS may worsen symptoms in a patient suffering from another subtype (Engel, 2007; 
Lorenzoni et al., 2012; Engel et al., 2015). The use of functional studies to enhance our 
understanding of the molecular mechanisms underlying a CMS subtype may prove 
useful when choosing a personalised treatment regime (Schara and Lochmüller, 2008; 
Barisic et al., 2011). 
Clinical manifestations amongst individuals harbouring the same genetic defect vary in 
terms of onset and course of disease which often hinders correct diagnosis. This is 
overcome by in vitro electrophysiological studies of the patient endplate and molecular 
genetic studies. A definitive genetic diagnosis is important for choosing treatment 
regimes, prognosis and genetic counselling (Engel, 2012). 
 
1.7.2 Treatment of CMS 
Common drugs used to alleviate CMS symptoms include AChE inhibitors, 3,4-DAP, 
fluoxetine, quinidine sulphate, salbutamol and ephedrine (Schara and Lochmüller, 
2008).  
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Pyridostigmine is an AChE inhibitor that has demonstrated positive effects in several 
different forms of CMS. AChE inhibitors prevent the hydrolysis of ACh in the synaptic 
cleft, prolonging ACh activity. Patients who suffer from CMS as a result of AChE 
deficiency should not be given AChE inhibitors as it may worsen muscle weakness and 
have harmful effects (Schara and Lochmüller, 2008). 3,4-DAP is a potassium channel 
blocker which acts on the presynaptic nerve terminal resulting in an increase in the 
quantal release of ACh into the she synaptic cleft. Again, it may be detrimental to 
administer 3,4-DAP to individuals with fast-channel CMS emphasising the importance 
of understanding the pathophysiology at the NMJ (Abicht et al., 2012). Both 
pyridostigmine and 3,4-DAP reduce myasthenic weakness by facilitating 
neurotransmission.  
Slow-channel CMS are often treated with quinidine sulphate and fluoxetine. Both drugs 
are AChR channel blockers which reduces the amount of time that the AChR pore 
remains open and may be harmful in the other forms of CMS (Engel, 2007).  
Orally administered salbutamol, a β2-adrenergic receptor agonist demonstrates 
improved muscle function in patients harbouring mutations in DOK-7 (Burke et al., 
2013). Ephedrine has also shown to exert positive effects in various forms of CMS. In 
vitro studies demonstrate its ability to increase quantal ACh release and reduce AChR 
opening time. However, this mechanism is yet to be seen in humans (Schara and 
Lochmüller, 2008). CMS drugs are frequently used in combinations to achieve optimal 
relief from symptoms.    
 
1.8 Functional models used to study CMS  
To date several experimental assays have been developed to help broaden our 
understanding of the molecular mechanisms responsible for the formation and 
maintenance of the NMJ. Whole exome sequencing has accelerated the rate at which 
new disease-causing genes are being discovered (Lyon and Wang, 2012). As more and 
more gene mutations are identified, we need to be able to investigate and understand the 
functions of NMJ proteins in order to choose the best possible treatment options for 
patients with CMS. Methods currently being used include observing structural and 
functional abnormalities in patient muscle biopsies and analysing changes in the level of 
protein expression (Belaya et al., 2012; Zoltowska et al., 2013). Functional assays 
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which have been developed include recombination expression studies, the use of 
siRNAs to knockdown gene function in cell culture and zebrafish, and in vitro 
electrophysiological tests to measure AChR activity (Senderek et al., 2011; Cossins et 
al., 2013; Zoltowska et al., 2013). Several in vivo mouse models have also been 
developed which have contributed to our understanding of major synaptic regulators at 
the NMJ which are implicated in CMS. These include models for studying the role 
MuSK (Chevessier et al., 2008; Messéant et al., 2015), AGRN (Bogdanik and Burgess, 
2011), DOK-7 (Okada et al., 2006), ChAT (Brandon et al., 2003), ColQ (Sigoillot et al., 
2016) and the AChR epsilon subunit at the NMJ (Chevessier et al., 2012; Webster et al., 
2013). As of yet, there are no mouse models for the 5 glycosylation genes found to be 
pathogenic in CMS.      
 
1.8.1 Functional studies that have contributed to understanding the role of GFPT1 at 
the NMJ  
Several experiments were conducted in attempt to deduce the molecular pathogenesis of 
GFPT1 in neurotransmission. There are several lines of evidence which suggest that 
GFPT1 has a direct effect on the number of AChR clusters expressed on the muscle 
membrane. The use of siRNA to silence GFPT1 and a chemical inhibitor to reduce the 
levels of GFPT1 in cell culture, have both demonstrated a reduction in AChR 
expression, consistent with AChR expression pattern in patient muscle biopsies 
(Zoltowska et al., 2013). Furthermore, treatment with tunicamycin, an N-glycosylation 
inhibitor was also found to reduce the levels of AChR expression in vitro (Merlie et al., 
1982; Belaya et al., 2012). Further investigation has shown that silencing GFPT1 results 
in a reduction in AChR α, δ, and ε subunits (Zoltowska et al., 2013). This observation is 
consistent with the idea that glycosylation is an essential process for the correct 
assembly and export of the AChR pentamer from the ER. The CMS phenotype was 
examined in zebrafish embryos using morpholino-mediated knockdown of gfpt1. 
Embryos show a delayed onset of NMJ maturation alongside aberrant motility and 
swimming behaviour (Senderek et al., 2011). Together these data reinforce the 
importance of GFPT1 in normal formation of the NMJ. 
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There is currently no knockout mouse model for studying the role of GFPT1 in muscle 
and NMJ structure and function. A Gfpt1 knockout mouse model will provide an 
invaluable tool for studying numerous pathological changes occurring because of 
glycosylation defects. 
 
1.9 The use of mouse models for studying CMS   
Mouse models serve as better tools for studying CMS related gene mutations than in 
vitro and zebrafish models due to the disparity between the latter and the patients. 
Morphological abnormalities in zebrafish can only be studied in the developmental 
phenotype as morpholino knockdowns that are currently available are only effective for 
4-5 days. This model therefore does not allow for long-term progression studies.  
There are many advantages of using mouse models over other model organisms. There 
is ~99% genetic homology between mice and humans (Waterston et al., 2002; 
Vandamme, 2014), whereas zebrafish display ~70% genetic homology to humans 
(Kerstin et al., 2013). Furthermore, the structural components and functional properties 
encompassing mouse muscle closely resembles that of human muscle. Knockout mice 
provide valuable information about the function of a gene and the pathways it is 
involved in. The development of transgenic mice has been greatly facilitated by 
advancements in technology that have made genetically modified mice widely 
available.  
In addition to the parameters measured in vitro, mouse models allow phenotype analysis 
and observation of general muscle pathology, examination of whole NMJ and testing 
for fatigue, which can be correlated to phenotypes seen in CMS patients. More 
importantly, they enable the assessment and development of therapeutic compounds.  
 
1.10 Strategies for generating knockout mouse models 
Advancements in mouse mutagenesis has made the mouse model a valuable tool for 
studying gene function. Numerous techniques have been developed to create knockin 
and knockout mouse models of human disease. Here we describe the gene targeting 
strategies used to modify Gfpt1 in the mouse genome for this study.     
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1.10.1 Gene targeting strategies 
In a germline knockout strain, the target gene is inactivated in all cells throughout 
development (Figure 1.7A). Often knockout mice homozygous for the null allele may 
result in embryonic or postnatal lethality due to unpredicted activity of that gene and 
whether it is essential for the viability of the mice. One method to overcome this 
problem is using a conditional knockout strategy which allows inactivation of the gene 
in specific cell types. In conditional knockout strains, the gene of interest is modified in 
the germline, but is only inactivated following intervention (Figure 1.7 B). A third 
strategy often used in an inducible-Cre transgenic mouse model. This model allows for 
spatial and temporal regulation of Cre-mediated recombination which can be activated 
by in vivo administration of tamoxifen (Figure 1.7C), (Friedel et al., 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Gene targeting strategies. (A) Germline inactivation of a gene results in 
inactivation of all cells. (B) Conditional mutants demonstrate knockout of a gene in 
targeted tissues only. (C) Selected cells are inactivated following administration of 
tamoxifen. Inactivation of genes are shown in grey. This image was adapted from 
(Friedel et al., 2011). 
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1.10.2 Site specific recombination using Cre/loxP technology  
One method of gene targeting is site-specific recombination widely used to carry out 
deletions, translocations and inversions at specific sites in DNA. This method relies on 
site-specific recombinases, Cre recombinase derived from bacteriophage P1 and 
flippase (FLP) recombinase derived from yeast which recombine DNA between 
identical loxP and FRT sites respectively. The 34 base pair recombinase target site 
sequence consists of an asymmetric 8bp sequenced flanked by 13bp palindromic 
sequences. The orientation of the loxP and FRT sites is important for determining the 
type of recombination (Nagy et al., 2000; Skarnes et al., 2011). The forthcoming 
chapters will further describe the Cre/loxP techniques used to generate a knockout 
mouse model in this study.  
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1.11 Statement of aims 
 
Chapter 3  
To generate a GFPT1 deficient mouse model using Cre/loxP technology. The efficiency 
and specificity of Cre activity will be assessed to verify GFPT1 deficiency.  
 
 
Chapter 4  
To observe the viability of homozygous and heterozygous Gfpt1tm1a and Gfpt1tm1b mice. 
Viable mouse models will be investigated to see whether they display phenotypical 
abnormalities. The Gfpt1tm1b allele will be used to track GFPT1 expression in mouse 
muscle using the lacZ-reporter. 
 
Chapter 5  
To further characterise the muscle-specific Gfpt1 knockout mouse model. The 
morphology of the synapse will be studied paying attention to the clustering properties 
of AChRs. This will be tested using immunohistochemical labelling of NMJs. Ultra-
structural analyses will be used to identify any abnormalities at the NMJ and in muscle. 
Functional tests will be used to assess muscle strength. Any failure of efficient assembly 
and maintenance of the structures at the synapse will be investigated. Proteomic studies 
will enhance our understanding of the pathophysiological changes in muscle because of 
GFPT1 deficiency.  
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Chapter 2. Material and methods 
 
2.1 Standard molecular biology techniques 
 
2.1.1 DNA extractions  
Ear clips and tail tips were digested in 0.5 mg/ml Proteinase K in DNA digestion buffer 
(Table 2.1) and incubated at 55˚C overnight. The next day 700 µl of 
phenol/chloroform/isoamyl alcohol was added and mixed vigorously. Samples were 
centrifuged at 14,000 rpm for 5 minutes. The supernatant was mixed with 100% ethanol 
and incubated at -80˚C for 2 hours. Samples were centrifuged at 14,000 rpm for 20 
minutes at 4˚C. Supernatants were discarded and pre-cooled 75% ethanol was added to 
each sample. Samples were centrifuged at 8,000 rpm for 5 minutes at 4˚C. Supernatants 
were discarded and pellets were suspended in TE buffer.   
 
DNA was extracted from muscle and heart tissues using a DNeasy Blood and Tissue kit 
(Qiagen). 25 mg of tissue was minced and transferred to a microcentrifuge tube. 
Samples were processed according to the manufacturer’s instructions.  
 
2.1.2 RNA extractions 
Tissues were homogenised with 1ml Trizol and incubated for 5 minutes at room 
temperature. Samples were then centrifuged at 12,000 g for 10 minutes at 4°C. The 
supernatant was mixed with 200 μl chloroform and samples were incubated for 3 
minutes at room temperature. Next, samples were centrifuged at 12,000 g for 15 
minutes at 4°C. The resulting upper aqueous phase was transferred to a fresh 
microcentrifuge tube and mixed with 500 μl of isopropanol. The samples were 
incubated for 10 minutes at room temperature and centrifuged at 12,000 g for 15 
minutes at 4°C. The supernatant was discarded. The remaining RNA pellet was washed 
with 500 μl 70% ethanol in DEPC-treated H2O and centrifuged at 12,000 g for 5 
minutes at 4 °C. The supernatant was discarded and the pellet was air dried. The pellet 
was resuspended in 30 μl DEPC-treated H2O.  
 
 
 
31 
 
 
2.1.3 Reverse transcription cDNA synthesis 
Reverse transcription was performed using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s guidelines.  
The reverse transcription master mix was prepared in a 10 μl reaction mixture listed 
below.  
 
 
 
 
 
 
 
 
10 μl of RNA was mixed with 10 μl of the reverse transcription master mix and the 
samples were placed in a thermocycler.   
The thermocycler was set to the following program:    
Step 1: 10 minutes at 25°C 
Step 2: 120 minutes at 37°C 
Step 3: 5 minutes at 85°C 
Step 4: ∞ at 4°C 
 
2.1.4 DNA and RNA measurement 
DNA and RNA concentrations were determined using a NanoDrop spectrophotometer 
(Thermo Scientific, NanoDrop 2000). 
 
 
 
 
 
 
 
 
 
 
 
Component Volume/Reaction  
10X RT Buffer 2.0 µl 
25X dNTP mix (100 mM) 0.8 µl 
10X RT Random Primers 2.0 µl 
MultiScribe™ Reverse Transcriptase 1.0 µl 
Nuclease-free H2O 4.2 µl 
Total per reaction 10 µl 
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2.1.5 Genotyping and RT-PCR 
Genotyping was performed by polymerase chain reaction (PCR) using genomic DNA 
isolated from ear punches and muscle tissue from adult mice, and tail tips from embryos 
and neonatal mice. RNA isolated from ear punches from adult mice was used for 
reverse transcription polymerase chain reaction (RT-PCR).  
 
2.1.6 Polymerase chain reaction 
PCR amplification was conducted using a thermal cycler (SensoQuest, Labcycler 48). 
Primers used are listed in Table 2.2, 2.3 and 2.4. The PCR reaction was prepared in a  
25 μl reaction mixture as listed below. 
 
Component  Volume (25 μl)  
dNTP mix 1 μl 
10x PCR Buffer 2.5 μl 
PCR Enhancer  2 μl 
Forward primer (10 µM) 1 μl 
Reverse primer (10 µM) 1 μl 
Template DNA (50 ng/μl) 1 μl 
Moltaq DNA polymerase 1 μl 
ddH2O 15.5 μl 
Total  25 μl 
 
 
PCR reactions were run using the following program: 
 
1. Initial denaturation: 94 °C for 5 minutes 
2. Denaturation: 94 °C for 30 seconds 
3. Annealing: 60 °C for 30 seconds 
4. Extension: 72 °C for 30 seconds 
5. Last extension: 72 °C for 5 minutes 
39 cycles for steps 2-4. Hold at 4 °C 
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2.1.7 Agarose gel electrophoresis  
0.8-2% agarose gels were prepared containing 1 x Tris-Acetate-EDTA (Table 2.1) and 
SafeView nucleic acid stain (NBS Biologicals). 5 µl of samples were mixed with 6x 
Blue/Orange loading dye (Promega) and loaded onto gels. Gels were run at 80V for 1 
hour. DNA was visualised under UV light using GelDoc-it 310 Imaging System (UVP). 
The size of the DNA fragments were measured relative to a 100 bp DNA ladder 
(Promega). 
 
2.1.8 DNA purification by gel extraction 
For the isolation and purification of a single DNA band, the desired product was 
visualised and excised under a UV transilluminator. The band was extracted and 
purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen) according to 
manufacturer’s instructions.  
 
2.1.9 DNA sequencing and alignments  
Sequencing was carried out by sequencing service MWG Biotech in Ebersberg, 
Germany. 15 μl of purified plasmid DNA at a concentration of 100 ng/μl was sent with 
15 μl of the appropriate primer at 5 pmol/μl. Sequence alignments were carried out 
using the online Basic Local Alignment Search Tool (BLAST).  
 
 
 
2.2 Immunofluorescence and histology  
 
2.2.1 Sample preparation 
Mice were euthanized via cervical dislocation. Tissues were dissected and mounted onto 
labelled cork disks. Tissues were covered in O.C.T compound and frozen by immersion 
in isopentane cooled on dry ice. Samples were stored at -80˚C until sectioning. 
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2.2.2 Cryosectioning tissues  
10 μm serial sections of frozen tissues were cut with a cryostat (Microm HM 560, Zeiss) 
and mounted on Superfrost Plus Slides (VWR). Slides were wrapped in cling film and 
stored at -80 °C.    
 
2.2.3 Immunofluorescence labelling of tissue sections 
Slides were thawed at room temperature and sections were circled with an ImmEdge 
Hydrophobic Barrier PAP Pen (Vector Laboratories). Sections were fixed in 4% PFA 
(Paraformaldehyde, Sigma) in 1x PBS (Phosphate Buffered Saline, Gibco) for 5 
minutes and permeabilised with 0.1% Triton X-100 (Sigma) in 1x PBS for 15 minutes. 
Sections were subsequently blocked with 4% BSA (Bovine Serum Albumin, Sigma) in 
1x PBS for 1 hour at room temperature. Sections were incubated with 50 μl primary 
antibody diluted in blocking medium (Table 2.1) at 4 °C overnight. The next day 
sections were incubated with a secondary antibody diluted in blocking medium for 1 
hour at room temperature. Sections were washed several times with 1x PBS between 
incubation periods. Sections were mounted in Vectashield mounting medium with 4,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories).   
 
2.2.4 Whole-mount staining of adult muscle 
Whole muscles were dissected and fixed in 1% PFA in 0.1 M phosphate buffer for 30 
minutes. They were then incubated with α-bungarotoxin, Alexa Fluor 594 conjugate 
(Life Technologies) in Liley’s solution (Table 2.1) for 1 hr, and washed thoroughly. 
Muscle fibres were teased into small bundles during washes. Muscles were 
permeabilised in ethanol followed by methanol (10 minutes at -20˚C each), followed by 
incubation in 0.1% Triton-X-100 in PBS for 15 minutes at room temperature. Tissues 
were washed thoroughly in PBS. Muscles were incubated with anti-neurofilament 
(1:200) and anti-synaptophysin (1:100) antibodies in PBS containing 3% BSA and     
0.1 M lysine (Sigma-Aldrich). The next day, muscles were washed thoroughly in PBS 
and incubated in goat anti-rabbit 488 (1:500) and goat anti-mouse 488 (1:500) 
secondary antibodies for 3 hours at room temperature. Bundles were washed in PBS 
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overnight. The next day they were mounted on slides with Vectashield mounting 
medium with DAPI (Vector Laboratories).  
 
2.2.5 In vivo visualization and measurement of AChR turnover rate 
Mice were administered an intramuscular injection of α-bungarotoxin 488 (green) in the 
tibialis anterior (TA) muscle. This was repeated using α-bungarotoxin 647 (red) 10 days 
later to label the old and new receptor pool respectively. Following the second 
administration, superficial TA muscles were examined immediately. Briefly, 3D stacks 
at 512 × 512 pixel resolution were taken of α-bungarotoxin 488 signals (“old 
receptors”) and of α-bungarotoxin 647 signals (“new receptors”) using a 63x objective 
and confocal in vivo imaging. The 3D stacks were automatically segmented using a 
custom-made algorithm, and pixel signal intensity values for each channel were 
extracted. The fraction of pixels per NMJ was calculated.  
 
2.2.6 Hematoxylin and eosin staining  
Frozen tissue sections were air-dried for 30 minutes and stained with Hematoxylin 
Harris (VWR) for 10 minutes. Slides were washed in running tap water for 1 minute, 
dipped in 1% HCl (Hydrochloric Acid, Fluka; diluted in 70% ethanol) for 5 seconds, 
and rinsed in tap water for 30 seconds. Slides were immersed in eosin for 30 seconds 
and rinsed in running tap water for 30 seconds. Slides were dipped in an ascending 
alcohol series of 70%, 90% and 100% ethanol for 5 seconds each and placed in 
Histoclear (National Diagnostics) twice for 2 minutes each. The slides were then 
mounted with DPX Mounting Medium (LAMB). 
 
 
2.2.7 β-galactosidase staining of whole mouse embryos  
Pregnant mice were sacrificed via cervical dislocation. The embryo sack was removed 
and immediately placed in cold PBS on ice. Embryos were separated from their 
extraembryonic membranes, washed twice with cold PBS and placed in fixing solution 
(Table 2.1) for 15 minutes at 4°C. Embryos were washed 3 times in wash buffer (Table 
2.1) at room temperature. Embryos were gently shaking during fixation and wash steps. 
36 
 
 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining solution (Table 
2.1) was prepared fresh, placed on ice for 10 minutes and the precipitate was spun down 
for 5 minutes. Embryos were incubated with X-gal staining solution between 4 hours to 
overnight at 37°C in the dark. Embryos were washed twice with wash buffer and fixed 
in 1% PFA overnight. The next day embryos were stored in fresh 1% PFA until 
imaging.  
 
 
2.2.8 β-galactosidase staining of adult mouse tissues 
Frozen tissue sections (10 µm) were air dried for 30 minutes and fixed in 1.5% 
gluteraldehyde in PBS pH 7.4 for 1 minute and washed briefly in pure H2O 3 times 
followed by PBS once. Sections were incubated overnight with X-gal staining solution 
(Table 2.1) at 37°C in a humidified chamber. Following the overnight incubation, 
sections were washed three times for 5 minutes each with PBS. Samples were mounted 
with DPX mounting medium.  
 
 
2.3 Electron microscopy 
 
2.3.1 Transmission electron microscopy 
Fresh tissue samples of intercostal muscles were fixed in 3.9 % buffered glutaraldehyde, 
osmicated in 1 % phosphate-buffered osmiumtetroxyde, dehydrated and embedded in 
epoxy resin. 1 μm semithin sections were stained with toluidine blue. Ultrathin sections 
(100 nm) of at least one transverse and one longitudinal block per animal were 
contrasted by uranyl acetate and lead citrate as previously described (Weis et al., 1995). 
Electron microscopy images were recorded using a CM10 transmission electron 
microscopy (Philips, Amsterdam, The Netherlands). 
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2.4 Protein extraction and western blotting    
 
2.4.1 Preparation of lysates 
Whole tissues were homogenised in 400 µl lysis buffer (Table 2.1) using a tissue raptor 
(Qiagen). The lysate was transferred to an eppendorf tube and spun at 700 g and 4 °C 
for 10 minutes. The supernatant was transferred into a clean eppendorf tube and spun 
down at 10,000 g for 30 minutes. The supernatant containing the cytosol fraction was 
collected. The resulting pellet containing membrane protein was lysed in 50 µl lysis 
buffer.  
 
 
2.4.2 Protein quantification 
Protein concentration was measured using the Qubit Fluorometer (Invitrogen by Life 
Sciences) according to the manufacturer’s recommendations.  
 
2.4.3 SDS-PAGE and western blotting   
25 µg of protein in a final volume of 20 µl was placed in an eppendorf tube. 7.5 µl 
NuPAGE LDS Sample Buffer 4x (Life Technologies) and 3 µl NuPAGE Reducing 
Agent 10x (Life Technologies) were added to the sample and denatured on a heat block 
at 95 °C for 5 minutes. 10 µl Chameleon Duo Ladder (Licor) and the total volume of 
samples (30 µl) were loaded on Novex NuPAGE 4-12% Bis-Tris Gels (Life 
Technologies), and the tank (Life Technologies, Novex Mini-Cell) was filled with 
MOPS running buffer. The gel was run at 200 V for 45 minutes. Proteins were 
transferred onto a PVDF membranes (Licor) in a transfer tank (Mini Trans-Blot 
Electrophoresis Transfer Cell, BIO-RAD). The chamber was filled with chilled 1x 
transfer buffer (Table 2.1) and surrounded by ice at 350 mA for 1.5 hours. Following 
transfer, the membrane was soaked in methanol for 1 minute then rinsed in ultra-pure 
water. The membrane was blocked in 1x TBS (Table 2.1) followed by an incubation in 
TBS blocking buffer (Licor) on a shaker for 1 hour. The membrane was incubated with 
primary antibodies diluted in TBS blocking buffer overnight. The next day primary 
antibodies were drained off and the membrane was rinsed three times in 1x TBS-T 
(Table 2.1) for 5 minutes each. The membrane was incubated with secondary antibodies 
diluted in TBS blocking buffer containing 0.2% tween and 0.01% SDS, at room 
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temperature on a shaker for 1 hour in the dark. Membranes were washed with TBS-T 3 
times for 5 minutes each, followed by a rinse in TBS. Protein bands were detected with 
an Odyssey Family Imaging System (Licor Biosicences). 
 
A list of primary antibodies and dilutions used for these experiments are shown in 
Table 2.5.  
 
2.5 Proteomic profiling experiments  
 
2.5.1 Cell lysis, sample preparation and trypsin digestion 
Approximately 5 mg of muscle tissue was lysed in 500 µl lysis buffer (Table 2.1) using 
a manual glass grinder, and samples were centrifuged for 5 minutes at 4°C and 5000 g. 
Protein concentration of the supernatant was determined using a BCA assay (Thermo 
Fisher Scientific, Dreieich, Germany) (according to the manufacturer’s protocol). 
Cysteines were reduced by addition of 10 mM dithiothreitol (Roche Diagnostics) and 
subsequent incubation at 56°C for 30 minutes. Free thiol groups were alkylated with   
30 mM iodoacetamide (Sigma Aldrich) at room temperature in the dark for 30 minutes. 
Sample preparation were performed using filter-aided sample preparation (FASP) 
(Wisniewski et al., 2009) with some minor changes. Briefly, 100 µg of protein lysate 
was diluted 10-fold with freshly prepared buffer composed of 8 M urea (Sigma Adrich) 
and 100 mM Tris-HCl (pH 8.5) (Kollipara and Zahedi, 2013) and placed on a Microcon 
centrifugal device (30 kDa cut off). The filter was centrifuged at 13,500 g at room 
temperature for 15 minutes (all the following centrifugation steps were performed under 
the same conditions). Three washing steps were carried out with 100 µl of 8 M urea/ 
100 mM Tris-HCl (pH 8.5). For buffer exchange, the device was washed three times 
with 100 µl of 50 mM NH4HCO3 (pH 7.8). 100 µl of digestion buffer (Table 2.1) was 
added to the concentrated proteins and the samples were incubated at 37°C for 14 hours. 
Resulting tryptic peptides were recovered by centrifugation with 50 µl NH4HCO3 (50 
mM) followed by 50 µl of ultra-pure water. Finally, acidification of the peptides was 
achieved by addition of 10% trifluoroacetic acid (Biosolve, Valkenswaard, The 
Netherlands(v/v)). The digests were quality controlled as described previously 
(Burkhart et al., 2012).  
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2.5.2 LC-MS/MS analysis 
Samples were measured using an Ultimate 3000 nano RSLC system coupled to an 
Orbitrap Fusion Lumos mass spectrometer (both Thermo Scientific) and analyzed in a 
randomized order to minimize systematic errors. Briefly, peptides were pre-
concentrated on a 100 µm x 2 cm C18 trapping column for 10 minutes using 0.1 % 
trifluoroacetic acid (v/v) at a flow rate of 20 µl/min followed by separation on a 75 µm 
x 50 cm C18 main column (both Pepmap, Thermo Scientific) with a 120 minutes LC 
gradient ranging from 3-35 % of 84 % acetonitrile (Biosolve, Valkenswaard, 
Netherlands), 0.1 % formic acid (Biosolve, Valkenswaard, Netherlands (v/v) at a flow 
rate of 230 nl/min. MS survey scans were acquired in the Orbitrap from 300 to 1500 
m/z at a resolution of 120000 using the polysiloxane ion at m/z 445.12003 as lock mass 
(Olsen et al., 2005), an automatic gain control target value of 2.0x105 and maximum 
injection times of 50 ms. Top speed most intense signals were selected for 
fragmentation by HCD with a collision energy of 30 % and MS/MS spectra were 
acquired in the Orbitrap using a target value of 2.0x103 ions, a maximum injection time 
of 300 ms and a dynamic exclusion of 15 s.   
 
 
2.6 Microscopy and image analysis  
 
2.6.1 Microscopy  
Whole-mount immunofluorescent samples were visualised using a Nikon A1R laser 
inverted scanning confocal microscope. Z-stack images were acquired and processed 
using NIS-elements AR 4.20.02 software. Images of histological sections were captured 
using a Zeiss Axioplan brightfield imaging microscope and AxioVision software. 
Embryos were imaged using a Zeiss stereomicroscope and AxioVision software.     
 
2.6.2 Image analysis 
Image analysis software ImageJ was used for the following: (i) quantification of AChR 
cluster area, (ii) quantification of muscle fibre cross-sectional area, (iii) to measure the 
relative expression levels of proteins in immunoblots using the gel analysis tool.  
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2.7 Statistical analysis 
Statistical analyses were performed with IBM SPSS Statistics 22.0 software. Data were 
analysed using a two-sample t-test. An independent sample Mann–Whitney U test was 
performed to compare myofibre size variation. Proteomic data were analysed using 
analysis of variance (ANOVA) (Progenesis Stats). p<0.05 was considered statistically 
significant. 
 
 
2.8 Transgenic mouse models 
 
2.8.1 Animal care and husbandry 
Mice used for this study were bred in the animal facility at the Functional Genomics 
Unit, Newcastle University, Institute of Genetic Medicine (Table 2.6). Breeders were 
housed as pairs of one male and one female, or trios of one male and two females. 
Offspring were housed together in groups of 2-6. All procedures were approved by the 
Home Office and were carried out under Animals Scientific Procedures Act of 1986 
under project licence PPL70/8538, and personal licence PIL I1D9CFB05. AChR 
turnover experiments were approved by German authorities and were conducted 
according to national law (TierSchG7).  
  
 
2.9 In vivo experiments 
 
2.9.1 Four limb inverted screen test  
Animals were suspended from an inverted wire grid and their latency to release the grid 
was recorded. Mice were allowed to hold on for a fixed maximum time of 600 seconds. 
Mice that released their grasp before reaching 600 seconds were allowed to rest for a 
period of 5 minutes and were given two more tries. The maximum hang time was used 
for further analysis. Data was collected from mice as early as 6 weeks old. Animals 
were tested once a week over a period of 6 months. This procedure was carried out in 
accordance with TREAT-NMD protocols (Carlson, 2011). 
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2.9.2 Ex vivo isometric tension analysis 
3 month old mice were sacrificed via cervical dislocation and a strip of diaphragm 
muscle from the central tendon to the ribs was excised immediately and assembled in a 
tissue organ bath (Aurora Scientific) filled with oxygenated Krebs- Ringer solution 
(Table 2.1) at pH 7.4, maintained at 22°C. One end of the diaphragm was attached to a 
300C dual-mode servomotor transducer (Aurora scientific) and the central tendon 
secured to a rigid post using 4-0 surgical thread. Diaphragm muscles were stimulated by 
supramaximal 0.2 ms square wave pulses delivered via platinum electrodes positioned 
on either side of the muscle. Data acquisition and control of the servomotor was 
conducted using a LabView based DMC program (Dynamic muscle control and Data 
Acquisition; Aurora Scientific, Version 3.2). We established a force-frequency 
relationship and assessed the muscles resistance to fatigue. The fatigue protocol 
involved 100 isometric contractions at a frequency of 150 Hz. This procedure was 
carried out in accordance with TREAT-NMD protocols (Barton, 2008). 
 
2.9.3 In situ force measurement 
Mice were anaesthetized with an intraperitoneal injection of 
Hypnorm®/Hypnovel®/water (1:1:2) at a dosage of 6 µl/g. Anaesthesia was maintained 
by mask inhalation of isoflurane vaporized at concentrations of up to 4% during surgical 
procedures and at 0.8-1.3% throughout the rest of the procedure. The distal tendon of 
the TA muscle was exposed and freed from surrounding fascia and the tendon tied with 
4-0 surgical braided silk. The sciatic nerve was exposed and all branches were severed 
except for the common peroneal nerve (CPN) that innervates the TA. A piece of silk 
thread was secured on the sciatic nerve and the nerve was transected proximal to this 
ligature. The mouse was placed on a heated stage (Aurora scientific) to maintain body 
temperature at 37˚C. The TA tendon was attached to the lever arm of a 300C dual-mode 
servomotor transducer (Aurora scientific). Contractions of the TA muscle were 
stimulated via supramaximal square-wave pulses of 0.02 ms (701B Stimulator; Aurora 
Scientific) to the distal part of the CPN via bipolar platinum electrodes. Data acquisition 
and control of the servomotor was conducted using a LabView based DMC program 
(Dynamic muscle control and Data Acquisition; Aurora Scientific, Version 3.2). We 
established the force-frequency relationship and assessed the susceptibility of the TA 
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muscle to fatigue. At the end of the experiment muscles were excised and weighed. This 
procedure was carried out in accordance with TREAT-NMD protocols (Lynch, 2009). 
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Reagent  Application Recipe  Supplier 
Blocking 
buffer  
Immunofluorescence  2.5 % BSA and 5 % goat serum in 0.5 % Triton 
X-100/PBS) 
BSA (NBS Biologicals), goat serum (Thermo 
Scientific), Triton X-100 (Sigma) 
Digestion 
Buffer  
DNA extraction 50 mM Tris, 20 mM NaCl, 1 mM EDTA, 1% 
SDS. pH 8.  
All chemicals from Sigma-Aldrich 
Digestion 
Buffer  
Proteomic profiling 
experiments 
Trypsin (Promega) (1:25 w/w, protease to 
substrate), 0.2 M GuHCl and 2 mM CaCl2 in 50 
mM NH4HCO3 (pH 7.8) 
Sequencing grade modified trypsin (Promega, 
Madison, WI USA), Benzonase®, CaCl2 (Merck, 
Darmstadt). All other components from sigma. 
Fixing Solution  β-galactosidase 
Staining Mouse 
Embryos   
0.1 M phosphate buffer, 2% PFA  
 5 mM EGTA pH 8, 0.2% glutaraldehyde, 2 
mM MgCl2  
All chemicals from Sigma-Aldrich 
Kreb’s-
Ringer’s 
Solution  
Ex vivo isometric 
tension analysis 
154 mM NaCl, 5 Mm KCl, 2 mM CaCl2,   1 
mM MgCl2, 11 mM Glucose, 5 mM HEPES 
All chemicals from Sigma-Aldrich  
Liley’s 
Solution  
Immunofluorescence  12 mM NaHCO3, 4 mM KCl, 1 mM KH2PO4, 
138.8 mM NaCl, 1 mM MgCl2,       2 mM CaCl2, 
11 mM Glucose  
All chemicals from Sigma-Aldrich  
Lysis Buffer  Proteomic profiling 
experiments 
50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 1 % 
SDS, and cOmplete Mini, EDTA-free protease 
inhibitor 
Tris-HCL (Applichem Biochemica, Darmstadt, 
Germany), NaCl (Merck, Darmstadt), Sodium 
dodecyl sulfate (Carl Roth, Karlsruhe, Germany), 
EDTA-free protease inhibitor (Complete Mini) 
(Roche Diagnostics) 
Lysis Buffer  Western Blots RIPA Buffer, 1 tablet cOmplete ULTRA 
Tablets, Mini, EDTA-free protease inhibitor 
RIPA buffer (Thermo Scientific), protease inhibitor 
(Roche)  
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Table 2.1. Reagents and buffers used in this project 
Reagent  Application Recipe  Supplier 
TBS (10 X) and 
TBS-T 
Western Blot  24 g Tris-HCl, 5.6 g Tris base, 88 g NaCl, 
Dissolve in 900 mL distilled water. For TBST-
add 0.1% Tween-20. 
 
All chemicals from Sigma-Aldrich 
Transfer Buffer  Western Blot 25 mM Tris, 190 mM glycine, 20% methanol. 
pH 8.3 
All chemicals from Sigma-Aldrich 
Tris-Acetate-
EDTA  
 
Agarose gel, gel 
electrophoresis 
40 mM Tris, 20 mM acetic acid, and 1mM 
EDTA 
All chemicals from Sigma-Aldrich 
Wash Buffer  β-galactosidase 
Staining of Whole 
Mouse Embryos   
0.1 M phosphate buffer, 0.01 % Na-
deoxycholate, 0.02% Igepal CA-630, 2 mM 
MgCl2  
 
All chemicals from Sigma-Aldrich 
X-gal staining 
solution  
β-galactosidase 
Staining of Whole 
Mouse Embryos 
10 mM Potassium Ferricyanide, 10 mM 
Potassium Ferrocyanide, 1 mg/ml X-Gal (made 
up in wash buffer) 
All chemicals from Sigma-Aldrich 
X-gal staining 
solution 
β-galactosidase 
Staining of adult 
mouse tissues 
5 mM Potassium Ferricyanide, 5 mM Potassium 
Ferrocyanide, 1 mM MgCl2 and 2mg/ml of X-gal 
All chemicals from Sigma-Aldrich 
 
 
45 
 
 
 
 
 
 
 
 
  
 
 
 
Table 2.2. Primers used for genotyping 
 
 
  
 
 
 
 
 
 
 
 
 
 
Table 2.3. Combinations of primers used for genotyping. Forward primers: 5arm-
WTF (F1), SV40-FRT-F (SV40F), Transgene Forward (CreF), FlpE-F1 (FlpE-F1). 
Reverse primers: Crit-WTR (R1), 5mut-R1 (mutR1), 3arm-WTR (R2), Cre R (CreR), 
FlpE1-R1 (FLpE1-R1).            
 
 
Primer name  Primer Sequence (5’-3’) 
5arm-WTF CAT GCG TGA ACC TGT GTA CA 
SV40-FRT-F            CGC GTC GAG AAG TTC CTA TT  
Crit-WTR GTC AGA GTT TGC TCA CAT CA 
5mut-R1     GCT TCA AGG ATA AGG CTT CAA G 
3arm-WTR    GGG TTT CGT AAT TGG AAG AG  
FlpE-F1 GGA CCG GCA ATT CTT CAA GCA 
FlpE-R1 CCA CGG CAG AAG CAC GCT TAT 
Transgene Forward TAA GTC TGA ACC CGG TCT GC 
Cre R GTG AAA CAG CAT TGC TGT CAC TT 
Genotype Forward Primer Reverse Primer  Band Size  
Wild type 5arm-WTF  Crit-WTR ~310bp 
All targeted alleles 5arm-WTF 5mut-R1     ~170bp 
Gfpt1tm1a SV40-FRT-F            3arm-WTR    ~910bp 
Gfpt1tm1b SV40-FRT-F            3arm-WTR    ~140bp 
Gfpt1tm1c 5arm-WTF Crit-WTR ~500bp 
Gfpt1tm1d 5arm-WTF 3arm-WTR    ~290bp 
Cre Transgene Forward Cre R ~450bp 
Flp FlpE-F1 FlpE-R1 ~230bp 
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Table 2.4. Primers used for RT-PCR 
 
 
Table 2.5. Antibodies used in this study  
Primer name  Primer Sequence (5’-3’) 
Exon6F TGA AAC AGA CAC AGA AAC CAT TGC C 
NeoF GAA TGG GCT GAC CGC TTC C 
NeoR GCT CGC GCC AGC CGA ACT G 
Exon7R GGC GCC TTT GCT CTT GTG 
Exon8R CGG AGT GAA CAT AAG CTT TC 
Exon8aR CAT GGT GGG GAT CAC AGG CAG 
Exon7/8R CAG TTG GCA CAA GGC GAG GTA 
Exon8/8aR GTA CAG AAC AGCT AGG ACT C 
Exon8/9R GTA CAG AAC AGG CAA AGA CAA G 
Antibody Description Application in this 
study  
Supplier 
Anti-Neurofilament 
heavy polypeptide 
Mouse 
monoclonal 
IHC (1:200) Abcam 
Anti-Synaptophysin Rabbit polyclonal IHC (1:100) Fisher Scientific 
Anti-GFPT1 Rabbit polyclonal WB (1:500) Proteintech 
Anti-GAPDH Mouse 
monoclonal 
WB (1:1000) Abcam 
Anti-Glypican 1 Rabbit polyclonal WB (1:1000) Abcam 
Anti-MuSK Rabbit polyclonal WB (1:1000) Abcam 
Anti-alpha Actinin  Mouse 
monoclonal 
WB (1:250) Sigma 
Alexa Fluor® 594  α-Bungarotoxin 
conjugate 
IHC (1:500) Life 
Technologies 
Alexa Fluor® 488  Goat anti-Mouse IHC (1:500) Life 
Technologies 
Alexa Fluor® 488 Goat anti-Rabbit IHC (1:500) Life 
Technologies 
IRDye® 800CW  Donkey anti-
Mouse IgG 
WB (1:15000) Licor 
IRDye® 680CW  Goat anti-Rabbit 
IgG 
WB (1:15000) Licor 
Alexa Fluor® 647  α-Bungarotoxin 
conjugate 
AChR Turnover 
(25 pmol) 
Life 
Technologies 
Alexa Fluor® 488 
 
α-Bungarotoxin 
conjugate 
AChR Turnover 
(25 pmol) 
Life 
Technologies 
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Table 2.6. Mice used in this study  
 
 
Strain name  Origin  
Wild type C57BL/6  MRC Mammalian Genetics Unit, Harwell 
C57BL/6NTac-Gfpt1tm1a(EUCOMM)Wtsi/H MRC Mammalian Genetics Unit, Harwell 
C57BL/6NTac-Gfpt1tm1b(EUCOMM)Wtsi/H  MRC Mammalian Genetics Unit, Harwell 
C57BL/6NTac-Gfpt1tm1c(EUCOMM)Wtsi/H  MRC Mammalian Genetics Unit, Harwell 
C57BL/6NTac-Gfpt1tm1d(EUCOMM)Wtsi/H  Functional Genomics Unit 
B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J The Jackson Laboratory 
B6;SJL-Tg(ACTFlpe)9205Dym/J FGU- originally from The Jackson 
Laboratory  
B6;129S4-Gt(ROSA)26Sortm1Sor/J FGU- originally from The Jackson 
Laboratory 
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Chapter 3: Generation of transgenic mice 
 
3.1 Introduction  
Over the years the use of rodents to model human disease has become increasingly 
popular. Rodents serve as powerful tools for studying disease progression, 
understanding the roles of specific genes in biological pathways, and preclinical 
screening and safety testing of new compounds. The advantages of using mice over 
other model organisms are numerous. Genomic studies have established that the house 
mouse (Mus musculus) exhibits a remarkable 99% genetic homology to humans 
(Waterston et al., 2002; Vandamme, 2014). Moreover, due to their small size, short 
gestation period and ease of maintenance in the laboratory, mice have become 
increasingly desirable models to use for scientific research.  
Advancements in technology which enable genetic manipulation of the mouse genome 
and the availability of a substantial number of knockin and knockout strains has rapidly 
enhanced our understanding of the pathology behind human diseases and the 
development of therapies (Vandamme, 2014). Deciding whether a germline or 
conditional knockout mouse is a more appropriate model for studying gene function 
depends on the viability of transgenic mice and the parameters that you wish to 
investigate. The Cre/loxP strategy utilises gene-trap mutagenesis which facilitates 
modification of the knockout first allele in crosses to transgenic Flp and Cre mice to 
generate null or conditional tissue-specific alleles (Skarnes et al., 2011; Heffner et al., 
2012). As of yet, there is currently no Gfpt1 knockout mouse model. A GFPT1 deficient 
mouse model will provide an invaluable tool in which to study numerous pathological 
changes occurring as a result of glycosylation defects. In this study we breed mice that 
will generate a complete Gfpt1 knockout mouse model. Offspring that inherit the lacZ 
reporter gene will allow us to track GFPT1 expression during development and in the 
adult mouse. One of the challenges we face is the viability of the Gfpt1 knockout 
mouse. Therefore, we also generate a conditional knockout mouse model which will 
overcome the problem of embryonic or early postnatal lethality in mice that harbour 
both copies of the null allele.   
A full understanding of Cre mediated excision of one or more exons relies on a well-
characterised Cre-line. Several reports have shown unspecific activity of a number of 
Cre-driver lines displaying gene excision beyond the desired cell type or time point, due 
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to poorly characterised expression of the promoter (Heffner et al., 2012). Premature Cre 
expression may result in a false positive phenotype or perhaps even embryonic lethality. 
There are also reports of inconsistent Cre activity depending on whether the Cre 
transgene is inherited maternally or paternally (Hayashi et al., 2003; Gallardo et al., 
2007). When using this experimental strategy, it is important to monitor Cre activity to 
ensure we achieve the desired spatio-temporal excision of our gene of interest. A 
number of transgenic Cre-reporter mouse lines have been developed to track Cre 
expression. In this study we use the [B6;129S4-Gt(ROSA)26Sortm1Sor/J] (ROSA26R-
lacZ) mouse line which allows us to evaluate expression of the Ckm-Cre transgene 
using β-galactosidase activity in the developing mouse embryo and adult tissues.  
 
 
3.1.1 Aims   
• To generate a GFPT1 knockout mouse model as part of the IMPC international 
effort at the MRC mammalian Genetics Unit, Harwell. Mice carrying one copy 
of the Gfpt1tm1a and Gfpt1tm1b allele obtained from the International Knockout 
Mouse Consortium will be bred and maintained at the Functional Genomics 
Unit, Newcastle University.   
 
• To generate a homozygous Gfpt1tm1c line through conversion of the Gfpt1tm1a 
allele using Flp recombinase.  
 
• To generate the conditional muscle-specific GFPT1 knockout mouse using a 
muscle-specific Cre line.   
 
• To demonstrate the efficiency and specificity of Cre activity using genomic 
PCR, western blotting and β-galactosidase activity in the ROSA26R reporter 
mouse.  
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3.2 Generation of transgenic mice 
The European Conditional Mouse Mutagenesis (EUCOMM) program uses promoterless 
and promotor-driven targeting cassettes to generate the ‘knockout-first allele’ in 
C57BL/6N embryonic stem (ES) cells. The design of conditional alleles is facilitated by 
a computational tool used to identify oligonucleotide sequences suitable for 
recombineering. These sequences are used to replace the coding sequence of GFPT1 
with a lacZ reporter and promoter-driven selection cassette using bacterial artificial 
chromosome (BAC) recombineering. Successful targeted events were identified using a 
novel high-throughput allele-counting assay. The final targeting constructs were used 
for ES cell electroporation. Homologous recombinants were screened using long-range 
PCR and sequencing. Positive clones were implanted into the host mouse blastocyst and 
implanted into the mouse (Friedel et al., 2011; Skarnes et al., 2011).  
3.2.1 Gene targeting via homologous recombination  
A gene-trap cassette containing a neomycin and lacZ-reporter gene flanked by FRT sites 
has been inserted in the intronic region of mouse Gfpt1 between exons 6 and exon 7. 
The critical exon (exon 7) is flanked by loxP sites producing the initial targeted allele 
Gfpt1tm1a. The marker allele Gfpt1tm1b, expected to be a null, and the conditional allele 
Gfpt1tm1c, expected to be wildtype, can be generated upon exposure to Cre or Flp 
recombinases respectively. The Gfpt1tm1b allele reports the activity of the promoter and 
can be used to track the expression pattern of GFPT1 during development and across 
tissues using lacZ staining. Upon Cre mediated recombination, the Gfpt1tm1c allele can 
be converted to the Gfpt1tm1d knockout allele (Figure 3.1).   
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Figure 3.1. Schematic diagram of the targeting strategy. The knockout-first allele 
Gfpt1tm1a contains a lacZ-neomycin trapping cassette. Cre deletes the loxP flanked exon 
of the Gfpt1tm1a allele to generate the lacZ-tagged marker allele, Gfpt1tm1b. The 
conditional allele Gfpt1tm1c is generated by removal of the gene-trap cassette by Flp 
recombinase which restores the allele to wild type except for insertion of loxP sites. Cre 
deletes the Gfpt1tm1c floxed exon to generate a frameshift mutation, Gfpt1tm1d.   
 
3.2.2 Generation of Gfpt1tm1a, Gfpt1tm1b and Gfpt1tm1c alleles 
Mice heterozygous for the Gfpt1tm1a and Gfpt1tm1b alleles were obtained from the 
International Knockout Mouse Consortium, Harwell. These mice were generated using 
the EUCOMM strategy to develop the ‘knockout-first’ conditional allele as previously 
described. Mouse lines were maintained via heterozygote crosses. To generate the 
Gfpt1tm1c allele, Gfpt1+/tm1a mice were bred with mice carrying the Flp transgene. The 
lacZ-neomycin cassette was excised upon FlpE recombinase activity to generate 
Gfpt1+/tm1c offspring which carry the Flp gene. Gfpt1+/tm1c mice were crossed with wild 
type mice. Gfpt1+/tm1c offspring negative for Flp were selected and crossed to generate 
Gfpt1tm1c/tm1c mice (Figure 3.2). 
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Figure 3.2. Generation of Gfpt1tm1c/tm1c mice. Gfpt1+/tm1a mice were crossed with mice 
hemizygous for FlpE recombinase resulting in the conversion of the Gfpt1tm1a allele to 
the Gfpt1tm1c allele in 25% of progeny (F1). Gfpt1+/tm1c mice carrying the FlpE transgene 
were crossed with wild type mice. Gfpt1+/tm1c offspring (F2) free of the FlpE transgene 
(25%) were selected and crossed to generate Gfpt1tm1c/tm1c mice. 25% of offspring were 
Gfpt1tm1c homozygous. These mice were obtained after 3 generations of breeding. 
 
3.2.3 Generation of the GFPT1 muscle-specific knockout mouse 
To generate a conditional Gfpt1 knockout allele, homozygous Gfpt1tm1c/tm1c mice were 
bred with mice harbouring the muscle creatine kinase, Ckm-Cre transgene 
[B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J] obtained from Jackson Laboratories. These 
mice express Cre recombinase under the control of the Ckm promoter. Cre mediated 
recombination results in the deletion of Gfpt1 in skeletal and cardiac muscle after 2 
generations of breeding. Offspring are referred to as muscle-specific Gfpt1tm1d/tm1d 
(Figure 3.3). 
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Figure 3.3. Breeding strategy for generating the muscle-specific Gfpt1 knockout 
mouse. The homozygous tm1c allele, Gfpt1tm1c/tm1c is bred with a hemizygous Ckm-Cre 
mouse. 50% of offspring are heterozygous for the tm1c allele, Gfpt1+/tm1c and express 
Cre recombinase activity in striated muscle only (F1). These mice are crossed with 
homozygous Gfpt1tm1c/tm1c mice. 25% of offspring are homozygous for the tm1c allele, 
Gfpt1tm1c/tm1c and express Cre recombinase activity in striated muscle only to generate 
the muscle-specific Gfpt1tm1d/tm1d mouse (F2).  
3.2.4 Genotyping and sequencing transgenic lines  
Insertion of the gene-trap cassette, deletion of the critical exon, conversion to the 
conditional allele and the presence of the Cre transgene was validated by PCR. Primers 
were designed to produce a fragment of ~310 bp in the Gfpt1 wild type allele. Primers 
positioned on the 5’ homology arm and the first FRT site produce bands of ~170 bp in 
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all targeted alleles (Gfpt1tm1a, Gfpt1tm1b, and Gfpt1tm1c). The Gfpt1tm1a allele also produces 
a band of ~910 bp band when amplified with primers flanking the floxed critical exon. 
Upon Cre-mediated recombination the same primers generate a smaller product of 
~140bp following excision of the critical exon to produce the Gfpt1tm1b allele. Flp 
mediated recombination of the Gfpt1tm1a allele removes the gene-trap cassette to 
produce the Gfpt1tm1c conditional allele producing a band of ~500bp. Upon Cre 
mediated recombination the conditional allele is converted to the Gfpt1tm1d allele by 
removal of the critical exon in muscle only. DNA extracted from ear clip biopsies from 
these mice are homozygous for the Gfpt1tm1c conditional allele in the presence of Cre 
(Gfpt1tm1c/tm1c Cre). Primers were designed within the Cre gene to produce a band of 
~450bp (Figure 3.4A, B). All alleles were verified via DNA sequencing. 
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Figure 3.4. Analysis of targeting events in the Gfpt1 gene. (A) Schematic 
representation of the targeting vector. Exons are shown in numbered rectangles and the 
positions of the inserted FRT and loxP sites are shown. The positions of primers used 
for genotyping and the length of the amplified PCR products in wild type, Gfpt1tm1a, 
Gfpt1tm1b, Gfpt1tm1c and Gfpt1tm1d are indicated. (B) PCR on genomic DNA extracted 
from ear clips showing amplified fragments of ~310bp for the Gfpt1 wild type allele, 
~170 bp fragment for all targeted alleles, ~910bp for the Gfpt1tm1a allele, ~140 bp for 
the Gfpt1tm1b allele and ~500 bp for the Gfpt1tm1c allele. All bands are measured against 
a 100 bp DNA ladder. Each gel represents PCR products derived from heterozygous 
mice (Gfpt1
+/tm1a
, Gfpt1
+/tm1b
 and Gfpt1
+/tm1c
).  Forward primers: 5arm-WTF (F1), 
SV40-FRT-F (SV40F). Reverse primers: Crit-WTR (R1), 5mut-R1 (mutR1), 3arm-
WTR (R2).
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3.3 Efficiency and specificity of Cre recombinase activity 
The efficiency and specificity of Cre-mediated activity was verified using genomic 
PCR, immunoblotting, and the ROSA26R-lacZ reporter line which demonstrates Cre 
expression.   
3.3.1 Tissue specific genotyping  
Cre-mediated gene alteration in muscle of Gfpt1 mutant mice was confirmed by 
genomic PCR. Primers were designed to detect the deletion of exon 7. PCR on genomic 
DNA extracted from muscle tissues and non-muscle tissues from Gfpt1tm1c/tm1c mice 
produce fragments of ~500 bp. DNA amplified from muscle specific Gfpt1tm1d/tm1d mice 
produce fragments of ~500 bp in non-muscle tissues and a band of ~290 bp in skeletal 
and cardiac muscle in the presence of Cre (~450 bp). All targeted alleles produce 
fragments of ~170 bp. Tissues analysed include ear clips, brain, kidney, heart and 
skeletal muscle (Figure 3.5).  
 
 
 
 
 
 
 
 
 
Figure 3.5. Muscle-specific allele conversion in Gfpt1tm1d mice. Representative 
images verifying the conversion of Gfpt1tm1c allele to the Gfpt1tm1d allele in skeletal and 
cardiac muscle of Gfpt1 mutant mice carrying the Cre transgene under the control of the 
Ckm promoter. Cre-mediated recombination does not take place in non-muscle tissues. 
Forward primers: 5arm-WTF (F1), Transgene Forward (CreF). Reverse primers: Crit-
WTR (R1), 5mut-R1 (mutR1), 3arm-WTR (R2), Cre R (CreR). 
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3.3.2 Immunoblot analysis of GFPT1 expression in control and Gfpt1tm1d/tm1d mice  
We performed immunoblotting analyses on lysates from control and Gfpt1tm1d/tm1d 
mouse tissues. Here Gfpt1tm1c/tm1c littermates were used as controls. Expression of 
GFPT1 in tissues was examined by western blotting using a polyclonal antibody against 
GFPT1. GFPT1 (~79 kDa) is expressed in muscle and non-muscle components in 
control mice. Results confirmed the absence of GFPT1 in skeletal and cardiac muscle 
from Gfpt1tm1d/tm1d mice but not in brain or kidney. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (~38 kDa) was used as a loading control (Figure 3.6).       
 
 
 
 
 
 
Figure 3.6. Western blot analysis of GFPT1 expression in muscle and non-muscle 
tissues from control and Gfpt1tm1d/tm1d mice. GFPT1 protein (~79kDa) is detected in 
muscle and non-muscle tissues in control mice. GFPT1 is not detected in skeletal 
muscle from Gfpt1tm1d/tm1d mice. GAPDH (~38kDa) was used as a loading control. All 
bands were measured against an 8-260 kDa Chameleon Duo Pre-stained protein ladder.  
 
 
3.3.3 ROSA26R-lacZ as a Cre reporter mouse line  
To understand the spatial and temporal expression of Cre recombinase we use the lacZ 
reporter mouse line ROSA26R-lacZ which demonstrates the activity of the Ckm 
promoter. ROSA26R mice have a loxP flanked transcriptional termination element, or a 
‘stop’ sequence inserted downstream of a transcription start site at the ubiquitously 
expressed ROSA26 locus, between the promoter and transgene lacZ sequence. When 
intact this cassette inhibits transcription of the lacZ reporter transgene. Tissues 
expressing Cre recombinase undergo Cre-mediated recombination resulting in excision 
of the ‘stop’ sequence allowing expression of β-galactosidase encoded by the lacZ 
transgene (Figure 3.7A).    
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Hemizygous Ckm-Cre mice were crossed with homozygous ROSA26R mice. Male and 
female mice were mated accordingly to generate offspring with either maternal or 
paternal Cre inheritance. Offspring were used to investigate whether Cre expression 
varied based on parental inheritance (Figure 3.7B).   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Mechanism of the ROSA26R-lacZ reporter line and generation of 
ROSA26R-Cre mice. (A) Schematic demonstrating Cre-mediated recombination 
events in the ROSA26R-lacZ reporter mouse. When intact the ‘stop’ cassette prevents 
the expression of β-galactosidase from the downstream lacZ coding sequence. Upon 
exposure to Cre recombinase, the stop cassette is excised by recombination of loxP 
sites, allowing the expression of β-galactosidase. (B) Schematic showing mice mated in 
order to generate offspring that acquire the Cre transgene via maternal or paternal 
inheritance. 50% of progeny will inherit the Cre transgene.  
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3.3.4 Ckm-Cre activity in the developing mouse embryo  
ROSA26R-Cre mice carry the lacZ-reporter gene which expresses β-galactosidase. To 
analyse Cre expression pattern in the mouse, we detected the enzymatic activity of β-
galactosidase using X-gal. Cells which express Cre recombinase are stained blue. We 
analysed Ckm-Cre expression in the developing mouse embryo. Whole ROSA26R-Cre 
embryos were isolated at E10.5, E11.5, E12.5 and E13.5, and were subsequently treated 
with X-gal. The expression of β-galactosidase activity is evident from E11.5 in muscles 
of the head and neck. As the embryo develops we see expression in the somites (E12.5) 
and a rapid accumulation in other skeletal muscles by E13.5. β-galactosidase expression 
appears to be restricted to muscle only (Figure 3.8). No differences were seen in 
embryos that inherited the Cre transgene via maternal or paternal inheritance, or 
amongst littermates.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Expression of β-galactosidase in ROSA26R-Cre embryos. Representative 
whole-mount images of embryos at various embryonic stages demonstrating the 
temporal and spatial specificity of Cre activity. Expression of the lacZ reporter 
transgene is restricted to skeletal and cardiac muscle only.  
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3.3.5 Ckm-Cre reporter activity in the adult mouse tissues   
To determine the expression pattern of the lacZ transgene in the adult mouse, transverse 
sections of muscle and non-muscle tissues from adult mice were sectioned and stained 
with X-gal. β-galactosidase activity is present in skeletal and cardiac muscle only. 
Gastrocnemius, TA, extensor digitorum longus (EDL), soleus, intercostal, extraocular 
and diaphragm muscles display β-galactosidase activity when treated with X-gal 
forming a blue precipitate. β-galactosidase activity was absent in non-muscle treated 
tissues including the brain, kidney and non-muscle components of the eye. There were 
no observed differences in the pattern of β-galactosidase activity between tissues 
obtained from mice that acquired the Cre transgene via maternal and paternal 
inheritance.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Expression of β-galactosidase in ROSA26R-Cre adult mouse tissues. 
There is abundant expression of β-glactosidase in skeletal (gastrocnemius, TA, EDL, 
soleus, intercostals, diaphragm and extraocular) and cardiac muscles. β-galactosidase 
activity is absent in non-muscle tissues (brain, kidney and eye). Scale bar = 400µm 
(brain), 20µm (all other tissues).   
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3.4 Discussion   
Our ability to understand the molecular mechanisms underlying disease states has 
rapidly progressed due to advancements in genomic manipulation, making the mouse 
model one of the most desirable research tools used for studying human disease 
(Perlman, 2016). Mouse models are particularly useful for the investigation of rare 
diseases as low patient numbers and phenotype heterogeneity greatly impede the 
establishment of clinical trials. The generation of CMS mouse models have enabled 
phenotype analysis which can be correlated to features seen in patients (Chevessier et 
al., 2008; Bogdanik and Burgess, 2011; Chevessier et al., 2012; Messéant et al., 2015). 
Here we report the generation of a GFPT1 deficient mouse model which will allow us to 
explore the pathological molecular involvement of GFPT1 which contributes to the 
phenotype observed in patients with CMS. We also describe the generation of mouse 
variants which will enhance our understanding of GFPT1 expression and allow us to 
investigate the spatio-temporal activity of Cre recombinase. Together these data verify 
that any phenotypes we observe in our mouse model will be purely as a consequence of 
GFPT1 deficiency.   
The gene-trap strategy used in our study relies on identification of the 5’-most critical 
exon that will lead to a frameshift mutation when deleted, is common to all transcript 
variants, and disrupts at least 50% of the protein-coding sequence of the gene of interest 
(Skarnes et al., 2011). Since alternative splicing of the GFPT1 muscle-specific exon 
occurs downstream of exon 7, positioning of the gene-trap cassette ensures disruption of 
both isoforms. Due to the ubiquitous nature of GFPT1 (Dehaven et al., 2001; Yang et 
al., 2007), it is highly probable that homozygous Gfpt1 knockout mice are embryonic 
lethal. For this reason, we have also generated a conditional model whereby GFPT1 is 
knocked out in skeletal and cardiac muscle only. Several studies have reported 
metabolic and behavioural phenotypes in mouse strains expressing Cre recombinase 
(Loonstra et al., 2001; Forni et al., 2006; Naiche and Papaioannou, 2007). It is therefore 
important to generate a pure model free from Flp and Cre recombinases, or use 
appropriate controls which rule out the possibility of false positive phenotypes. In our 
conversion of the Gfpt1tm1a allele to the Gfpt1tm1c allele, we ensure that progeny used for 
subsequent breeding steps are free from FlpE recombinase. Since our conditional 
Gfpt1tm1d/tm1d mice maintain the expression of Cre recombinase, we will also use the Cre 
line for some initial characterisation to ensure that the presence of Cre is not a 
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confounding variable which contributes to the observed phenotype. High levels of Cre 
expression can also lead to Cre toxicity affecting cell physiology and possibly the 
viability of animals. Thus, when setting up matings we ensure that offspring only inherit 
one copy of the Cre transgene, making it is less likely that the mice will acquire a Cre 
phenotype.  
Optimising gene targeting relies largely on the choice of the Cre recombinase 
expressing mouse line, which needs to target the gene of interest in the correct tissues at 
the right time. Therefore, when choosing a Cre recombinase it is important to keep in 
mind the aims of the study. In this project we want to understand the role of GFPT1 in 
the formation and maintenance of the NMJ. Formation of the NMJ begins with pre-
patterning of AChRs from embryonic day 12.5, and by embryonic day 18.5 AChR 
clusters have differentiated and are well innervated (Lin et al., 2001; Wu et al., 2010). 
The expression of muscle creatine kinase has been reported in skeletal and cardiac 
muscle of the mouse embryo 13 days post coitum, which rapidly increases by 
embryonic day 15 (Lyons et al., 1991; Bruning et al., 1998). Using a Ckm-Cre mouse 
line is ideal for generating a mouse model which will allow us to achieve our aims as 
the expression of Ckm-Cre and hence depletion of GFPT1 temporally correlates with 
events taking place during the formation of the NMJ. Consequently, the phenotype we 
observe is a reflection of pathophysiology of the formation as well as the maintenance 
of the NMJ.  
 
Reproducible excision is vital for the analysis of experimental data. Numerous studies 
have reported mosaic or inconsistent Cre activity in other Cre lines (Heffner et al., 
2012). Discrepancies arise depending on whether the Cre transgene is maternally or 
paternally inherited due to persistence of the Cre protein in the female germline 
(Hayashi et al., 2003; Gallardo et al., 2007; Heffner et al., 2012), inconsistent Cre 
recombination between littermates and unreported Cre activity in certain tissues due to 
poorly characterised promoters (Heffner et al., 2012). Therefore, in order to interpret 
our data informatively, we need to be certain of time/tissue-specific Cre activity. 
Several Cre-reporter lines have been developed which express fluorescent proteins such 
as green fluorescent protein (GFP) and other fluorescent colour variants, EYFP and 
ECFP (Srinivas et al., 2001). Additional Cre reporter lines include luciferase reporters 
(Ishikawa and Herschman, 2011) and the ROSA26R-lacZ reporter (Soriano, 1999). 
Extensive characterisation of the different Cre-reporter lines have demonstrated the 
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ROSA26R-lacZ reporter line appears to be amongst the most desirable due to their 
reliability and minimal level of background signal, allowing easy identification of 
reporter expression (Heffner et al., 2012). We examined offspring produced from 
hemizygous Ckm-Cre and ROSA26R matings and tracked Cre activity by tracing β-
galactosidase expression. Cre activity seems to be present in the head mesenchyme in 
the mouse embryo at E11.5, consistent with reports which first detect Ckm mRNA in 
the head and neck region, followed by remaining skeletal muscles in the developing 
mouse embryo (Lyons et al., 1991). Here we also show that Cre activity is restricted to 
skeletal and cardiac tissue only in the adult mouse.  
Collectively, our immunoblot analyses, tissue-specific genotyping and analysis of Cre 
expression data verify that GFPT1 is knocked out in the desired tissues in our model. 
We confirm the generation of a robust GFPT1 deficient mouse model which will 
subsequently be characterised to enhance our understanding of the pathological changes 
occurring as a result of hypoglycosylation.  
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Chapter 4: Characterisation of the Gfpt1tm1a  
and Gfpt1tm1b allele 
 
4.1 Introduction  
Full understanding of the pathophysiological consequences of a knockout mouse model 
is dependent on knowing where and when the gene of interest is expressed. Only then 
can we make informative genotype-phenotype correlations in transgenic mice. The 
Gfpt1tm1blacZ reporter allele provides a means of detecting where GFPT1 is normally 
expressed in the mouse. One advantage of using this line is that β-galactosidase 
expression can easily be detected in the developing mouse embryo and in adult tissues 
using simple well established protocols. This overcomes having to design and 
troubleshoot a protocol specific to the gene of interest. There is currently no GFPT1 
antibody that demonstrates the localisation of GFPT1 in mouse tissues. Furthermore, the 
specificity of antibodies in general is often poor and requires optimisation. Since a 
single copy of the lacZ transgene expresses sufficient levels of β-galactosidase 
(Coleman et al., 2015), we are able to use the Gfpt1+/tm1b line to track GFPT1 
expression.  
Occasionally heterozygous knockout mice display a sufficient reduction in the amount 
of protein expressed to produce a phenotype. In some cases, these mice can be used to 
further investigate gene function. Based on the positioning of insertion of the lacZ-
neomycin trapping cassette, the Gfpt1tm1a allele is predicted to produce either a 
hypormorphic or null allele, and the Gfpt1tm1b allele a null allele. Should homozygous 
mice be viable, or heterozygous mice demonstrate an adequate reduction in the amount 
of GFPT1 expression to produce a muscle phenotype, these mice could serve as 
potential models to investigate GFPT1 deficiency. 
The most prominent feature examined in existing mouse models of CMS is the 
morphology of the neuromuscular junction. The neuromuscular junction in adult mouse 
muscle has a highly specialised ending. AChR display a ’pretzel’-like structure which 
are innervated by presynaptic motor axons. Endplate pathologies commonly seen in 
mouse models of CMS include smaller and fragmented AChRs, reduced intensity of 
AChR staining, and reduced expression of AChRs. Motor nerves often project beyond 
their target, lose their ability to innervate AChR, and sprouting is often observed in 
nerve terminals (Brandon et al., 2003; Chevessier et al., 2008; Bogdanik and Burgess, 
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2011; Chevessier et al., 2012; Barik et al., 2014; Messéant et al., 2015). A 
developmental delay in maturation of the NMJ is also observed in both MuSK and agrin 
associated mouse models of CMS (Chevessier et al., 2008; Kim and Burden, 2008; 
Bogdanik and Burgess, 2011).  
In this study, we wish to investigate the pathophysiology of the NMJ as a consequence 
of GFPT1 deficiency. Furthermore, due to the ubiquitous nature of GFPT1, it is highly 
probable that we will observe pathological changes in muscle which we will examine 
using standard histological techniques.  
 
 
4.1.1 Aims 
 
• To breed and observe the viability of Gfpt1+/tm1a, Gfpt1+/tm1b, Gfpt1tm1a/tm1a and 
Gfpt1tm1b/tm1b mice.  
 
• To validate mutant transcripts from the Gfpt1tm1a and Gfpt1tm1b allele using     
RT-PCR. 
 
• To study the morphology of the synapse and perform histological analyses on 
muscle from viable mouse models. 
 
• To study the relative expression levels of GFPT1 in mouse tissues using 
immunoblot analyses.  
 
• To track GFPT1 expression in mouse tissues using the lacZ-reporter in the 
Gfpt1tm1b allele.  
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4.2 Viability of mice harbouring the Gfpt1tm1a and Gfpt1tm1b allele 
 
4.2.1 Frequency of heterozygous and homozygous Gfpt1tm1a and Gfpt1tm1b mice  
Offspring generated from heterozygote crosses do not follow the expected Mendelian 
pattern of inheritance with an expected genotypic ratio of 1:2:1; (Gfpt1+/+ :Gfpt1+/tm1a : 
Gfpt1tm1a/tm1a ); (Gfpt1+/+ :Gfpt1+/tm1b : Gfpt1tm1b/tm1b) . Only wild type (27%) and 
Gfpt1+/tm1a (73%) mice were obtained from heterozygote Gfpt1tm1a crosses (Figure 4.1A). 
No Gfpt1tm1a/tm1a mice were observed. Similarly, only wild type (39%) and Gfpt1+/tm1b 
(61%) mice were obtained from heterozygote Gfpt1tm1b crosses. No Gfpt1tm1b/tm1b mice 
were born (Figure 4.1B).   
 
 
 
 
 
 
 
Figure 4.1 The percentage of offspring representing each genotype. (A) Gfpt1+/tm1a 
crosses generated wild type and Gfpt1+/tm1a offspring only. Gfpt1tm1a/tm1a mice were never 
observed (n=132). (B) Gfpt1+/tm1b crosses generated wild type and Gfpt1+/tm1b offspring 
only. Gfpt1tm1b/tm1b mice were never observed (n= 153). 
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4.2.2 Frequency of heterozygous and homozygous Gfpt1tm1a and Gfpt1tm1b embryos  
Since no homozygous offspring were observed, we analysed the genotype of embryos 
generated from heterozygote crosses. The age of embryos taken ranged from E11.5 to 
E15.5. No Gfpt1tm1a/tm1a or Gfpt1tm1b/tm1b embryos were observed (Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. The percentage of embryos representing each genotype between E11.5-
E15.5. (A) Gfpt1tm1a crosses generated wild type and Gfpt1+/tm1a embryos only. 
Gfpt1tm1a/tm1a embryos were never observed (n=28). (B) Gfpt1tm1b crosses generated wild 
type and Gfpt1+/tm1b embryos only. Gfpt1tm1b/tm1b embryos were never observed (n= 33).       
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4.3 Validation of mutant transcripts by RT-PCR 
We used RT-PCR to identify transcripts generated from wild type, Gfpt1tm1a and 
Gfpt1tm1b alleles. RNA extracted from heterozygous Gfpt1+/tm1a and Gfpt1+/tm1b mice was 
transcribed to cDNA. A forward primer was designed in exon 6 and reverse primers in 
exons 7, 8, 8a. For further confirmation, we designed reverse primers in 7/8, 8/8a, and 
8/9. Fragments from the wild type allele produces expected bands of 130 bp, 217 bp, 
293 bp, 179 bp, 260 bp and 262 bp (Figure 4.3A, Table 4.1). The Gfpt1tm1a allele is 
predicted to produce either a hypormorphic or null allele, and the Gfpt1tm1b is expected 
to produce a null allele. To detect Gfpt1tm1a and Gfpt1tm1b transcripts, reactions were run 
using a forward primer designed in the gene trapping neomycin cassette, and reverse 
primers in the neomycin cassette and exons 7, 8, 8a, 7/8, 8/8a, and 8/9. We observe a 
control band of 220 bp corresponding to an amplicon within the neomycin cassette from 
Gfpt1tm1a and Gfpt1tm1b transcripts. No transcripts were detected downstream of the 
neomycin cassette (Table 4.1, Figure 4.3B).      
 
Table 4.1. PCR reactions used to detect transcripts from wild type, Gfpt1tm1a and 
Gfpt1tm1b alleles. A list of primers used with the expected and observed band size for each 
reaction are shown.   
Allele Forward Primer Reverse 
Primer 
Expected 
Amplicon 
Observed 
Amplicon 
 
 
Wild type 
 
 
 
 
Exon6F 
 
 
Exon7R 130 bp ✓ 
Exon8R 217 bp ✓ 
Exon8aR 293 bp ✓ 
Exon7/8R 179 bp ✓ 
Exon8/8aR 260 bp ✓ 
Exon8/9R 262 bp ✓ 
 
 
Gfpt1tm1a 
 
 
NeoF 
 
NeoR 220bp ✓ 
Exon7R None/211 bp  
Exon8R None/298 bp  
Exon8aR None/374 bp  
Exon7/8R None/260 bp  
Exon8/8aR None/341 bp  
Exon8/9R None/343 bp  
 
 
Gfpt1tm1b 
 
 
NeoF 
 
NeoR 220bp ✓ 
Exon7R No bands  
Exon8R No bands  
Exon8aR No bands  
Exon7/8R No bands  
Exon8/8aR No bands  
Exon8/9R No bands  
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Figure 4.3. Representative RT-PCR showing transcripts from Gfpt1+/tm1a and 
Gfpt1+/tm1b mice. (A) We observe bands with expected sizes corresponding to transcripts 
from the wild type allele. (B) Example of PCR products from the Gfpt1tm1a and 
Gfpt1tm1b allele. We observe a 220 bp band for the control reaction (NeoF and NeoR), 
but no bands were detected in all other reactions. All bands are measured against a 100 
bp DNA ladder. 
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4.4 Histological analysis of skeletal muscle in Gfpt1+/tm1b mice 
 
4.4.1 Hematoxylin and eosin staining of skeletal mouse muscle 
Histological analysis of skeletal muscle was achieved by staining with hematoxylin and 
eosin (H&E). TA, gastrocnemius, diaphragm, intercostal, soleus and EDL muscles were 
dissected from 3 month old wild type and Gfpt1+/tm1b mice. 10 µm thick transverse 
sections were prepared and the muscles were stained with H&E. There appears to be no 
histological difference between wild type and Gfpt1+/tm1b mice. Myofibres maintain their 
characteristic polygonal shape with peripheral nuclei. The sarcolemma and sarcoplasm 
remain intact and muscle tissues show a homogenous fibre size distribution (Figure 
4.4).  
 
Figure 4.4 Histological analysis of skeletal muscle in wild type and Gfpt1+/tm1b mice. 
Brightfield images of H&E stained TA, gastrocnemius, diaphragm, intercostal, soleus, 
and EDL muscles from wild type and Gfpt1+/tm1b mice. Eosin labels the sarcoplasm 
(pink). Hematoxylin labels the nuclei (blue). No histological difference was observed in 
Gfpt1+/tm1b muscle tissue compared to controls. Scale bar = 10µm for diaphragm, and 20 
µm for all remaining tissues. 
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4.4.2 Quantification of myofibre area 
The cross-sectional area of individual myofibres were measured using ImageJ software 
(Figure 4.5A). There were no significant differences in myofibre size in all muscles 
examined compared to their corresponding controls (Figure 4.5B).  
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Quantitative analysis of the area of individual myofibres in skeletal 
muscle. (A) Screenshot image demonstrating how myofibre area was calculated using 
ImageJ software. (B) Muscles analysed include TA, gastrocnemius, diaphragm, 
intercostal, soleus, and EDL muscles from wild type and Gfpt1+/tm1b mice. No significant 
differences in the area of individual myofibres was observed. Data represent mean + 
SEM. (n=4 mice per genotype) p>0.05, ns, not significant.   
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4.5 Analysis of the NMJ in Gfpt1+/tm1b mice 
 
4.5.1 Immunofluorescence staining of AChRs 
In order to establish whether transgenic mice display an NMJ phenotype, we analysed 
AChRs in TA, diaphragm, intercostal, and EDL muscles from 3 month old control and 
Gfpt1+/tm1b mice. Whole-mount muscles were stained with α-bungarotoxin to label 
AChRs. AChRs maintain their characteristic ‘pretzel’-like structure and appear normal 
in size in all muscles analysed (Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Immunofluorescence analysis of AChRs in skeletal mouse muscle from 
wild type and Gfpt1+/tm1b mice. Confocal Z-stack projections of whole-mount TA, 
diaphragm, intercostal and EDL muscles were labelled with Alexa fluor 594 α-
bungarotoxin (red) to label AChRs. Scale bar = 20µm.  
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4.5.2 Quantification of AChR cluster area  
For quantification of AChR cluster area, single-projected images derived from 
overlaying image stacks were quantified using ImageJ analysis software (Figure 4.7A). 
No significant differences in the area of individual AChR clusters was observed 
between wild type and Gfpt1+/tm1b mice (Figure 4.7B).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Quantitative analysis demonstrating AChR cluster area. (A) Screenshot 
image demonstrating how the area of individual AChR clusters was calculated using 
ImageJ software. (B) No differences in the size of AChR was observed between wild 
type and Gfpt1+/tm1b mice. (n=4 mice per genotype). Data are mean + SEM. (n=6) 
p>0.05, ns, not significant.   
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4.5.3 Immunofluorescence staining of presynaptic and postsynaptic components of 
the NMJ 
To study presynaptic and postsynaptic co-localisation and morphology, whole-mount 
muscles were stained with α-bungarotoxin to label AChRs and antibodies against 
neurofilament and synaptophysin to label axonal branches and nerve terminals, 
respectively. Neurofilament is a key component of the neuronal cytoskeleton and 
synaptophysin is a major synaptic vesicle protein p38. In control mice, axonal branches 
project normally and innervate the well-defined ‘Pretzel’-like AChR. Gfpt1+/tm1b show 
normal morphology of the NMJ which resemble endplates seen in wild type mice. 
AChRs maintain their characteristic ‘Pretzel’-shape and axons project normally forming 
synaptic contacts with AChRs (Figure 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Immunofluorescence analysis of endplates in skeletal mouse muscle 
from wild type and Gfpt1+/tm1b mice. Confocal Z-stack projections of whole-mount TA 
muscles labelled with Alexa fluor 594 α-bungarotoxin (red), anti-neurofilament (green) 
and anti-synaptophysin (green). Neurofilament (NF), Synaptophysin (Syn). Scale bar = 
10µm.  
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4.6 Summary of phenotypes observed in Gfpt1+/tm1b mice 
The International Mouse Phenotyping Consortium (IMPC) is a collaborative team of 
research centres and funding organisations whose goal is to discover a functional insight 
for every gene by generating and systematically characterising knockout mouse strains. 
Each mutant line available is characterised according to a broad criterion which covers 
all the major adult organ systems and human disease. The phenotype data collected for 
the Gfpt1+/tm1b mouse line demonstrates that the Gfpt1tm1b allele results in 
happloinsufficiency which is evident in some organ systems. We have collected and 
summarised the phenotype data from Gfpt1+/tm1b mice (Table 4.2) (Brown and Moore, 
2012).  
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Table 4.2. A summary of clinical findings observed in Gfpt1+/tm1b mice. Data 
collected from the IMPC and in-house (bold) demonstrates some phenotypical 
differences between wild type and Gfpt1+/tm1b mice.  
System  Outcome 
Statistical 
Significance  
Spleen Decreased weight  
 
p<0.001 
Tibia length Reduction in length   
Eye morphology 
Persistence of hyaloid vascular 
system 
Intraperitoneal glucose tolerance 
test  
Increased mean blood glucose 
concentration 
Body Composition (DEXA 
lean/fat) 
 
Reduced bone area (BMC/BMD) 
 
p<0.01 
Reduced bone mineral content 
(excluding skull) 
X-ray Abnormal shape of vertebrae 
Organ Weight Increase weight of kidney 
Clinical Blood Chemistry Increased levels of potassium 
Hematology Increased red blood cell count 
Body Composition (DEXA 
lean/fat) 
Reduced lean mass 
 
p<0.05 
 
 
 
Clinical Blood Chemistry 
 
 
Increased HDL-cholesterol 
Increased total cholesterol 
Variable Iron 
Variable alkaline phosphatase 
Variable total bilirubin 
Contact Righting Impaired righting reflex 
 
Electrocardiogram (ECG) 
 
Variable ST 
Variable PR 
Variable QRS 
Haematology 
 
Variable white blood cell count 
Variable platelet count 
Increased haemoglobin 
Decreased mean cell volume 
Intraperitoneal glucose tolerance 
test  
Increased mean blood glucose 
concentration (fasting) 
X-ray Abnormal pelvis shape 
Muscle 
Grip strength  
Not 
significant, 
p>0.05  
Myofibre area  
Neuromuscular junction – 
AChR cluster area  
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4.7 Analysis of GFPT1 expression  
 
4.7.1 Western blot analysis of GFPT1 expression  
Expression of GFPT1 in tissues from wild type mice was examined by western blotting 
using a polyclonal antibody against GFPT1. GFPT1 (~79 kDa) is expressed in the heart, 
TA, gastrocnemius, diaphragm, intercostal, soleus, brain and kidney. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (~38 kDa) was used as a loading control (Figure 
4.9).  
 
 
 
 
 
 
Figure 4.9. Western blot analysis of GFPT1 expression in muscle and non-muscle 
tissues from wild type mice. GFPT1 protein (~79kDa) is detected in the gastrocnemius, 
TA, diaphragm, intercostal, EDL, soleus, heart, brain and kidney. GAPDH (~38kDa) was 
used as a loading control. All bands were measured against an 8-260 kDa Chameleon 
Duo Ladder protein ladder. 
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4.7.2 Densitometry analysis showing the relative expression of GFPT1 in mouse 
tissues 
The relative expression levels between tissues was analysed using the gel analysis tool 
on ImageJ software. All blots were converted to greyscale images and bands were 
analysed by producing profile plots representing the relative density of each band 
(Figure 4.10A). The area of the peaks in the profile plots correspond to the intensity of 
the bands. The software subtracts the background and represents each peak as a 
percentage of the total intensity. The density of GFPT1 bands were normalised, 
followed by that of GAPDH loading control bands. The relative density of GFPT1 was 
then divided by the relative density of the corresponding loading control. The levels of 
GFPT1 expression varies between different tissues. The greatest amount of GFPT1 
appears to be expressed in the brain, followed by the kidney, heart and skeletal muscles. 
The level of GFPT1 expression varies between different skeletal muscles (Figure 
4.10B). 
Figure 4.10. Quantitative analysis showing the relative expression levels of GFPT1 
in mouse tissues. (A) Modified screenshot image of a profile plot demonstrating how 
band intensity was quantified using ImageJ gel analysis. (B) Graph demonstrating 
GFPT1 expression levels normalised to their corresponding GAPDH loading controls. 
Data corresponds to immunoblot bands seen in Figure 4.9.  
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4.7.3 GFPT1 expression detected by β-galactosidase activity in mice   
Gfpt1+/tm1b mice carry the lacZ-reporter gene which expresses β-galactosidase under the 
control of the Gfpt1 promoter. To analyse the pattern of GFPT1 expression we detected 
the enzymatic activity of β-galactosidase using X-gal in mouse embryos and adult 
tissues.  
 
β-galactosidase activity in the mouse embryo 
 
We mated Gfpt1+/tm1b mice which generated wild type and Gfpt1+/tm1b embryos. Embryos 
aged E11.5, E12.5 and E13.5 were isolated and stained with X-gal. We observe 
ubiquitous expression of β-galactosidase in Gfpt1+/tm1b embryos but not in control 
littermates. Tail tips were taken from the embryos which was used for genotype 
verification.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Gfpt1 lacZ transgene expression in mouse embryos. E11.5, E12.5 and 
E13.5 wild type and Gfpt1+/tm1b embryos were stained with X-gal. β-galactosidase 
activity (blue) was detected throughout the entire Gfpt1+/tm1b embryo at all time points. 
β-galactosidase activity is not observed in wild type embryos.  
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β-galactosidase activity in adult mouse tissues 
We analysed the pattern of GFPT1 expression in the adult mouse by tracking the 
enzymatic activity of β-galactosidase in the gastrocnemius, TA, diaphragm, EDL, 
intercostal, soleus, and heart muscles. We also analysed non-muscle tissues including 
the eye, kidney and brain. Transverse sections of adult mouse tissues were sectioned 
and stained with X-gal. We observed β-galactosidase activity in all skeletal muscles and 
the heart. GFPT1 is also expressed in extraocular muscles, eyes, kidneys and the brain.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Gfpt1 lacZ transgene expression in adult mouse tissues.                        
β-galactosidase activity was detected with X-Gal as a substrate on sections of tissues 
from 3 month old Gfpt1+/tm1b mice. β-galactosidase activity (blue) is present in all 
tissues analysed. Scale bar = 400µm in the brain; 20µm in all remaining tissues.  
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4.7.4 Summary of GFPT1 expression in Gfpt1+/tm1b mice 
The IMPC also work on understanding the pattern of protein expression of mouse lines 
which harbour the lacZ-reporter gene that expresses β-galactosidase. The GFPT1 
expression data collected for the Gfpt1+/tm1b mouse line demonstrates ubiquitous 
expression of GFPT1 in numerous organ systems (Table 4.3) (Dehaven et al., 2001; 
Petryszak et al., 2016).  
 
Table 4.3. A summary of GFPT1 expression in adult mouse tissues. Data 
summarised represents observations of β-galactosidase activity in numerous organ 
systems. Data collected from the IMPC and those generated in-house (bold) are shown.  
 
 
 
 
Systems/structures Adult tissues 
Cardiovascular  Heart, aorta 
Musculoskeletal Gastrocnemius, TA, diaphragm, EDL, soleus, 
intercostal, bone, cartilage 
Nervous  Cerebral cortex, hippocampus, striatum, olfactory 
lobe, hypothalamus, cerebellum, brainstem, spinal cord, 
peripheral nervous system 
Reproductive Ovary, oviduct, uterus, prostate, lower urinary tract, 
testis, prostate 
Sensory Eye - including extraocular muscles 
Integumentary  Skin, mammary glands 
Endocrine  Adrenal gland, thyroid gland, parathyroid gland, pituitary 
gland 
Renal/urinary  Lower urinary tract, kidney - renal medulla, renal 
cortex 
Respiratory  Trachea, lungs, cartilage 
Digestive/ alimentary 
system 
Large intestine, liver, gall bladder, small intestine, 
stomach, esophagus 
Lymphatic  Lymph node, spleen 
Immune  Thymus, payers patch  
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4.8 Discussion 
The frequency of mice born does not reflect the Mendelian frequencies for the expected 
genotypes. Homozygous Gfpt1tm1a/tm1a and Gfpt1tm1b/tm1b mice were never obtained from 
heterozygote crosses, but Gfpt1+/tm1a and Gfpt1+/tm1b are viable. Genotype analysis of 
embryos revealed no GFPT1 deficient homozygous mice were observed as early as 
embryonic day 11.5. This information is supported by data from the IMPC, which states 
that no viable homozygous embryos were observed at E12, but when screening E9.5 
Gfpt1tm1b embryos few were viable (Brown and Moore, 2012). For the purpose of our 
study, we need to examine the morphology of the NMJ. AChR cluster formation and 
innervation occurs between E12-E18.5 in the mouse embryo (Lin et al., 2001; Wu et al., 
2010). Therefore, viable embryos younger than E12 are inadequate for our study as they 
do not permit investigation of the NMJ.  
We do not detect transcripts from the Gfpt1tm1a and Gfpt1tm1b alleles, suggesting that 
insertion of the lacZ gene-trap cassette in the Gfpt1 gene completely disrupts its 
function generating a null allele. Since both alleles are essentially nulls, we selected one 
model (Gfpt1+/tm1b) to analyse whether these mice present with happloinsufficiency. 
Gfpt1+/tm1b display normal morphology of both the presynaptic and postsynaptic 
components at the NMJ in all muscles analysed. Moreover, histological analysis of 
different muscles revealed no signs of a muscle pathology. Analysis of myasthenia 
conducted using a grip strength assay carried out as part of the IMPC revealed no 
significant changes in Gfpt1+/tm1b mice when compared to age-matched controls. 
Together these data suggest that happloinsufficiency does not impair muscle function in 
Gfpt1+/tm1b mice. These findings reflect the asymptomatic status of human carriers with 
loss of function GFPT1 mutations. The IMPC report significant variations in a number 
of non-muscle related phenotypes in Gfpt1+/tm1b mice. Although many of these findings 
are not representative of the human GFPT1-CMS phenotype, previous reports have 
established that GFPT1 is implicated in glucose metabolism and insulin resistance in 
humans (Elbein et al., 2004) and mice (Hebert et al., 1996; Cooksey et al., 1999). More 
recently, studies have demonstrated that upregulation of SIL-1, which is commonly 
found in surviving neurons of Alzheimer’s patients, leads to an increase in GFPT1 
expression (Labisch et al., 2017).  
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Immunoblot analyses of control tissue shows ubiquitous expression of GFPT1 in both 
muscle and non-muscle tissues consistent with findings from previous studies (Dehaven 
et al., 2001; Niimi et al., 2001). Furthermore, there appears to be differences in the 
relative expression levels between individual muscle and non-muscle tissues. Increasing 
the number of replicates in immunoblot experiments will confirm these preliminary 
findings. β-galactosidase activity used to analyse GFPT1 expression further 
demonstrates widespread GFPT1 expression in tissues from numerous organ systems. 
This data emphasises the importance of GFPT1 for normal development and function, 
and is indicative as to why homozygous knockout mice are not viable.   
In summary, these data suggest that GFPT1 is essential for mouse embryogenesis and is 
responsible for proper functioning of numerous organ systems. Although 
happloinsufficiency is apparent in the Gfpt1+/tm1b model, the phenotypes observed are 
not specific to muscle or the NMJ. This model is therefore not particularly useful for 
investigating pathomechanisms in CMS, but has proven useful for tracking GFPT1 
expression.   
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Chapter 5: Characterisation of the muscle-specific GFPT1              
deficient mouse model 
 
5.1 Introduction    
The overall aim of this project is to generate a mouse model that recapitulates the 
phenotypes seen in patients with CMS as a result of GFPT1 deficiency. Most of these 
patients harbour mutations in the ubiquitous GFPT1 isoform, resulting in reduced, but 
not complete loss of GFPT1 expression (Guergueltcheva et al., 2012; Huh et al., 2012). 
The only exception is seen in a single patient with a nonsense mutation in the muscle-
specific exon, which is predicted to result in complete loss of GFPT1-L, but conserves 
the ubiquitous isoform (Selcen et al., 2013). Since homozygous Gfpt1 knockout mice 
are embryonic lethal, we generated the Gfpt1 muscle-specific knockout mouse model 
which disrupts both isoforms in muscle only. All remaining tissues continue to express 
the ubiquitous GFPT1 isoform.     
To evaluate the validity of the GFPT1 deficient mouse model, we must investigate 
whether this model exhibits phenotypes observed in human GFPT1-CMS. The general 
pathological changes observed in human CMS include morphological alterations at the 
endplate, and histopathological changes in muscle including the presence of tubular 
aggregates due to a deficiency in glycosylation enzymes. Initially, these features will be 
analysed in the Gfpt1tm1d/tm1d model.  
Patients with CMS present with fatigable muscle weakness. A series of tests have been 
devised to assess muscle function in mouse models. Tests that do not enhance disease 
progression allows evaluation of the natural course of disease and the efficacy of 
potential treatments on muscle function. The four-limb inverted screen test is a 
functional tool which measures the ability of mice to oppose their gravitational force 
through sustained limb tension. This test has proven useful for demonstrating fatigable 
muscle weakness in mice with neuromuscular disorders (Bogdanik and Burgess, 2011; 
Webster et al., 2013; Messéant et al., 2015). In situ isometric force measurements 
provide a means of assessing muscle fatigue through neural stimulation under 
physiological conditions. In vitro isometric force measurements allow critical 
evaluation of muscle contractile function. These tests are commonly used to assess 
myopathic and dystrophic phenotypes in mice (Chiu et al., 2009; Sharp et al., 2011; 
85 
 
 
Tamayo et al., 2016) and can be used to identify changes in muscle strength and fatigue 
in GFPT1 deficient mice.  
Ultimately, our goal is to discover the pathological mechanisms which can be 
therapeutically targeted with the aim of relieving CMS symptoms. This requires a 
thorough understanding of the molecular mechanisms underlying glycosylation 
deficient CMS. One method of enhancing our knowledge of disease causing 
mechanisms, and subsequently how the body responds to these changes, is through 
investigation of differentially regulated proteins. Proteome profiling is a powerful tool 
which can be used for the unbiased investigation of pathophysiological processes in 
neuromuscular disorders (Roos et al., 2016). Identification of regulated proteins as a 
consequence of abnormal glycosylation will prove useful in deducing the molecular 
pathways implicated in the CMS phenotype observed.  
In this chapter Gfpt1tm1c/tm1c mice are used as controls and muscle-specific GFPT1 
knockout mice are referred to as Gfpt1tm1d/tm1d. We also show preliminary 
characterisation of the Cre line using Ckm-Cre mice.   
 
5.1.1 Aims  
The overall aim of this chapter is to characterise the muscle-specific Gfpt1 knockout 
mouse model, Gfpt1tm1d/tm1d. This entails the following: 
 
• To study the morphology of presynaptic and postsynaptic components of the 
NMJ. 
 
• To investigate histopathological changes in mouse muscle. 
 
• To use functional tests to assess muscle strength and fatigue in mutant mice.   
 
• To analyse contractile properties of the diaphragm muscle using an in vitro test 
apparatus.  
 
• Global proteomic analysis of regulated proteins as a result of GFPT1 deficiency.  
 
• Immunoblot analysis of protein targets downstream of GFPT1.  
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5.2 Frequency and gross phenotype of Gfpt1tm1d/tm1d mice 
5.2.1 Frequency of Gfpt1tm1d/tm1d mice 
Gfpt1tm1c/tm1c mice were mated with Gfpt1+/tm1c Ckm-Cre mice to generate Gfpt1tm1c/tm1c 
Ckm-Cre (Gfpt1tm1d/tm1d) mice. According to our breeding strategy, offspring generated 
do not follow the expected Mendelian pattern of inheritance with an expected genotypic 
ratio of 1:1:1:1 (Gfpt1tm1c/tm1c: Gfpt1+/tm1c: Gfpt1+/tm1c Ckm-Cre: Gfpt1tm1c/tm1c Ckm-Cre). 
Instead Gfpt1+/tm1c (5%), Gfpt1+/tm1c Ckm-Cre (50%), Gfpt1tm1c/tm1c (41%), and 
Gfpt1tm1c/tm1c Ckm-Cre (4%) of mice were obtained from crosses using this breeding 
strategy (Figure 5.1). We observe a very low frequency of Gfpt1tm1d/tm1d mice.     
 
 
 
 
 
 
 
 
 
 
Figure 5.1. The percentage of offspring representing each genotype. 50% of 
offspring from Gfpt1tm1c/tm1c and Ckm-Cre crosses carry the Cre allele (F1). We acquire 
offpring from all the expected genotypes; Gfpt1+/tm1c, Gfpt1+/tm1c Ckm-Cre, Gfpt1tm1c/tm1c 
and Gfpt1tm1c/tm1c Ckm-Cre. The frequency of mice expected (blue boxes) and obtained 
(red boxes) for each genotype are shown (F2).  
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5.2.2 Gross phenotype and growth of Gfpt1tm1d/tm1d mice 
Gfpt1tm1d/tm1d mice do not exhibit gross phenotypical defects when compared to age-
matched control mice. Control, Ckm-Cre controls and Gfpt1tm1d/tm1d were weighed 
weekly from 6 weeks old to 6 months old. The general trend shows that Gfpt1tm1d/tm1d 
mice are slightly smaller when compared to control mice over the course of 
development. However, no significant difference was observed in the growth curve 
between control and Gfpt1tm1d/tm1d mice (Figure 5.2). We further demonstrate there is no 
change in body weight between control mice (Cre negative) and mice carrying the Cre 
transgene (Figure 5.2). 
 
 
Figure 5.2. Growth curve of control, Ckm-Cre and Gfpt1tm1d/tm1d mice. Growth curves 
demonstrating changes in body weight over a 6 month period. Data = mean + SEM. 
p>0.05. Not significant. Control and Gfpt1tm1d/tm1d mice (n=8), Cre (n=6).  
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5.3 Morphology of the neuromuscular junction  
5.3.1 Immunofluorescence of the NMJ  
We analysed the presynaptic and postsynaptic structure of NMJ in TA, intercostal, 
soleus, lumbrical and EDL muscles from 3 month old mice. Whole-mount muscles were 
stained with α-bungarotoxin to label AChRs, and with antibodies against neurofilament 
and synaptophysin to label axonal branches and nerve terminals, respectively. In control 
mice, axonal branches project normally and innervate the well-defined ‘Pretzel’-like 
AChR. Observation of presynaptic components showed that Gfpt1tm1d/tm1d mice exhibit 
some morphological differences including the appearance of discontinuous and rather 
disorganised axonal projections. Nevertheless, axons project to endplates and form 
synaptic contacts with existing AChR. We do not observe overshooting, retractions or 
axonal sprouting. Analysis of postsynaptic structures revealed that AChR in 
Gfpt1tm1d/tm1d mice do not maintain the characteristic ‘Pretzel’-shape that we see in 
control mice. Instead they appear smaller and fragmented in all muscles analysed in 
comparison to control mice (Figure 5.3).  
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Figure 5.3 
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Figure 5.3. Aberrant NMJ in 3 month old Gfpt1tm1d/tm1d mice. Confocal Z-stack 
projections of whole-mount TA (A), intercostal (B), soleus (C), lumbrical (D) and EDL 
(E) muscles were labelled with anti-neurofilament (green), anti-synaptophysin (green) 
and Alexa fluor 594 α-bungarotoxin (red). Neurofilament (NF), Synaptophysin (Syn). 
Scale bar = 20μm. 
 
 
 
Figure 5.3 continued 
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5.3.2 Co-localisation of presynaptic and postsynaptic components of the NMJ 
To further analyse remodelling of endplates in Gfpt1tm1d/tm1d mice, whole-mount TA, 
intercostal, soleus, lumbrical and EDL muscles from 3 month old mice were stained 
with α-bungarotoxin to label AChR and with antibodies against synaptophysin to 
visualise nerve terminals. In control mice, we see a precise spatial overlap of nerve 
terminals and their respective AChR. Synaptophysin labelling in Gfpt1tm1d/tm1d mice 
revealed fragmented nerve terminals which appear to align and form synaptic contacts 
with the existing AChR fragments. The overlap of nerve terminals and their respective 
AChR appear normal, as seen in control mice. These findings are consistent across all 
muscles analysed (Figure 5.4).  
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Figure 5.4. Co-localisation of nerve terminals and AChR. Confocal Z-stack 
projections of whole-mount muscles labelled with Alexa fluor 594 α-bungarotoxin (red) 
and anti-synaptophysin (green) demonstrate the degree of nerve terminal and AChR 
overlap from TA (A), intercostal (B), soleus (C), lumbrical (D) and EDL (E) muscles. 
Synaptophysin (Syn). Scale bar = 20μm (A-E).  
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5.3.3 Quantitative analysis demonstrating the changes in AChR structure and the 
area of synaptic contacts between presynaptic and postsynaptic components 
To study presynaptic and postsynaptic changes at the NMJ, TA, intercostal, EDL, 
lumbrical and soleus muscles from 3 month old control and Gfpt1tm1d/tm1d mice were 
used to analyse the area, degree of fragmentation, and expression of AChR clusters. We 
further analysed the overlap area between presynaptic and postsynaptic components 
using AChR and nerve terminal stained muscles.  
Single-projected images derived from overlaying image stacks were quantified using 
ImageJ analysis software as previously described. Quantitative analysis revealed a 
reduction in the size of AChRs which were greatest in the lumbrical muscles, followed 
by the TA, EDL, soleus and intercostals muscles (Figure 5.5A), (Percentage decrease in 
AChR cluster area lumbrical: 62.8% TA: 45%, EDL: 33%, soleus: 28%, intercostals: 
27%.). The degree of fragmentation was measured by a mean fold increase in the no. of 
fragments per AChR cluster, (TA: 2.2 fold, EDL: 1.9 fold, intercostals: 1.8 fold, soleus: 
1.3 fold and lumbrical: 0.3). Statistical analysis revealed the greatest degree of 
fragmentation was observed in the soleus, followed by the EDL, intercostal, TA and 
lumbrical muscles (Figure 5.5B). The number of AChR clusters expressed per field 
view remained unchanged in all muscles analysed (Figure 5.5C). Analysis of the 
overlap area between presynaptic and postsynaptic components revealed no significant 
difference in NMJ from control and Gfpt1tm1d/tm1d mice (Figure 5.5D).  
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Figure 5.5. Quantification of AChR cluster area, fragmentation, expression and 
overlap area of presynaptic and postsynaptic elements. Quantitative analysis 
demonstrating area of AChR clusters (A), fragmentation of AChR clusters (B), the 
number of AChR clusters expressed per field view (C), and the presynaptic and 
postsynaptic overlap in control and Gfpt1tm1d/tm1d mice (n = 6-8 animals per genotype). 
Data are mean + SEM. *p<0.05, **p<0.01 ***p<0.001. ns, Not significant. 
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5.4 Electron microscopy 
To gain an enhanced understanding of the phenotype observed in Gfpt1tm1d/tm1d mice, we 
examined endplates and muscle at the ultrastructural level using electron microscopy in 
intercostal muscles from 3 month old control and mutant mice.  
 
5.4.1 Examination of NMJ ultrastructures  
Endplates in control mice exhibit uniform postsynaptic junctional folds at the NMJ. We 
also observe subcellular specialisations such mitochondria and synaptic vesicles in the 
presynaptic nerve terminal (Figure 5.6A). In contrast, analysis of endplates from 
Gfpt1tm1d/tm1d mice revealed fewer, simplified or highly disorganised junctional folds. 
Presynaptic terminals appear smaller, but maintain their subcellular specialisations 
(Figures 5.6B and 5.6C). Further examination of presynaptic elements show that control 
mice display regular concentric myelin sheaths (Figure 5.6D). Differences observed in 
Gfpt1tm1d/tm1d mice include occasional highly irregular convoluted myelin sheaths 
surrounding axons (Figures 5.6E and 5.6F).   
Examination of the sarcoplasm revealed an abundant accumulation of tubular 
aggregates beneath the sarcolemma in mutant mice (Figure 5.6G). We also see the 
presence of subsarcolemmal vesicular structures that may correspond to caveolae 
(Figure 5.6H). Tubular aggregates were absent in control mouse muscle. These data 
indicate both presynaptic and postsynaptic alterations in Gfpt1tm1d/tm1d mice. 
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Figure 5.6 
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Figure 5.6. Altered morphology at the ultrastructural level in Gfpt1tm1d/tm1d mouse 
muscle. Representative electron micrographs from 3 month old control and 
Gfpt1tm1d/tm1d intercostal muscles. Examples of NMJs from control (A), and Gfpt1tm1d/tm1d 
(B, C) mice. Examples of control (D), and Gfpt1tm1d/tm1d (E, F) myelin sheaths. 
Accumulation of tubular aggregates (G) and subsarcolemmal vesicular structures (H) in 
Gfpt1tm1d/tm1d mouse muscle. Synaptic vesicles (*), junctional folds (black arrow), 
mitochondria (M), myelin sheaths (white arrows), rounded tubular aggregates (TA), 
subsarcolemmal vesicular structures (black arrow head). Scale bar = 1μm (A,B,G,H); 
2μm (C,D,E,F).   
 
 
 
 
 
 
 
 
 
Figure 5.6 continued 
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 5.4.2 Quantification of presynaptic and postsynaptic changes in Gfpt1tm1d/tm1d mouse 
muscle 
Presynaptic and postsynaptic changes in Gfpt1tm1d/tm1d mouse muscle were quantified by 
analysing the number of postsynaptic junctional folds per nerve terminal, the diameter of 
myelin sheaths, and sarcomere length by measuring the distance between z-lines.    
The number of junctional folds were counted manually, and the diameter of myelin 
sheaths and the distance between z-lines were measured using ImageJ software. Mutant 
mice display fewer junctional folds (34% decrease) on the postsynaptic membrane 
(Figure 5.7A). Analysis of myelin sheaths showed a reduction in diameter (32% 
decrease) (Figure 5.7B). Analysis of the sarcoplasm revealed smaller sarcomeres shown 
by a decrease in the distance between z-lines (11%) (Figure 5.7C). All data were 
analysed relative to data from control mice.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Quantification analyses demonstrating presynaptic and postsynaptic 
alterations in Gfpt1tm1d/tm1d mouse muscle. Quantitative analysis demonstrating the 
number of junctional folds (A), myelin sheath diameter (B), and distance between z-
lines (C), in control and Gfpt1tm1d/tm1d mouse muscle. (n=4 animals per genotype). Data 
are mean + SEM. *p<0.05, ***p<0.001. 
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5.5 Histological analysis of skeletal muscle in Gfpt1tm1d/tm1d mice 
 
5.5.1 Histological analysis of skeletal muscle using hematoxylin and eosin staining  
TA, intercostal, soleus, EDL and diaphragm muscles were dissected from 3 month old 
control and Gfpt1tm1d/tm1d mice. 10 µm thick transverse sections were prepared and the 
muscles were stained with hematoxylin and eosin.  
Whilst control mice maintain their characteristic polygonal shape and peripherally 
located nuclei, we observe numerous myopathic changes in Gfpt1tm1d/tm1d mouse muscle 
(Figure 5.8). Muscles from Gfpt1tm1d/tm1d mice exhibit occasional rounded myofibres, 
and a few fibres with internal nuclei indicative of regenerating fibres. There also 
appears to be a greater variability in myofibre size due to the presence of atrophic and 
hypertrophic myofibres, which occasionally exhibit splitting. We observe necrotic fibres 
in the TA, EDL and diaphragm muscles, and the presence of tubular aggregates which 
are stained as dark aggregates or appear like slits within the myofibre. Tubular 
aggregates are found in some myofibres in all muscles examined. Analysis of the EDL 
and diaphragm muscle demonstrates the replacement of myofibres with fibro-adipose 
tissue. This finding is more prevalent in the diaphragm muscle.  
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Figure 5.8 
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Figure 5.8 continued 
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Figure 5.8. Myopathic changes in muscle from Gfpt1tm1d/tm1d mice. Brightfield images 
of TA, intercostal, soleus, EDL and diaphragm muscles stained with hematoxylin and 
eosin from 3 month old control and Gfpt1tm1d/tm1d mice. Legend: Black star indicates 
rounded myofibres, black arrow points to centrally-located nuclei in myofibres, black 
arrow head points to tubular aggregates, white arrow head points to necrotic fibres, 
white arrow points to adipose tissues. Hypertrophic and atrophic myofibres are also 
present. Scale bar = 20µm for main figures and 10µm for insets.      
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5.5.2 Quantification of myofibre variation  
The cross-sectional area of individual myofibres from control and Gfpt1tm1d/tm1d mice 
were measured using ImageJ software as described previously. Quantitative analysis of 
myofibre area showed higher variability in Gfpt1tm1d/tm1d mouse muscle when compared 
to control mouse muscle. Variations in fibre size between control and Gfpt1tm1d/tm1d 
mouse muscle are greatest in the EDL (61%), followed by the soleus (56%), intercostal 
(29%) and TA (26%) muscles as shown by the percentage difference of the interquartile 
range. Median cross-sectional area measurements are indicative of the proportion of 
fibres that tend to be either smaller or larger when comparing control and mutant 
muscles. The intercostal (28.91%) and soleus (25.84%) muscles exhibit a shift towards 
smaller fibres, the EDL exhibits a shift towards larger fibres (17.72%), whilst the TA 
fibres remain unchanged in Gfpt1tm1d/tm1d mice (Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Quantitative analyses demonstrating the distribution of myofibre size 
according to cross-sectional area. The cross-sectional area of individual myofibres 
from control and Gfpt1tm1d/tm1d mice were measured (n=4 animals per genotype). Data 
are median, 25th percentile, 75th percentile, minimum and maximum values (including 
outliers). **p<0.01,***p<0.001. ns, Not significant.  
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5.6 Evaluation of myasthenia in transgenic mice  
 
5.6.1 The four limb inverted screen test  
Fatigable muscle weakness was measured using an inverted screen test. Mice were 
suspended from a wire grid and the length of time it took for the mice to release their 
grasp of all four limbs was recorded. Data was collected from mice from 6 weeks of 
age. The mice were set a maximum time of 10 minutes. Control mice up to the age of 
18 weeks old demonstrate the ability to hold on for the maximum threshold of 10 
minutes. There was a small reduction in the latency to fall in older mice which is 
accounted for by an increase in body weight. Gfpt1tm1d/tm1d mice demonstrate poor motor 
performance detected as early as 6 weeks old up until 6 months old as shown by a 
reduction in the latency to fall from the grid compared to controls (Latency decrease: 8 
weeks old, 62%; 12 weeks old, 69%; 16 weeks old, 66%; 20 weeks old, 64%; 24 weeks 
old, 63%; Figure 5.10). The deficit in motor performance is not progressive over time. 
We further demonstrate there is no difference in the longest hang time between control 
mice (Cre negative) and mice carrying the Cre transgene over the 6 month period.  
 
 
 
 
 
 
 
 
 
 
Figure 5.10. A comparison of muscle strength between control, Ckm-Cre controls 
and Gfpt1tm1d/tm1d mice. Quantitative analysis of latency to fall from a wire grid at 
various time points up to the age of 6 months. Gfpt1tm1d/tm1d mice perform worse than 
control mice at all time points (p<0.01) (n=8). Ckm-Cre control mice do not exhibit any 
changes compared to controls (n=6). p>0.05, not significant. Data are mean + SEM. 
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5.6.2 Isometric force measurements in situ 
The main procedure for preparing the mouse for measuring force measurements 
produced by the TA muscle is described in the materials and methods chapter of this 
thesis. The electrophysiology measurements were made using an in vivo protocol that 
has been previously described (Dellorusso et al., 2001; Sharp et al., 2008; Sharp et al., 
2011; TREAT- NMD protocols). 
Surgical preparation 
The sciatic nerve branches into the sural, tibial and peroneal nerves. The sural and tibial 
nerves were transected, but the peroneal nerve was left intact. This ensures that only the 
TA muscle remains innervated, and there is no contraction from any other muscle. The 
sciatic nerve was also transected proximally. The sciatic nerve was then placed over 
bipolar platinum electrodes (Figure 5.11).     
 
 
 
 
 
 
 
 
Figure 5.11. Schematic demonstrating surgical preparation required prior to in 
situ force measurements. The tibial and sural nerves were transected. The peroneal 
nerve that innervates the TA muscle was left intact. Finally, the sciatic nerve was 
transected proximally, and bipolar platinum electrodes (grey), were place beneath the 
sciatic nerve. All nerves were transected as indicated (red dotted lines). Medial 
Gastrocnemius (MG), Lateral Gastrocnemius (LG), Plantaris (PL), Soleus (SOL), 
Tibialis Anterior (TA). This image was adapted from (Duraku et al., 2012; Lorenz and 
Jones, 2014). 
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Isometric force measurements  
To confirm the presence of muscle weakness in Gfpt1tm1d/tm1d mice, we studied the 
ability of TA muscles from 3 month old control and Gfpt1tm1d/tm1d mice to evoke twitch 
and tetanic contractions in response to stimulation of the sciatic nerve in situ. Muscles 
were stimulated using a warm up protocol which consisted of 5 stimulations at 50 Hz 
with a minute rest period between each stimulation. The muscle was subject to a series 
of single twitches at increasing tensions (Figure 5.12). The muscle’s optimum length 
(Lo) was determined and the resting tension that produced the strongest twitch was used 
for the remainder of the experiment. The force frequency relationship was determined 
using a series of stimulations at 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz, each 1 
minute apart. A small drop in force occurs during the contractions elicited at stimulation 
frequencies of 150 Hz and 180 Hz, which is indicative of fatigue. A stimulation 
frequency 120 Hz produces a fully fused tetanus with no reduction in force over the 
stimulation period (Figure 5.13). This is the maximum isometric tetanic force (Po) 
which is used for the remaining fatigue experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Representative trace demonstrating the force produced by a single 
twitch in the TA muscle. Twitches were produced by stimulation of the common 
peroneal branch of the sciatic nerve. The resting tension was adjusted until the 
maximum twitch force was produced. The resulting trace was analysed to obtain the 
peak twitch force.  
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Figure 5.13. Representative traces demonstrating the force produced by tetanic 
stimulation of the TA muscle. The sciatic nerve was stimulated at increasing 
frequencies (10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz) with a rest period of 1 
minute between each stimulation.  
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Determining specific force 
The force readings at each frequency recorded in grams (absolute force) were converted 
to specific force (kN/m2). Specific force is the absolute force normalised to cross-
sectional area (CSA) of the of the muscle.  
The following formula was used to determine the CSA of the muscle:   
 
The force produced at each stimulation frequency was measured in grams and converted 
to Newtons (N) by multiplying by 0.00981.  
 
Specific force (N/cm2) was calculated using the following formula: 
 
Specific force was plotted against frequency. Our data demonstrates that there is no 
significant difference in muscle strength between control and Gfpt1tm1d/tm1d mouse 
following upon tetanic stimulations (Figure 5.14).  
 
 
 
 
 
 
 
 
 
 
 
 
Specific force (N/cm2) = Absolute force (N)/CSA (cm2) 
CSA = muscle weight (g)/[Optimum TA fibre length (Lf, cm) × 1.06 (g/cm3] 
 
1.06g/cm3 is the density of mammalian skeletal muscle.  
Lf = optimal length (Lo) x 0.6 which represents the fibre length: muscle length ratio 
for the TA (Brooks and Faulkner, 1988).  
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Figure 5.14. Mean specific force produced by the TA muscle following tetanic 
stimulation of the sciatic nerve at increasing stimulation frequencies in 3 month 
old control and Gfpt1tm1d/tm1d mice. The sciatic nerve was stimulated by a series of 
isometric contractions with frequencies of 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz, 
with a delay of 1 minute between each stimulation. There is no observed difference in 
the force produced between control and Gfpt1tm1d/tm1d mice. (n=5). Data are mean + SEM. 
p>0.05. ns, not significant at any frequency. 
 
Testing for fatigue in Gfpt1tm1d/tm1d mice  
We assessed muscle fatigue following a series of tetanic nerve stimulations at 120 Hz 
(the frequency that usually resulted in Po) over 100 stimulations. Muscle fatigue was 
observed in both control and Gfpt1tm1d/tm1d mice. After 100 stimulations control mice 
demonstrated a 26.1% reduction in force produced compared to baseline, whereas 
Gfpt1tm1d/tm1d mice showed a 64.7% deficit, exhibiting a more pronounced degree of 
fatigue. A progressive decrease in the force produced in Gfpt1tm1d/tm1d mice is evident 
from 60 stimulations (60, 22.3%; 70, 26.0%; 80, 42.9; 90, 47.7%; 100, 64.7%), whereas 
a significant reduction in control mice is only evident following 100 stimulations 
compared to baseline (Figure 5.15A). A comparison of fatigability between control and 
Gfpt1tm1d/tm1d mice showed the latter exhibit a significant and progressive reduction in 
force produced after 80 (20.77%), 90 (26.37%) and 100 (38.67%) stimulations (Figure 
5.15B). Our data demonstrates that although Gfpt1tm1d/tm1d mice do not display 
pronounced changes in TA muscle strength, the muscle is more susceptible to 
fatigability.  
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Figure 5.15. Analysis of muscle fatigue. (A) Quantitative analysis of force generated 
by the TA muscle after every 10 stimulations of the sciatic nerve in 3 month old control 
and Gfpt1tm1d/tm1d mice (n=5). Data are expressed as a percentage of baseline force. (B) 
Quantification of fatigability of the TA muscle after 80, 90 and 100 stimulations of the 
sciatic nerve in 3 month old control and Gfpt1tm1d/tm1d mice (n=5). Data are expressed as 
the percentage decrease of baseline force. Data are mean + SEM. *p<0.05, **p<0.01, 
***p<0.001.  
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5.6.3 Isometric force measurements in vitro 
We assessed the contractile properties of the diaphragm muscle from Gfpt1tm1d/tm1d mice 
using an in vitro test apparatus which has been previously described in Chapter 2 of this 
thesis. We examined the ability of muscles to contract following a series of tetanic 
stimulations. Control and Gfpt1tm1d/tm1d muscles maintained tetanic contractions with 
stimulation frequencies ranging from 30-150 Hz. However, Gfpt1tm1d/tm1d muscles 
develop less force than control ones (Figure 5.16). Quantitative analysis revealed that 
the isometric tetanic maximal force on muscle strength was significantly reduced 
compared to controls (150 Hz, 35.3%).  
 
 
 
 
 
 
 
 
 
Figure 5.16. Analysis of contractile properties of diaphragm muscle from 
Gfpt1tm1d/tm1d mice. Average isometric tetanic maximal force at 150 Hz on diaphragm 
muscle from control and Gfpt1tm1d/tm1d mice (n = 4). Data are mean + SEM. ***p<0.001.  
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Fatigue 
We tested for fatigue using a series 100 tetanic nerve stimulations at 150 Hz (the 
frequency resulting in Po). We did not observe signs of fatigue in control diaphragms, 
but we see a progressive reduction in force between 50 and 100 stimulations in 
Gfpt1tm1d/tm1d diaphragms compared to baseline (50, 5.6%; 60, 16.8%; 70 19.4%; 80, 
20.9%; 90, 23.5%; 100, 29.8%) (Figure 5.17A). We compared the reduction in force 
produced between control and Gfpt1tm1d/tm1d mice expressed as percentage fatigability. 
Gfpt1tm1d/tm1d mice demonstrate a significant and progressive reduction in force from 50-
100 stimulations when compared to controls, (50, 5.6%; 60, 16.8%; 70, 19.4%; 80, 
20.9%; 90, 23.5%; 100, 29.8%) (Figure 5.17B).  
 
 
Figure 5.17. Analysis of fatigue in diaphragm muscle from Gfpt1tm1d/tm1d mice. (A) 
Quantitative analysis of force generated by the diaphragm muscle after every 10 
stimulations in 3 month old control and Gfpt1tm1d/tm1d mice. Data are expressed as a 
percentage of baseline force. (B) Quantification of fatigability of the diaphragm muscle 
between 50 and 100 stimulations in 3 month old control and Gfpt1tm1d/tm1d mice. Data are 
expressed as a percentage reduction in force. (n=4). Data are mean + SEM. NC, no 
change. *p<0.05, **p<0.01,***p<0.001.  
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5.7 Evaluation of AChR stability   
To establish whether the stability of AChRs is compromised in Gfpt1tm1d/tm1d mice, we 
assessed the turnover rate of AChR in the TA muscle of 3 month old control and mutant 
mice over a 10 day period. Fluorescence signals of ‘old’ and ‘new’ receptors labelled 
green and red respectively were monitored using confocal microscopy (Figure 5.18A). 
Quantitative assessment of relative pixel intensities using automated image analysis 
demonstrates no significant difference between Gfpt1tm1d/tm1d and control mice (Figure 
5.18B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18. AChR turnover in TA muscles from control and Gfpt1tm1d/tm1d mice. 
(A) Confocal Z-stack images of old-receptor signals labelled with BGT-488 (green), 
new-receptor signals labelled with BGT-647 (red) and overlay. (B) Quantification of 
relative pixel intensity between control and Gfpt1tm1d/tm1d mouse muscle (n=3). Data are 
mean + SEM. p>0.05, ns, not significant.  
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5.8 Proteomic profiling experiments  
5.8.1 Effects of GFPT1 deficiency on the intercostal muscle proteome 
Proteomics is a powerful tool for the unbiased investigation of pathophysiological 
processes in neuromuscular disorders (Roos et al., 2016). We compared the proteome 
profile of intercostal muscles from 3 month old control and Gfpt1tm1d/tm1d mice using 
quantitative mass spectrometry (label-free shotgun proteomic approach). We found that 
2.8 % of the quantified proteins (43 out of 1517) were differentially expressed upon 
GFPT1 deficiency in intercostal muscles, 39 of these proteins were upregulated (29 
identified with two or more unique peptides and 10 with one unique peptide) and 4 
downregulated (all identified with one unique peptide). Most of the affected proteins are 
localized in the ER-Golgi network, plasma membrane, cytoplasm, nucleus and 
mitochondria. For a list of regulated proteins, their subcellular localization and proposed 
functions, see Appendix A (Pundir et al., 2017). 5 out of the 39 upregulated proteins, 
and 1 out of the 4 downregulated proteins harbour N-glycosylation (N-GlcNAc) sites. 1 
out of the 4 downregulated proteins harbor O-glycosylation (O-GlcNAc) sites, (Table 
5.1). To provide insight into GFPT1 myopathology, the spectrum of affected proteins 
was analyzed for enriched gene ontology (GO) terms using STRING (Figure 5.19). 
Regulated proteins found to have connections with each other are shown in the 
STRING.     
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Table 5.1. Regulated proteins with N- and O-glycosylation sites.  
Protein Gene Abundance Type and no. of 
glycosylation sites 
Aminopeptidase N Anpep Upregulated N- GlcNAc (17) 
 
Complement C4-B  C4b Upregulated N- GlcNAc (4) 
 
Glypican-1  Gpc1 Upregulated N- GlcNAc (2)  
O-Xylose (3) 
Vesicular integral-membrane 
protein  
Lman2 Upregulated N- GlcNAc (1) 
 
Vitronectin Vtn Upregulated N- GlcNAc (3) 
UDP-N-acetylglucosamine-peptide 
N-acetylglucosaminyltransferase  
 
Ogt Upregulated O- GlcNAc (2) 
Uncharacterized family 31 
glucosidase KIAA1161  
 
Kiaa1161 Downregulated  N- GlcNAc (3) 
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Figure 5.19. Analysis of protein interaction network by STRING. The spectrum of 
affected proteins was analyzed for enriched gene ontology (GO) terms. Upregulated 
proteins are shown in green and downregulated proteins are shown in red; p< 0.05. The 
relative expression of remaining proteins did not change. All proteins shown 
demonstrate known and predicted protein-protein interactions. 
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5.8.2 Immunoblot analysis showing the relative expression of glypican-1 and MuSK 
in control and Gfpt1tm1d/tm1d mouse tissues 
Using immunoblot studies, we have verified the proteomic findings for glypican-1, a 
cell surface proteoglycan that bears heparan sulfate and participates in axon guidance, 
Schwann cell myelination and is required for proper skeletal muscle differentiation. 
Moreover, we demonstrated an increased abundance of the MuSK protein, a major 
regulator required for the formation and maintenance of the NMJ (Figure 5.20A). 
Muscles used for analysis were derived from 3 month old control and Gfpt1tm1d/tm1d 
intercostal muscles. The relative expression levels between control and mutant 
intercostal tissues was analysed using the gel analysis tool on ImageJ software. 
Glypican-1 (Figure 5.20B) and MuSK (5.20C) are considerably more abundant in 
Gfpt1tm1d/tm1d mice when compared to controls.  
 
 
 
Figure 5.20. Immunoblot analyses showing the relative expression levels of 
glypican-1 and MuSK in mouse tissues. Glypican-1 (~62 kDa) and MuSK (~97 kDa) 
proteins are upregulated in Gfpt1tm1d/tm1d intercostal muscles (A). Alpha-actinin (~103 
kDa) was used as a loading control. All bands were measured against an 8-260 kDa 
Chameleon Duo Ladder protein ladder. Graph demonstrating the relative expression 
levels of glypican-1 (B) (n=3), and MuSK (C) (n=2), normalised to their corresponding 
alpha-actinin loading controls.  
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5.9 Discussion 
The frequency of mice born does not reflect the Mendelian frequencies of the four 
expected genotypes. Only 4% of offspring harbour the Gfpt1tm1d/tm1d genotype, instead 
of the expected 25%. These findings suggest potential embryonic lethality upon 
disruption of Gfpt1. Why some mutant mice survive and not others will require further 
investigation. In Chapter 3 we describe the spatial and temporal expression of Cre 
recombinase using the ROSA26R-lacZ reporter line. Although we rule out inconsistent 
Cre activity in the developing embryo and major adult tissues, there may be some Cre 
activity which remains undetected. Ckm-Cre may be expressed prematurely in embryos 
or in extraembryonic tissues, which consequently depletes GFPT1 required for survival. 
Since we observe normal litter sizes, it is possible that the mice are lethal prior to pre-
implantation due to premature GFPT1 depletion. Alternatively, it is possible that the 
embryos that experience Cre activity on the lower end of the spectrum, i.e. lower 
recombination efficiency, can survive through to adulthood due to small amounts of 
residual GFPT1 expression. Although we do not address the level of GFPT1 depletion 
at different stages in the developing embryo, we demonstrate complete knockout of 
GFPT1 in skeletal and cardiac tissues of the adult mouse using immunoblot analyses, 
which validates this model for studying the maintenance of the NMJ. Whilst the 
survival of CMS knockout mouse models often result in embryonic or early postnatal 
lethality (Dechiara et al., 1996; Gautam et al., 1996; Okada et al., 2006; Weatherbee et 
al., 2006), Gfpt1tm1d/tm1d offspring survive through to adulthood and do not die 
prematurely. Furthermore, we do not observe any gross phenotypical defects or 
significant changes in body weight in mutant mice.   
In humans GFPT1 expression is ubiquitous. Consequently, the NMJ phenotypes we see 
in patients may be due to a deficiency of GFPT1 in both presynaptic and postsynaptic 
structures at the NMJ. The Gfpt1tm1d/tm1d mouse model conserves GFPT1 expression in 
all tissues except muscle. Prior to this study it was unknown whether depletion of 
GFPT1 in muscle only would be sufficient to produce a CMS-like phenotype.  
 
Examination of NMJs in muscles from Gfpt1tm1d/tm1d mice demonstrate changes in 
endplate architecture, highlighting the importance of muscle derived GFPT1 in NMJ 
differentiation. Pathology of the AChR is illustrated by fragmentation and reduction in 
size of AChR clusters in all muscles examined.  
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Pathological endplates were also evident at the ultrastructural level in NMJs of 
intercostal muscles which harboured fewer, simplified junctional folds; a common 
feature seen in GFPT1 patients (Selcen et al., 2013; Maselli et al., 2014), as well as 
other mouse models of congenital myasthenia (Chevessier et al., 2008; Bogdanik and 
Burgess, 2011; Messéant et al., 2015). Structural changes in the presynaptic or 
postsynaptic components of the NMJ may compromise the safety margin of 
neurotransmission. Junctional folds harbour a high density of Na+ channels in the 
troughs of the folds as well as increase the series resistance of the postsynaptic 
membrane. Both factors are important for membrane depolarisation. Simplification of 
the folds may therefore be a major contributor to impaired neurotransmission. Another 
possible pathomechanism is an increased chance of acetylcholine escaping the synaptic 
cleft before it reaches the postsynaptic membrane (Wood and Slater, 2001). This theory 
is supported by patient use of cholinesterase inhibitors which ameliorate muscle 
weakness in many subtypes of CMS. A reduction in the number of junctional folds may 
therefore be accountable for the fatigable muscle weakness we observe in Gfpt1tm1d/tm1d 
mice.  
 
We also observe presynaptic morphological alterations in mutant mice. We see 
remodelling of motor nerve terminals which form synaptic contacts with the fragmented 
AChRs. Since our model conserves GFPT1 expression in non-muscle tissues we 
hypothesise that the presynaptic alterations we observe in Gfpt1tm1d/tm1d NMJs are 
secondary to the pathological changes in the postsynaptic apparatus, via impaired 
retrograde signalling required for axon guidance during synaptogenesis (Chen and 
Cheng, 2009; Wu et al., 2010). Previous studies have shown the implication of muscle 
derived BMP in stimulating presynaptic growth and development (Ball et al., 2010; 
Berke et al., 2013). Furthermore, the inducible LRP4 muscle-specific knockout mouse 
model displays both presynaptic and postsynaptic remodelling (Barik et al., 2014), 
where muscle derived LRP4 has been shown to mediate presynaptic differentiation via a 
retrograde signalling mechanism (Yumoto et al., 2012). Similarly, a muscle-specific 
conditional β-catenin knockout mouse strain demonstrates morphological and functional 
defects in nerve terminals at the NMJ, yet in motor neuron specific β-catenin knockout 
mice, the morphology and function of the NMJ remains unaffected (Li et al., 2008).  
These findings indicate the roles of muscle-derived proteins in regulating presynaptic 
differentiation and function. It is therefore highly plausible that the presynaptic changes 
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we observe in Gfpt1tm1d/tm1d mice, occurs due to defective secreted proteins from the 
muscle. We speculate that misglycosylation of muscle derived proteins in this mouse 
model impairs retrograde signalling mechanisms required for neuronal differentiation or 
maintenance. Interestingly BMP and LRP4 harbour N-glycosylation sites for GlcNAc 
and β-catenin undergoes O-GlcNAcylation. These proteins could potentially be affected 
by GFPT1 deficiency. Alternatively, misglycosylated binding partners or activators of 
retrograde signalling proteins can also disrupt their function. Examples include N-linked 
Wnt glycoproteins of Wnt/β-catenin pathway and N-glycosylated LRP4 binding 
partners such as agrin and MuSK (Zhang et al., 2009).  
 
We also observe thinner, irregular myelin sheaths in mutant mice. Perisynaptic 
Schwann cells that myelinate motor axons at the NMJ are known contributors of 
synaptogenesis and synaptic transmission (Feng et al., 2005; Cao and Ko, 2007; Wu et 
al., 2010). Cross-talk between proteins of the postsynaptic membrane, motor nerve and 
Schwann cells is essential for the integrity and function of the synapse (Wu et al., 
2010). Previous studies have shown the role of laminin β2 (Maselli et al., 2009), agrin 
(Maselli et al., 2012) and COL13A1 (Latvanlehto et al., 2010; Logan et al., 2015) in the 
correct organisation of Schwann cells. A deficiency in these proteins results in 
remodelling of Schwann cells often resulting is encasement of the nerve terminal and 
invasion of the synaptic space, which subsequently impairs surface contact for 
neurotransmission. The changes we see in myelination in GFPT1 deficient mice may 
occur because of misglycosylated muscle proteins that directly affect Schwann cell 
morphology and function. Alternatively, the changes we observe in the motor neuron 
may subsequently induce changes in Schwann cell myelination. It is challenging to 
study the precise mechanisms underlying presynaptic alterations due to the complexity 
of processes underlying NMJ differentiation, together with the ubiquitous nature of the 
GFPT1 glycosylation pathway which may give rise to thousands of NMJ proteins that 
are potentially affected.  
 
Examination of muscle biopsies from patients with mutations in GFPT1 revealed 
variations in myofibre size, an increase in the number of central nuclei, atrophic fibres, 
fibres that showed splitting and few necrotic and regenerating fibres. Additionally, there 
is an increase in glycogen staining, rimmed vacuoles and tubular aggregates (Selcen et 
al., 2013; Brady et al., 2016). Analyses of second biopsies from the same patients 
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demonstrate that pathological changes are progressive over time. Tubular aggregates 
further appear to increase in size, but their relative expression remains unchanged 
(Brady et al., 2016). Histopathological alterations seen in muscle biopsies from patients 
with mutations in GFPT1 closely resembles those with mutations in DPAGT1.  
 
Examination of Gfpt1tm1d/tm1d mouse muscle revealed abnormal variations in myofibre 
size, few regenerating and necrotic fibres and the presence of tubular aggregates. Our 
model more closely resembles the myopathic phenotype that we see in a single patient 
harbouring the c.686-2A>G mutation which disrupts the longer muscle-specific isoform 
of GFPT1 resulting in the absence of glycosylated protein expression (Selcen et al., 
2013). In the diaphragm muscle, we observe a progressive replacement of muscle tissue 
by fibroadipose tissue, indicative of muscle fibre atrophy, which was not apparent in 
younger (6 week old) mice. Similar features are also seen in muscle biopsies from 
DPAGT1-CMS patients (Basiri et al., 2013). Recent investigations into myopathic 
changes in patients has been facilitated by muscle MRI. Findings demonstrate fatty 
infiltration in muscle which is more pronounced in patients with mutations in genes 
encoding proteins in the glycosylation pathway (Finlayson et al., 2016). Whilst minor 
myopathic changes are sometimes seen in some subtypes of CMS, secondary to 
neurotransmission failure (Selcen et al., 2011; Nicole et al., 2014), myopathic changes 
are more pronounced in patients with mutations in GFPT1 and DPAGT1. Dystrophic 
changes are also observed in patients with GMPPB mutations. These findings are not 
surprising due to the ubiquitous activity of these glycosylation enzymes.   
 
Since glycosylation is a ubiquitous post-translational modification, it is highly probable 
that glycosylation of proteins other than those required for the formation and 
maintenance of the NMJ complex are misglycosylated in GFPT1 deficient mice, which 
explains the myopathic phenotype and disruption of contractile properties observed. 
Hypoglycosylation may disrupt cytoskeletal proteins that maintain the integrity of 
skeletal muscle during muscle contractions (Huizing et al., 2004; Reed et al., 2004; 
Herbst et al., 2009) or affect regulatory and contractile proteins that modulate Ca2+ 
homeostasis and muscle contraction, as well as structural proteins of the sarcomere 
(Hedou et al., 2007; Cieniewski-Bernard et al., 2012; Leung et al., 2013; Cieniewski-
Bernard et al., 2014a). Many of these proteins harbour N- and O-linked GlcNAc 
acceptor sites, making them potential candidates subject to misglycosylation 
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downstream of impaired glycosylation enzymes implicated in CMS. Proteins that 
maintain the integrity of the sarcolemma which are modified by N-GlcNAc moieties 
include the sarcoglycan subunits (α, β, δ, γ), α-dystroglycan and β-dystrogylcan. 
Contractile proteins such as actin, myosin heavy chain and myosin light chain proteins 
as well as key proteins involved in the sarcomeric structure including desmin, actinin, 
αB-crystallin, and ZASP are known to be O-GlcNAc modified (Hedou et al., 2007; 
Cieniewski-Bernard et al., 2012; Leung et al., 2013). Localisation of OGT (the enzyme 
that mediates O-GlcNAcylation) at the sarcomere, and in particular the Z-disk region, 
suggests an important role of O-GlcNAcylation of sarcomeric proteins (Cieniewski-
Bernard et al., 2014b). Our preliminary data shows a reduction in sarcomere length in 
mutant mice which may be attributed to misglycoslylated structural proteins of the 
sarcomere. Identification of affected proteins will require further investigation.  
 
Analysis of muscle from 3 month old Gfpt1tm1d/tm1d mice shows the presence of tubular 
aggregates, which was absent in muscle tissues from younger (6 week old) mice. These 
findings are consistent with the idea that tubular aggregate formation is age-dependent 
(Boncompagni et al., 2012). Not only are they present in muscle biopsies from patients 
with mutations in proteins involved in the glycosylation pathway (Belaya et al., 2012; 
Huh et al., 2012; Cossins et al., 2013; Selcen et al., 2013; Selcen et al., 2014), but they 
are also implicated in other myopathies as a result of STIM1 and ORAI1 mutations 
(Chevessier et al., 2005; Bohm et al., 2014; Endo et al., 2015). Tubular aggregates have 
also been identified in Caveolin1-/- and Caveolin2-/- mouse models (Schubert et al., 
2007), and wild type inbred male or ageing mice (Chevessier et al., 2004). 
Subsarcolemmal tubular aggregates are classified as densely packed vesicular or tubular 
membranes derived from the terminal cisternae or longitudinal components of the SR, 
and are located between myofibrils beneath the sarcolemma (Chevessier et al., 2004; 
Schubert et al., 2007; Schiaffino, 2012). Other studies have demonstrated that 
mitochondria may be implicated in the formation of tubular aggregates (Novotova et al., 
2002; Schubert et al., 2007). Whether tubular aggregates are direct pathological 
components contributing to the observed phenotype, or whether they represent a 
compensatory mechanism to pathological events, is poorly understood. 
The main function of the SR is to regulate muscle contraction through calcium uptake, 
storage and release (Brady et al., 2016). A common hypothesis is that tubular 
aggregates are products of a disruption of Ca2+ homeostasis. Immunohistochemistry 
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studies on inbred mouse muscle have shown that tubular aggregates are immunoreactive 
to SR markers SERCA1, sarcalumenin, calsequestrin, Ryanodine receptor 1 (RyR1), 
and triadin (Chevessier et al., 2004). Furthermore, SERCA-1, SERCA-2, GRP78 and 
calsequestrin were identified in tubular aggregates found in caveolin-2 deficient mice 
(Schubert et al., 2007). Analysis of cytoskeleton markers, spectrin, dystrophin, and 
desmin remain undetected (Chevessier et al., 2004). Immunoblot studies further 
demonstrate that the expression levels of these SR proteins remained unchanged when 
compared to control mice, suggesting the formation of tubular aggregates is not because 
of an increase in SR proteins, but rather translocation of existing proteins (Schubert et 
al., 2007).   
In the context of defective glycosylation induced-CMS, one hypothesis is that the 
tubular aggregates occur due to an accumulation of hypoglycosylated proteins. 
Immunohistochemistry studies on GFPT1-CMS and DPAGT1-CMS patient muscle 
biopsies have confirmed the presence of proteins that regulate Ca2+ homeostasis, RyR1, 
SERCA1, SERCA2 and DHPR (dihydropyridine receptors) in tubular aggregates. Some 
tubular aggregates also contain dysferlin in some, but not all patient biopsies. Since 
these proteins do not harbour N- and O- glycosylation (GlcNAc) sites, we hypothesise 
that these findings occur secondary to misglycosylated muscle proteins. SR markers 
calsequestrin, triadin and sarcalumenin are known to harbour N-GlcNAc sites. Further 
investigation is required to see whether these proteins are observed in tubular aggregates 
of Gfpt1tm1d/tm1d muscle.   
 
Interactions between stromal interaction molecule 1 (STIM1) and calcium release-
activated calcium channel protein 1 (ORAI1), are also involved in Ca2+ regulation and 
are responsible for store-operated Ca2+ entry (Wang et al., 2015). Stromal interaction 
molecule 1 (STIM1) contains an extracellular SAM domain which is modified by N-
linked glycosylation (Williams et al., 2002). One hypothesis that deficiency in GFPT1 
may impair glycosylation of STIM1, destabilising the Ca2+ channel ORAI1 (Kilch et 
al., 2013) resulting in the formation of tubular aggregates (Endo et al., 2015). Notably, 
STIM1 mutations identified outside of the SAM domain also induce the formation of 
tubular aggregates (Böhm et al., 2014). Therefore, the presence of tubular aggregates is 
not solely attributed to hypoglycosylation of STIM1, but may occur because of a 
combination of pathomechanisms.  
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Analysis of tubular aggregates in biopsies from patients with tubular aggregate 
myopathies are immunoreactive to some but not all proteins mentioned here (Brady et 
al., 2016). This further demonstrates that tubular aggregates are not defined by a 
conserved group of proteins but differ between patients and disease causing 
mechanisms. Moreover, tubular aggregates vary in size and morphology suggesting 
there are different subtypes of tubular aggregates with different compositions (Brady et 
al., 2016).  
 
We also observe abnormal subsarcolemmal vesicular structures in Gfpt1tm1d/tm1d mouse 
muscle that may correspond to caveolae. Caveolae are plasma membrane invaginations 
found in numerous cell types found under normal conditions (Cohen et al., 2004; Lo et 
al., 2016). They are characterised by their size, morphology and are accompanied by 
presence of caveolin proteins. Caveolins are known to have multiple functions, and are 
required for the formation of caveolae (Williams and Lisanti, 2004). One proposition 
for the functional role of caveolae in skeletal muscle is protection of muscle 
sarcolemma against damage. Caveolae provide an increased surface area of the 
sarcolemma which serves as a reservoir during excess membrane activity during muscle 
contraction. The number of caveolae might be upregulated as a protective mechanism in 
muscle disease (Lo et al., 2016). There are currently no reports of distinct caveolae 
structures in GFPT1-CMS or DPAGT1-CMS patient muscle biopsies, nor were they 
immunoreactive for caveolin proteins (Brady et al., 2016). Identification of caveolins in 
Gfpt1tm1d/tm1d mouse muscle will confirm whether these structures are indeed caveolae. 
These studies can be facilitated by immunoelectron microscopy.   
 
Muscle weakness and fatigue are common characteristics of numerous muscle 
disorders, with several possible causes. Fatigable muscle weakness can be induced by a 
disruption in neuromuscular transmission, defective propagation of an action potential, 
or aberrant excitation-contraction coupling and contractile mechanisms (Boyas and 
Guevel, 2011). Whilst morphological differences are often observed in human CMS and 
other mouse models of CMS, suggesting impairment of the NMJ, they are not 
necessarily indicators of impaired neurotransmission. This is evident in recent 
investigations that reveal no decline in neurotransmission in age-related fragmentation 
of AChRs (Willadt et al., 2016). It is therefore important to use direct methods to 
evaluate the efficacy of neurotransmission by testing muscle strength and fatigue. Here 
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we use functional tests including the inverted screen test and isometric force 
measurements of the TA muscle by direct stimulation of the sciatic nerve which 
demonstrates that Gfpt1tm1d/tm1d mice show a greater susceptibility to fatigue. This a 
common feature seen in other mouse models of congenital myasthenia (Chevessier et 
al., 2008; Bogdanik and Burgess, 2011; Messéant et al., 2015) and characteristic of 
human CMS (Guergueltcheva et al., 2012; Huh et al., 2012; Belaya et al., 2015).     
Interestingly, we also see a pronounced deficit in muscle strength and fatigue following 
direct stimulation of the diaphragm muscle from GFPT1 deficient mice. These findings 
are indicative of a myopathic phenotype consistent with our histopathological findings 
and EMG recordings in patients with mutations in GFPT1 as well as other genes in the 
glycosylation pathway such as ALG2, ALG14, DPAGT1, and GMPPB (Guergueltcheva 
et al., 2012; Huh et al., 2012; Basiri et al., 2013; Cossins et al., 2013; Selcen et al., 
2013; Maselli et al., 2014; Selcen et al., 2014; Belaya et al., 2015). Since Gfpt1tm1d/tm1d 
mice demonstrate fatigue following direct stimulation of the muscle, the force deficit we 
observe resulting from direct stimulation of the sciatic nerve is likely to be due to a 
combination of impaired neurotransmission and myopathic changes. Further 
investigation would involve isolated nerve-muscle preparations of the diaphragm which 
would allow us to compare differences between contractile response upon electrical 
stimulation of the nerve and direct stimulation of the muscle membrane. Any changes 
between the two contractile responses can be attributed to a defect in NMJ function. 
Alternatively, ex vivo electrophysiological recordings can be used to measure miniature 
EPPs and nerve-evoked EPPs which can also be used to estimate quantal release (Plomp 
et al., 2015). 
 
Under normal conditions, AChRs cluster and stabilise at the postsynaptic membrane. 
Thereafter they are endocytosed, recycled back to the membrane or are degraded. The 
AChR turnover rate is rapid (half-life ~ 1 day) in newly formed synapses. In adult 
synapses the turnover rate is slower (half-life ~10days) (Fumagalli et al., 1982; 
Yampolsky et al., 2010; Rudell and Ferns, 2013; Rudolf et al., 2013; Khan et al., 2014). 
Recycling of the AChR may serve as a quality control mechanism whereby defective 
AChRs are degraded, and new ones are generated and reinserted into the muscle 
membrane (Yampolsky et al., 2010). One hypothesis is that the pathological findings 
seen in CMS maybe be due to instability of AChRs. In the context of GFPT1 
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deficiency, we hypothesise that the turnover rate of AChRs may be increased due to 
defective glycosylation of the AChR subunits. Alternatively, hypoglycosylation of 
proteins that stabilise AChRs on the muscle membrane may also increase the AChR 
turnover rate. Here we found that not only is the relative expression of AChRs in the 
Gfpt1tm1d/tm1d model maintained, but there is also no change in the turnover rate of 
AChRs, suggesting that the stability of AChRs are not compromised. It may be the case 
that (i) impaired glycosylation of individual AChR subunits is not pathogenic with 
regards to AChR stability, or perhaps (ii) GFPT1 is not primarily responsible for the 
glycosylation of NMJ proteins involved in the formation and stability of AChRs.  
Our proteomic data has highlighted many differentially regulated proteins in GFPT1 
deficient intercostal muscle. We observe regulation of proteins involved in organisation 
of the cytoskeleton (Rho GDP-dissociation inhibitor 2, Annexin A1, Ras GTPase-
activating-like protein IQGAP1, KN motif and ankyrin repeat domain-containing 
protein 2), transport and sorting of glycoproteins (Vesicular integral-membrane protein 
VIP36), and extracellular matrix proteins important for skeletal muscle fibre integrity 
(Vitronectin). Proteins of interest discussed here include those involved in the 
glycosylation pathway, proteins that harbour N- and O- GlcNAc acceptor sites, and 
proteins that have a functional role at the NMJ.   
 
We identify an upregulation of UDP-N-acetylglucosamine-peptide N 
acetylglucosaminyltransferase, also referred to as O-GlcNAc transferase (OGT), 
encoded by the Ogt gene. OGT is responsible for catalysing the addition of a single 
GlcNAc to a serine or threonine residue in the O-GlcNAcylation pathway (Hanover et 
al., 2010). There are several possible reasons why we observe an increase in OGT 
expression resulting from GFPT1 deficiency. Notably, the most important factor that 
regulates OGT activity is the cellular levels of UDP and UDP-GlcNAc. Under normal 
conditions, upon transfer of the GlcNAc moiety, the UDP released acts as a feedback 
inhibitor of OGT. When UDP is removed from cells, OGT is dependent on the levels of 
UDP-GlcNAc. It is likely that the abnormally abundant expression of OGT we observe 
in GFPT1 deficient muscle occurs due to a lack of the precursor donor UDP-GlcNAc, 
and reduced suppression of OGT (Hart and Akimoto, 2009). Interestingly, a global 
increase in O-GlcNAcylation of proteins is known to occur in all mammalian cell types 
in response to cellular stress. An increase in OGT activity results in cells that are more 
tolerant to cellular stress, by upregulating heat shock proteins that protect cells from 
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stress, amongst numerous other mechanisms (Groves et al., 2013). Therefore, it is 
possible that the upregulation of OGT we observe in Gfpt1tm1d/tm1d mouse muscle may 
occur because of the pathological changes taking place in the muscle. 
Finally, OGT itself is O-GlcNAcylated. One possible explanation for the upregulation 
of OGT is to compensate for defective OGT activity. 
Our proteomic profiling data also highlights an increase in the expression levels of the 
farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (FNTA) protein, an 
essential subunit of the geranylgeranyltransferase (GGT) complex which is implicated 
in synapse formation by playing an active role in the agrin/MuSK pathway (Luo et al., 
2003). The α subunit of GGT interacts with the kinase domain of MuSK. Thereafter, 
agrin increases tyrosine phosphorylation of GGT which facilitates Rho GTPase 
activation required for the regulation of actin dynamics responsible for AChR 
trafficking (Wu et al., 2010). Inhibition of GGT activity prevents agrin-induced AChR 
clustering (Luo et al., 2003; Strochlic et al., 2005). Since we observe aberrant AChR 
clusters in GFPT1 deficient mouse muscle, we speculate that GGT is upregulated in 
attempt to recruit and cluster more AChRs to the muscle membrane. Notably, we also 
see an increase in the expression of MuSK proteins, also essential for AChR clustering 
(Chevessier et al., 2008; Maselli et al., 2010; Messéant et al., 2015), which we 
hypothesise may serve a similar purpose. This idea stems from experimental evidence 
from denervation studies which show that under normal conditions MuSK is restricted 
to the motor endplate, but upon denervation there is a marked upregulation of MuSK in 
the extrasynaptic membrane (Bowen et al., 1998). Moreover, increasing MuSK activity 
was shown to delay denervation and improve motor function mice (Perez-Garcia and 
Burden, 2012). Despite an upregulation of MuSK in Gfpt1tm1d/tm1d mice, AChR clusters 
appear smaller than those in control mice. This finding suggests that increased levels of 
MuSK is unable to promote AChR clustering. Further studies would involve 
investigating proteins downstream of MuSK in attempt to identify proteins with 
possible pathogenic mechanisms.   
 
We see a robust increase in the expression levels of glypican-1, a cell surface, lipid- raft 
associated heparan sulphate proteoglycan (HSPG) that participates in axon guidance, 
Schwann cell myelination (Chernousov et al., 2006), and is important for modulating 
growth factors and influencing skeletal muscle differentiation (Litwack et al., 1998). 
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Since suppression of glypican-1 significantly inhibits myelination (Chernousov et al., 
2006), it is possible that hypomyelination of the presynaptic nerve that we observe in 
Gfpt1tm1d/tm1d mice may induce upregulation of glypican-1 as a compensatory 
mechanism. Interestingly, glypican-1 also harbours N-GlcNAc glycans, but was shown 
to maintain its folded conformation in the absence of N-linked glycans (Svensson et al., 
2012). Glypican-1 is mainly expressed in neural tissues and skeletal muscle, with some 
expression in other tissues. Expression of glypican-1 in skeletal muscle typically occurs 
during late embryonic development and in the early postnatal stages in rodents (Litwack 
et al., 1998; Yamaguchi, 2002; Casar et al., 2004; Gutierrez and Brandan, 2010; 
Sigoillot et al., 2010). Although there is no obvious evidence of a muscle phenotype in 
glypican-1 knockout mice, myoblasts display defective differentiation in the absence of 
glypican-1 expression. Studies have also shown that glypican-1, as well as other 
heparan sulphate proteoglycans perlecan, syndecan-3, and syndecan-4 are upregulated 
during skeletal muscle regeneration (Casar et al., 2004; Gutierrez and Brandan, 2010; 
Brandan and Gutierrez, 2013). This may account for the robust increase in glypican-1 
expression we observe in GFPT1 deficient mice.  
 
The experiments performed in this chapter establishes a muscle-specific GFPT1 
deficient mouse model representative of the human GFPT1-CMS phenotype. This is the 
first report of a CMS mouse model depicting defective glycosylation. Since GFPT1 lies 
upstream of other glycosylation enzymes also implicated in CMS, it is possible that 
some of findings from this model may also be true for DPAGT1, ALG2, and ALG14 
CMS. Our model provides new insights into differentially regulated proteins that 
demonstrates possible pathological and compensatory mechanisms, and highlights the 
importance of protein glycosylation in maintaining the integrity of the NMJ and muscle.   
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Chapter 6: General discussion and future directions 
 
6.1 Pre-clinical studies for CMS 
An increase in the number of individuals diagnosed with CMS, together with the 
discovery of novel CMS-causing genes, has driven the expansion of research within this 
field. Genotype-phenotype correlations in CMS are greatly impeded by the rarity of the 
disease with few patients harbouring the same mutation, giving rise to heterogenous 
phenotypes. Successful treatment of CMS requires an understanding of the pathogenic 
mechanisms underlying the disease, making it increasingly important for conducting 
pre-clinical research.  
So far, mouse models of CMS have been developed to facilitate the investigation of 
defective NMJ proteins that have a direct effect on neurotransmission, depolarisation of 
the endplate or the development and maintenance of the synapse. These studies have 
provided insights into affected pathways that give rise to the observed CMS phenotype, 
and demonstrate the benefits of treatment with therapeutic compounds (Webster et al., 
2013; Barik et al., 2014; Messéant et al., 2015). 
Whilst CDGs have been widely studied over the years, only recently were mutations in 
genes encoding enzymes in the glycosylation pathway identified as CMS-causing. 
Correct diagnoses of disorders of glycosylation are often hindered, as patients often 
present with multisystem disorders that display highly variable phenotypes. Even if a 
patient were to present exclusively with a CMS phenotype, discovery of the exact 
pathological mechanisms remains challenging due to the multitude of proteins that are 
potentially misglycosylated. This emphasises the need for in vivo models designed to 
facilitate functional studies. A mouse model displaying aberrant glycosylation is 
particularly useful for testing the effects of drug therapies, as the precise molecular 
targets underlying this subtype of CMS remains largely unknown. 
Until now, a mouse model representative of defective glycosylation in CMS had not 
been generated. The work presented in this thesis establishes a mouse model to 
investigate the pathological molecular mechanisms underlying GFPT1 deficiency. We 
report the generation of a novel muscle-specific GFPT1 knockout mouse model which 
recapitulates many aspects of the phenotype observed in patients with GFPT1-CMS. 
We further identify potential molecular pathways which are altered in response to a 
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deficit in GFPT1. We speculate that some of the changes in comparison to wild type 
animals serve as compensatory mechanisms, whilst others may contribute directly to the 
CMS phenotype. 
 
6.2 Evaluation of mouse models for studying CMS 
 
6.2.1 The use of mouse models for investigating CMS  
Although cell culture techniques and zebrafish studies have proven useful for the initial 
characterisation of CMS phenotypes, they are limited to short-term studies and are not 
representative of the complex systems of the human body. In vivo mouse models are 
particularly useful for studying neuromuscular disorders as they permit examination of 
NMJ morphology, muscle pathology and allow testing of motor abilities. Mouse models 
can further be used to study disease progression and the benefits of therapeutic 
treatments.   
There are however some discrepancies between humans and mice which can sometimes 
affect the ability to reproduce mouse models representative of human disease. An 
example specific to neuromuscular disorders is difference in the safety margin of the 
NMJ. The safety margin in humans is quite small whereby neurotransmission is 
impaired due to subtle pathological changes. By contrast, the safety margin in the 
mouse has a higher threshold (Wood and Slater, 2001; Trontelj et al., 2002). This may 
explain why transgenic mouse models of neuromuscular diseases do not always show a 
phenotype, or display abnormalities that are less severe than the patient phenotype. 
Differences in the severity of phenotype between humans and mice are usually 
anticipated by the investigator and can be overcome by critical evaluation of the 
experimental design. Once a valid transgenic mouse line has been established, the 
model becomes a valuable tool for understanding the pathogenesis of the disorder and 
for testing therapeutic compounds (Vainzof et al., 2008).   
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6.2.2 The Gfpt1tm1d/tm1d mouse model for CMS    
The ubiquitous GFPT1 isoform in humans and the house mouse (Mus musculus) share 
approximately 99% of their amino acid sequence (Dehaven et al., 2001), making 
GFPT1 transgenic mice good models for studying human CMS. In human GFPT1-
CMS, mutations reside predominantly in the ubiquitous GFPT1 isoform which often 
results in a reduction in either one of both GFPT1 isoforms. Interestingly, even though 
the muscle-specific knockout mouse model results in complete loss of both isoforms, 
these mice are viable and do not display the debilitating symptoms seen in some 
patients with GFPT1 mutations. One possible explanation for these findings is the 
disparity of the safety margin between humans and mice.  
The Gfpt1tm1d/tm1d model is muscle-specific and does not address functions of the 
presynaptic apparatus that are potentially disrupted. Although this can be regarded as a 
limitation to the model, we demonstrate that GFPT1 deficiency in the postsynaptic 
apparatus alone is enough to cause a CMS phenotype in mice. Moreover, we discovered 
morphological alterations of presynaptic components which is secondary to GFPT1 
deficiency in muscle. Whether the CMS phenotype we observe in patients is exclusively 
attributed to postsynaptic GFPT1 deficiency, requires further investigation. It would be 
interesting to compare data from the muscle-specific knockout model with data from a 
motor neuron-specific Gfpt1 knockout mouse model, to establish the extent to which 
neural and muscle GFPT1 deficiency contributes to the CMS phenotype we observe in 
patients with a global reduction of GFPT1.   
Although GFPT1 is also expressed in cardiac tissues in humans (Dehaven et al., 2001), 
very few patients present with a developing cardiomyopathy. This phenotype occurs 
because of aberrant glycosylation of cardiac proteins (Lewis et al., 2014). GFPT1 is 
also depleted in cardiac tissues in the Gfpt1tm1d/tm1d mouse model. Although we do not 
investigate the possibility of cardiac phenotype in this study, which has the potential to 
influence our muscle fatigue data, we validate our data using unbiased ex vivo and in 
situ techniques to measure force from mouse muscle. Studies to deduce whether these 
mice develop a cardiac phenotype can be facilitated by histopathological staining and 
MRI studies (Stuckey et al., 2012). 
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6.2.3 Alternative gene targeting approaches  
Developments in gene targeting strategies have revolutionised manipulation of the 
genome making it easier and faster to generate transgenic models of human disease. 
Prior to selecting the best approach for generating our transgenic mouse line, we 
critically evaluated the different Cre strains available at The Jackson Laboratory Cre 
Repository. Alternative muscle-specific Cre lines that were considered did not offer any 
advantage over the Ckm-Cre strain. Rather, some strains expressed Cre earlier in the 
developing embryo, whilst others illustrated ectopic expression and mosaicism making 
embryonic lethality more likely (Miniou et al., 1999; Guo et al., 2002).  
CRISPR/Cas9 gene editing technology has proven highly successful for studying 
human diseases (Ablain et al., 2015; Logan et al., 2015; Qin et al., 2016; Torres-Ruiz 
and Rodriguez-Perales, 2017). The advantages of CRISPR/Cas9 over conventional gene 
targeting approaches include improved efficiency, simplicity of the target design and 
allowing mutations to be introduced in multiple genes at the same time. Global 
knockouts and tissue-specific knockout mice are achievable using CRISPR/Cas9, but is 
currently limited to small insertions into the genome which may not be suitable for 
some studies. Due to the novelty of CRISPR/Cas9 and the uncertainty of some of its 
off-site effects, the EUCOMM knockout-first approach is often the preferred choice as 
it is well characterised and most embryonic stem cells are readily available in the 
EUCOMM repository. Another advantage of using the EUCOMM knockout-first 
strategy is its flexibility to generate different alleles. If the global or tissue-specific 
knockout model happens to be embryonic lethal, an inducible Cre strain can be 
incorporated into the strategy to overcome this problem. For now, it is recommended 
that the CRISPR/Cas9 approach is used in parallel to EUCOMM strategies if possible 
(Coleman et al., 2015).   
 
6.3 Congenital disorders of glycosylation  
Since glycosylation is a ubiquitous process, it is not surprising that patients with 
mutations in glycosylation genes exhibit multisystem disorders. An attempt to 
understand why some patients present with certain disease states and not others, as well 
as the selective vulnerability of certain tissues and organ systems remains challenging.  
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The diversity of processes required for glycosylation gives rise to thousands of 
potentially pathogenic mechanisms. CDG may occur because of defects in one or more 
of the following processes: (i) activation or transport of sugar residues, (ii) dolichol and 
dolichol-linked glycan synthesis, (iii) translocation of glycans to different compartments 
(eg. cytoplasmic to lumen of the ER), (iv) transfer of oligosaccharides to the protein (v) 
trafficking or processing of the glycoprotein through the Golgi apparatus, (vi) secretion 
at the end of the multistep pathway (Scott et al., 2014).  
DPAGT1 (Wu et al., 2003; Carrera et al., 2012; Imtiaz et al., 2012; Wurde et al., 2012; 
Jaeken et al., 2015), ALG2 (Thiel et al., 2003) and GMPPB (Carss et al., 2013) have 
previously been associated with CDG. It is yet to be determined why the clinical 
outcome is variable amongst patients with mutations in the same gene. Some patients 
present with multisystem disorders such as CDG, whilst others exhibit a CMS 
phenotype which predominantly results in myasthenia due to impaired neuromuscular 
transmission (Cossins et al., 2003). Analysis of serum transferrin glycoform, commonly 
used to detect defective glycosylation (Sparks and Krasnewich, 2005; Jeppsson et al., 
2007), suggests mild impairment of N-glycosylation in CMS patients in comparison 
with that from CDG patients (Cossins et al., 2003). Thus, it is possible that we observe 
a wide spectrum of clinical outcomes based on the pathogenicity of different mutations 
(Marklova and Albahri et al., 2007).   
Defects in the O-linked glycosylation pathway have also been found to be responsible 
for multiple forms of muscular dystrophy (Martin, 2005; Muntoni et al., 2007; Muntoni 
et al., 2008). So far, mutations in 6 glycotransferases have been discovered which result 
in hypoglycosylation of α-dystroglycan through aberrant events in the O-mannosylation 
pathway. These mutations give rise to dystroglycanopathies with variable phenotypes 
(Muntoni et al., 2007). More recently, reports of overlapping phenotypes of myasthenic 
disorders and dystroglycanopathies as a result of GMPPB mutations have been 
described (Belaya et al., 2015; Montagenese et al., 2016). GMMPB-associated muscular 
dystrophy is marked by hypoglycosylation of α-dystrogylcan (Carrs et al., 2013; 
Raphael et al., 2014). These patients exhibit dystrophic features with variable severities. 
Some patients present with a more severe congenital muscular dystrophy phenotype 
with brain and eye abnormalities, whilst others display a milder limb-girdle muscular 
dystrophy in the proximal limb muscles. Furthermore, a neurotransmission defect is 
only evident in a subset of patients with GMPPB-muscular dystrophy 
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dystroglycanopathy and not others (Belaya et al., 2015). Further reports demonstrate an 
expansion in the phenotypic spectrum of GMPPB mutations including limb-girdle 
muscular dystrophies, with some cases involving intellectual impairment and 
rhabdomyolysis (Cabrera-Serrano et al., 2015). These expanding phenotypes are likely 
due to the ubiquitous nature of GMPPB and its involvement in the glycosylation of 
numerous proteins. The widespread and variable clinical outcomes due to mutations 
within the same gene is yet to be determined.  
It is likely that patients with glycosylation deficient CMS remain undiagnosed due to 
presentation of a complex clinical phenotype which hinders correct diagnosis. Some 
patients also present with a myopathic phenotype which can often be misleading. It is 
possible that with time, more and more genes implicated in CDG will also be identified 
as pathogenic for CMS. Similarly, patients with CMS are also likely to present with 
multisystem disorders, and the characteristic CMS phenotype is likely to expand with 
time (Wurde et al., 2012).  
Common glycotherapies that have been proposed or implemented include the delivery 
of synthetic glycans or glycoproteins downstream of the defective biosynthetic steps, 
upregulating glycosyltransferase expression or activity, and the delivery of 
glycosyltransferase genes via cell or gene therapy techniques (Martin, 2003; Hudak and 
Bertozzi, 2014). One example which demonstrates the successful use of glycotherapies 
in mice, is an overexpression of LARGE in Large myd mice that exhibit impaired 
glycosylation of α-dystroglycan. The outcome of this study demonstrates that 
hyperglycosylation of α-dystroglycan ameliorates muscle pathology and contractile 
performance, and restores neuromuscular junction architecture and transmission deficits 
(Gumerson et al., 2013). Although the NMJ alterations observed in Large myd mice are 
likely to be secondary to the dystrophic phenotype, and thus an improvement in 
neurotransmission occurs through stabilizing the endplate, the idea of restoring 
glycosylation as a therapy, looks promising and can potentially be implemented in 
CMS-CDGs.   
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6.4 Future directions 
Prospective studies will include characterisation of tubular aggregates in Gfpt1tm1d/tm1d 
mice. Tubular aggregates in mouse muscle can be tested for proteins that have 
previously been described in biopsies from GFPT1-CMS and DPAGT1-CMS patients 
and other myopathies. They can also be tested for proteins that harbour GlcNAc 
acceptor sites which have known functions in neurotransmission, muscle stability and 
muscle contraction. Identification of these aggregates will help deduce whether tubular 
aggregates are pathogenic or merely secondary to the CMS phenotype.   
An understanding of the molecular pathology is vital for developing more targeted 
therapies. It is therefore important to perform studies to determine the functional 
significance of regulated proteins that we identified using proteomic profiling studies. 
Investigation of ubiquitous enzymes can be extremely challenging, and it is not feasible 
to address hundreds of potentially modified proteins. An alternative to proteomic 
profiling experiments, which will be particularly useful in this study is the use of 
glycomic studies to address changes in the glycosylation status of proteins. Additional 
experiments will involve investigating the implication of GFPT1 deficiency in cardiac 
tissues and further characterisation of nerve pathology. 
Ultimately, the long-term goal is the discovery of therapeutic strategies that will reverse 
the myasthenic phenotype observed in patients with CMS. To date there are no cures for 
CMS but symptomatic off-label treatments are available. Clinical trial studies are 
currently recruiting CMS patients for the evaluation of 3,4 DAP and amifampridine 
phosphate (phosphate form of 3,4 DAP). These trials involve studies that will enhance 
our understanding of the effects of therapies on the natural course of the disease. Other 
trials involve dose optimisation and drug combination studies to improve muscle 
strength. Some trials aim to provide substantial evidence for the therapeutic benefits of 
these compounds in attempt to make them commercially available.   
Therapies used for CMS are limited as the underlying mechanisms of action are not 
well understood. Some drugs display variable efficacies and side effects amongst 
patients and in different subtypes of CMS. The Gfpt1tm1d/tm1d mouse model will prove 
useful for testing current treatments in attempt to deduce the mode of action which will 
help maximise their clinical use. Further studies will involve the development of new 
compounds. Gfpt1tm1d/tm1d mice can be used to test the efficacy of compounds, determine 
their optimal doses, and examine potential adverse effects.  
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As the number of patients diagnosed with glycosylation associated CMS increases, 
together with the discovery of novel glycosylation enzymes, it is likely that future 
studies will involve the development of glycotherapies aiming to restore NMJ function. 
Although proven successful in muscular dystrophies, such studies will be the first of its 
kind for CMS. Whilst restoring glycosylation may reverse the myasthenic phenotype 
observed in CMS, and perhaps even reverse primary myopathic changes, it is less likely 
that myopathic alterations secondary to NMJ dysfunction can be reversed. Pre-clinical 
studies in mice that prove efficacious in ameliorating myasthenic symptoms, or perhaps 
even stabilising and restoring NMJ function will provide crucial evidence needed to 
drive forward patient therapies.  
 
 
137 
 
 
Appendix A 
Differentially regulated proteins in Gfpt1tm1d/tm1d intercostal muscles, their subcellular localisation, and proposed functions. Proteins 1-29 are 
upregulated with 2 or more unique peptides, 30-39 are upregulated with 1 unique peptide, 40-43 are downregulated with 1 unique peptide, p<0.05.  
 
Protein  Subcellular 
Localisation  
Proposed Functions 
1 Galectin-3  Cytoplasm, 
extracellular space, 
nucleus 
Involved in acute inflammatory responses including neutrophil activation and 
adhesion, chemoattraction of monocytes macrophages, opsonisation of apoptotic 
neutrophils, and activation of mast cells. 
2 UDP-N-acetylglucosamine-peptide 
N-acetylglucosaminyltransferase  
Cytoplasm, 
nucleus, plasma 
membrane 
Catalyses the transfer of a single N-acetylglucosamine from UDP-GlcNAc to a 
serine or threonine residue in cytoplasmic and nuclear proteins. 
3 Plastin-2  Cytoplasm Actin-binding protein. Plays a role in the activation of T-cells.  
4 Actin-related protein 2/3 complex 
subunit 1B  
Cytoplasm Functions as component of the Arp2/3 complex which is involved in regulation 
of actin polymerization and together with an activating nucleation-promoting 
factor mediates the formation of branched actin networks. 
5 Vitronectin Extracellular space Cell adhesion and spreading factor found in serum and tissues. Vitronectin 
interacts with glycosaminoglycans and proteoglycans. It is recognized by certain 
members of the integrin family and serves as a cell-to-substrate adhesion 
molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic 
complement pathway. 
6 Perilipin-1 ER-Golgi network  Modulator of adipocyte lipid metabolism. Coats lipid storage droplets to protect 
them from breakdown by hormone-sensitive lipase (HSL). Its absence may result 
in leanness. Plays a role in unilocular lipid droplet formation by activating 
CIDEC.  
7 Membrane primary amine oxidase  Plasma membrane  Has monoamine oxidase activity. May play a role in adipogenesis. 
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Protein  Subcellular 
Localisation  
Proposed Functions 
8 Histone H1.5  Nucleus Histone H1 protein binds to linker DNA between nucleosomes forming the 
macromolecular structure known as the chromatin fibre.  
9 BTB/POZ domain-containing 
protein KCTD12  
Extracellular space, 
plasma membrane 
Auxiliary subunit of GABA-B receptors that determines the pharmacology and 
kinetics of the receptor response. Increases agonist potency and markedly alters 
the G-protein signalling of the receptors by accelerating onset and promoting 
desensitization.  
10 Rho GDP-dissociation inhibitor 2 Cytoplasm  Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the 
dissociation of GDP from them, and the subsequent binding of GTP to them. 
Regulates reorganization of the actin cytoskeleton mediated by Rho family 
members.  
11 Sec1 family domain-containing 
protein 1  
Cytoplasm, ER-
Golgi network 
Plays a role in SNARE-pin assembly and Golgi-to-ER retrograde transport via its 
interaction with COG4. Involved in vesicular transport between the endoplasmic 
reticulum and the Golgi. 
12 Annexin A1  Cytoplasm, 
nucleus, plasma 
membrane 
Plays a role in glucocorticoid-mediated down-regulation of the early phase of the 
inflammatory response. Promotes rearrangement of the actin cytoskeleton, cell 
polarization and cell migration. Negatively regulates hormone exocytosis via 
activation of the formyl peptide receptors and reorganization of the actin 
cytoskeleton. Has high affinity for Ca2+ and can bind up to eight Ca2+ ions. 
13 Protein 
farnesyltransferase/geranylgeranyl
transferase type-1 subunit alpha  
Cytoplasm, plasma 
membrane 
Essential subunit of both the farnesyltransferase and the 
geranylgeranyltransferase complex. May positively regulate neuromuscular 
junction development downstream of MuSK. 
14 Macrophage-capping protein  Cytoplasm, nucleus   Calcium-sensitive protein which reversibly blocks the barbed ends of actin 
filaments but does not sever preformed actin filaments. May play an important 
role in macrophage function.  
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Protein  Subcellular 
Localisation  
Proposed Functions 
15 Glypican-1  Plasma membrane Required for proper skeletal muscle differentiation by sequestering FGF2 in lipid 
rafts preventing its binding to receptors (FGFRs) and inhibiting the FGF-
mediated signalling.  
16 Cysteine-rich protein 1  Cytoplasm  Participates in zinc absorption and may function as an intracellular zinc transport 
protein. 
17 Ras GTPase-activating-like 
protein IQGAP1  
Plasma membrane  Binds to activated CDC42 but does not stimulate its GTPase activity. It 
associates with calmodulin. May serve as an assembly scaffold for the 
organization of a multimolecular complex that would interface incoming signals 
to the reorganization of the actin cytoskeleton at the plasma membrane. May 
promote neurite outgrowth. 
18 Vesicular integral-membrane 
protein VIP36  
ER-Golgi network  Plays a role as an intracellular lectin in the early secretory pathway. Interacts 
with N-acetyl-D-galactosamine and high-mannose type glycans and may also 
bind to O-linked glycans. Involved in the transport and sorting of glycoproteins 
carrying high mannose-type glycans  
19 Complement C4-B Extracellular space Non-enzymatic component of C3 and C5 convertases and thus essential for the 
propagation of the classical complement pathway.  
20 Tubulin-specific chaperone A  Cytoplasm  Tubulin-folding protein. 
21 Aminopeptidase N  Plasma membrane  Plays a role in the final digestion of peptides generated from hydrolysis of 
proteins by gastric and pancreatic proteases. May be involved in the metabolism 
of regulatory peptides of diverse cell types, responsible for the processing of 
peptide hormones, such as angiotensin III and IV, neuropeptides, and 
chemokines. May have a role in angiogenesis.  
22 SH3 domain-binding glutamic 
acid-rich-like protein 3  
Cytoplasm, nucleus May act as a modulator of glutaredoxin biological activity. 
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Protein  Subcellular 
Localisation  
Proposed Functions 
23 Syntaxin-7  Plasma membrane May be involved in protein trafficking from the plasma membrane to the early 
endosome as well as in homotypic fusion of endocytic organelles. Mediates the 
endocytic trafficking from early endosomes to late endosomes and lysosomes. 
24 Coatomer subunit gamma-1  Cytoplasm, ER-
Golgi network 
Reversibly associates with Golgi non-clathrin-coated vesicles which further 
mediates biosynthetic protein transport from the ER, via the Golgi up to the trans 
Golgi network.  
 
25 Ras-related protein Rab-7a  Cytoplasm Key regulator in endo-lysosomal trafficking. Governs early-to-late endosomal 
maturation, microtubule minus-end as well as plus-end directed endosomal 
migration and positioning, and endosome-lysosome transport through different 
protein-protein interaction cascades.  
26 Myristoylated alanine-rich C-
kinase substrate  
Cytoplasm, plasma 
membrane 
The most prominent cellular substrate for protein kinase C. This protein binds 
calmodulin, actin, and synapsin. It is a filamentous actin cross-linking protein. 
27 Transcription intermediary factor 
1-beta  
Nucleus  Nuclear corepressor for KRAB domain-containing zinc finger proteins. Mediates 
gene silencing. Ubiquitinates p53/TP53 leading to its proteosomal degradation;  
28 Coatomer subunit beta Cytoplasm, ER-
Golgi network, 
plasma membrane  
A cytosolic protein complex that binds to dilysine motifs and reversibly 
associates with Golgi non-clathrin-coated vesicles, which further mediate 
biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi 
network.  
29 Protein disulfide-isomerase A3  ER-Golgi network Catalyzes the rearrangement of -S-S- bonds in proteins. 
30 60S ribosomal protein L3 Cytoplasm, nucleus  The L3 protein is a component of the large subunit of cytoplasmic ribosomes. 
31 Periostin  ER-Golgi network Induces cell attachment and spreading and plays a role in cell adhesion. 
Enhances incorporation of BMP1 in the fibronectin matrix of connective tissues, 
and subsequent proteolytic activation of lysyl oxidase. 
32 Complement C1q subcomponent 
subunit B  
Extracellular space  C1q associates with the proenzymes C1r and C1s to yield C1, the first 
component of the serum complement system. 
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Protein  Subcellular 
Localisation  
Proposed Functions 
33 Coiled-coil domain-containing 
protein 127  
ER-Golgi network, 
extracellular space 
Function is unknown. 
34 Bone marrow proteoglycan Cytoplasm Induces non-cytolytic histamine release from basophils. It is involved in 
antiparasitic defense mechanisms and immune hypersensitivity reactions. 
35 Minor histocompatibility antigen 
H13  
ER-Golgi network, 
plasma membrane 
Catalyzes intramembrane proteolysis of some signal peptides after they have 
been cleaved from a preprotein, resulting in the release of the fragment from the 
ER membrane into the cytoplasm. May play a role in graft rejection. 
36 KN motif and ankyrin repeat 
domain-containing protein 2  
Cytoplasm, 
mitochondria 
Involved in transcription regulation. Involved in the negative control of vitamin 
D receptor signalling pathway. May be involved in the control of cytoskeleton 
formation by regulating actin polymerization. Involved in regulation of caspase-
independent apoptosis. May be involved in promotion of cell proliferation 
37 Heme oxygenase 2 ER-Golgi network Heme oxygenase cleaves the heme ring at the alpha methene bridge to form 
biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin 
reductase. Heme oxygenase 2 could be implicated in the production of carbon 
monoxide in brain where it could act as a neurotransmitter. 
38 Histone H1.3 Nucleus Histone H1 protein binds to linker DNA between nucleosomes forming the 
macromolecular structure known as the chromatin fibre.  
39 Cytochrome P450 20A1  Plasma membrane Catalyses oxidation of flavoproteins.  
40 Selenoprotein T  ER-Golgi network Involved in glucose homeostasis, insulin secretion, cellular response to glucose 
stimulus and response to glucose.  
41 Fructosamine-3-kinase Cytoplasm May initiate a process leading to the deglycation of fructoselysine and of 
glycated proteins. May play a role in the phosphorylation of 1-deoxy-1-
morpholinofructose (DMF), fructoselysine, fructoseglycine, fructose and 
glycated lysozymes. 
42 Uncharacterized family 31 
glucosidase KIAA1161  
Plasma membrane  Putative glucosidase. 
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Protein  Subcellular 
Localisation  
Proposed Functions 
43 Nitric oxide synthase, brain Plasma membrane  Produces nitric oxide (NO) which is a messenger molecule with diverse 
functions throughout the body. In the brain and peripheral nervous system, NO 
displays many properties of a neurotransmitter.  
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